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Preface 	   	  	  	   Aging	   is	   still	   the	   greatest	   risk	   factor	   for	   neurodegenerative	   diseases.	  These	  diseases,	  such	  as	  Alzheimer’s	  and	  Parkinson’s,	  and	  also	  others	  that	  equally	  result	   from	   protein	   misfolding,	   such	   as	   Cystic	   Fibrosis,	   continue	   to	   affect	   a	  significant	  number	  of	  people	  and	  have	  no	  cure.	  Many	  current	  therapeutic	  efforts	  aim	  at	  better	  understanding	  the	  genetic	  mechanisms	  underlying	  these	  disorders,	  and	   new	   treatments	   have	   started	   to	   appear	  where	   small	  molecule	   compounds	  are	   used	   to	   help	   cellular	   defensive	   mechanisms	   to	   battle	   these	   constant	   and	  accumulating	  challenges.	  In	  light	  of	  this,	  our	  goal	  in	  pursuing	  this	  doctoral	  thesis	  was	   to	   elucidate	   how	   chemical	   manipulation	   of	   the	   pathways	   maintaining	  cellular	  health	  and	  homeostasis	  (the	  proteostasis	  network	  or	  PN)	  can	  be	  of	  use	  for	  developing	  potential	   therapeutics	   for	  diseases	  of	  protein	   conformation	   that	  affect	  the	  human	  population.	  The	  General	  Introduction	  of	  this	  dissertation	  gives	  an	  overview	  of	  the	  literature	  that	  is	  relevant	  to	  frame	  our	  work	  within	  the	  state	  of	  the	  art	  of	  the	  folding	  and	  proteostasis	  fields	  of	  science.	  	  	   The	  Materials	  and	  Methods	  section	  describes	  the	  techniques	  that	  we	  used	  to	  perform	  the	  experiments	  here	  described.	  	   In	  Chapter	  III,	  we	  wanted	  to	  further	  understand	  the	  effects	  of	  a	  previously	  described	   small	   molecule	   on	   proteostasis	   and	   its	   mechanism	   of	   action.	   	   We	  planned	   to	   find	   the	  chemical	  moieties	   that	   regulate	   function	  of	   this	   compound,	  F1,	  and	  to	  determine	  which	  stress	  pathways	  are	  activated	  by	  this	  small	  molecule	  and	   a	   selected	   group	   of	   structural	   analogues,	   across	   different	   cell	   types	   (with	  different	  cellular	  environments).	  We	  also	  tested	  F1	  and	  its	  analogues	  in	  various	  new	  models	  of	  protein	  misfolding,	  with	  relevance	  for	  human	  disease.	  Finally,	  we	  tested	   the	   requirement	   of	   the	   activation	   of	   different	   stress	   pathways	   (HSR,	   ER	  UPR,	  mtUPR	  and	  oxidative	  stress)	  for	  F1	  function.	  	   The	  discovery	  of	  new	  compounds	  with	  applications	  in	  diseases	  of	  protein	  conformation	   remains	   pertinent.	   In	   fact,	   alternative	   strategies	   like	   protein	  replacement	   therapy	   have	   showed	   some	   promising	   results,	   but	   are	   limited	  because	   the	   injected	  protein	  needs	   to	   find	   its	  way	   to	   the	   appropriate	   cell	   type	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and	  cellular	  compartment.	  This	  is	  a	  problem	  since	  recombinant	  proteins	  do	  not	  cross	  the	  blood-­‐brain	  barrier.	  In	  Chapter	  IV,	  our	  goal	  was	  to	  search	  for	  new	  small	  molecule	   regulators	   of	   the	   heat	   shock	   response	   (HSR)	   of	   different	   classes	  (activators,	  inhibitors	  and	  co-­‐activators),	  with	  a	  view	  for	  making	  them	  applicable	  for	   the	   study,	   or	   even	   treatment,	   of	   loss-­‐	   or	   gain-­‐of-­‐function	   conformational	  disorders.	  Because	  there	  is	  still	  new	  chemical	  space	  to	  be	  explored	  when	  looking	  for	   promising	   new	   compounds,	   we	   used	   a	   new	   chemical	   library	   that	   was	  engineered	   to	   be	   skeletally	   diverse,	   containing	   a	   diverse	   distribution	   of	  molecular	  shapes	  and	  excellent	  physicochemical	  properties.	  We	  also	  planned	  to	  validate	   our	   screen	   hits	   both	   by	   different	   rounds	   of	   testing	   and	   by	   assessing	  effect	   on	   endogenous	   levels	   of	   HSR	   genes.	   We	   aimed	   to	   check	   for	   the	  requirement	  of	  HSF1	  for	  the	  activity	  of	  these	  new	  compounds	  and	  to	  test	  them	  in	  
C.	  elegans	  models	  of	  protein	  misfolding.	  This	  would	  make	  them	  interesting	  new	  small	  molecules,	  for	  more	  advanced	  studies.	  	   Finally,	  in	  the	  General	  Discussion	  and	  Conclusions	  chapter,	  we	  summarize	  our	  most	   important	   findings	  and	   integrate	   them	   into	  what	  other	  studies	   in	   the	  same	  area	  of	  work	  have	  found.	  We	  also	  speculate	  of	  how	  our	  new	  findings	  might	  be	   of	   worth	   to	   the	   field,	   and	  which	   next	   steps	   should	   be	   taken	   to	  make	   them	  more	  complete.	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Summary 	  	  	   A	   better	   definition	   of	   the	   mechanisms	   that	   maintain	   a	   healthy	   cellular	  environment	   and,	   therefore,	   proteins	   homeostasis	   (proteostasis)	   have	  contributed	  significantly	  to	  an	  improved	  understanding	  of	  the	  factors	  leading	  to	  protein	   conformational	   diseases,	   such	   as	   Alzheimer’s	   disease,	   Huntington’s	  disease,	   Cystic	   Fibrosis	   or	   Gaucher’s	   disease.	   In	   fact,	   the	   identification	   of	   the	  proteostasis	  network	  (PN)	  components,	  mostly	  molecular	  chaperones,	  created	  a	  repository	   of	   genes	   involved	   in	   the	   important	   cellular	   functions	   of	   synthesis,	  folding,	   transport	   and	   degradation.	   This	   allowed	   a	   better	   definition	   of	   the	  potential	   targets	   for	   pharmacological	   intervention	   in	   these	   diseases,	  characterized	  by	  an	  aggregation-­‐related	  gain-­‐of-­‐toxic-­‐function	  or	  by	  misfolding	  and	  premature	  degradation	  loss-­‐of-­‐function.	  	   Our	   goal	   was	   to	   contribute	   for	   the	   development	   of	   small	   molecule	  compounds	  with	  a	  role	   in	  regulating	  the	  heat	  shock	  response	  (HSR),	  one	  of	  the	  main	  cellular	  stress	  response	  pathways,	  which	  enhances	  proteostasis	  when	  the	  cell	  is	  challenged	  by	  misfolding	  species.	  	   We	  studied	  a	  previously	  described	  small	  molecule,	  in	  detail,	  and	  revealed	  its	   chemical	   features	   that	   enable	   it	   to	   function	   as	   an	   HSR	   activator	   and	   to	  ameliorate	   proteostasis	   in	   mammalian	   and	   C.	   elegans	   models	   of	   protein	  misfolding.	  By	  studying	  structural	  analogues	  of	  SKM-­‐4/F1,	  we	  determined	  how	  that	   chemical	   structure	   could	   be	   altered	   to	  modulate	   its	   activation	   of	   different	  cellular	   stress	   pathways,	   like	   the	   unfolded	   protein	   response	   (UPR)	   or	   the	  oxidative	   stress	   response.	   We	   also	   showed	   that	   SKM-­‐4/F1	   rescues	   the	  proteotoxicity	   of	   aggregation-­‐prone	   proteins	   in	   neuronal	   models	   of	   C.	   elegans	  and	   rat	   primary	   brain	   slices	   and	   neuronal	   co-­‐cultures,	   further	   highlighting	   its	  potential	   use	   in	   more	   advanced	   therapeutics.	  We	   concluded	   that	   even	   though	  SKM-­‐4/F1	  activates	  different	   stress	  pathways	   in	   the	   cell,	   only	   the	   activation	  of	  the	  HSR	  seems	  to	  be	  necessary	  for	  its	  rescue	  of	  misfolding	  phenotypes.	  	   The	   finding	   of	   novel	   regulators	   of	   the	   HSR	   is	   still	   a	   major	   goal	   in	   the	  search	   for	   new	   and	   better	   therapies	   for	   conformational	   diseases.	   We	   have	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therefore	   performed	   a	   high	   throughput	   screen	   (HTS)	   for	   activators,	   inhibitors	  and	   co-­‐activators	   of	   the	   HSR,	   which	   resulted	   in	   three	   newly	   described	   small	  molecules.	  Activator	  A731	  is	  an	  HSF1-­‐dependent	  activator	  of	  a	  general	  HSR	  and	  already	  showed	  an	  ability	  to	  improve	  aggregation	  and	  toxicity	  phenotypes	  in	  C.	  
elegans	   models	   for	   conformational	   disorders.	   We	   also	   identified	   an	   inhibitor,	  I632,	  which	   showed	   low	   potency	   but	   a	   reduced	   cellular	   toxicity,	   and	   could	   be	  potentially	   developed	   into	   a	   better	   compound	   by	   a	   structure/activity	  relationship	   (SAR)	   study.	   Finally,	  we	   identified	  C732,	   a	   co-­‐activator	   of	  MG132-­‐induced	  HSR,	  an	  intriguing	  compound	  that	  shares	  structural	  similarities	  to	  A731	  but	  could	  only	  activate	  HSR	  in	  the	  presence	  of	  the	  agonist	  MG132	  and	  not	  in	  its	  absence.	  	   The	  work	  described	  here	  contributed	  for	  a	  better	  comprehension	  of	  new	  and	  previously	  described	  small	  molecule	  proteostasis	  regulators,	  and	  how	  they	  can	   be	   used	   to	   ameliorate	   diseases	   of	   protein	   conformation,	   by	   further	  understanding	  their	  chemistry	  and	  their	  mechanism	  of	  action	  (MoA).	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Resumo 	  	  	   As	   proteínas	   são	   um	   dos	   principais	   componentes	   das	   células,	   e	  responsáveis	   pela	   maioria	   das	   funções	   celulares.	   Para	   manter	   a	   célula	   num	  estado	   funcional	   e	   saudável,	   é	   necessário	   garantir	   a	   funcionalidade	   dos	  processos	   de	   síntese,	   processamento,	   transporte	   e	   degradação,	   cuja	   regulação	  constantemente	  desafia	  a	  manutenção	  celular.	  	   A	   integridade	   do	   proteoma	   (ou	   seja,	   a	   totalidade	   das	   proteínas	   numa	  célula,	   num	   dado	   momento)	   é	   mantida	   principalmente	   por	   fatores	   auxiliares,	  denominados	   chaperones	   moleculares,	   cuja	   principal	   função	   consiste	   em	  garantir	  que	  as	  proteínas	  estejam	  no	  seu	  estado	  funcional	  e	  nativo.	  Visto	  que	  as	  chaperones	   são	   a	   base	   molecular	   de	   vias	   celulares	   desde	   a	   síntese	   até	   à	  degradação	  de	  proteínas,	  são	  também	  o	  foco	  central	  de	  mecanismos	  de	  controlo	  de	  qualidade,	  essenciais	  para	  manter	  a	  homeostase	  proteica	  ou	  proteostase	  (do	  inglês	   proteostasis).	   Estes	   mecanismos	   de	   controlo	   de	   qualidade	   incluem	  chaperones	   com	   uma	   ação	   geral	   na	   célula	   e	   outras	   que	   agem	   em	   localizações	  celulares	   específicas.	   Deste	  modo,	   é	   constituído	   um	   sistema	   de	   vigilância	   com	  requisitos	   de	   conformação	   que	   as	   proteínas	   devem	   cumprir,	   para	   que	   possam	  atingir	   o	   seu	   estado	   funcional	   e	   nativo,	   além	  do	   seu	  destino	  na	   célula.	  Quando	  erros	   são	  detectados,	   o	   sistema	  de	   controlo	  de	  qualidade	  pode	   contribuir	  para	  novas	   tentativas	   de	   processamento	   do	   péptido	   ou,	   se	   isso	   falhar,	   para	   a	   sua	  degradação,	   de	  modo	   a	   evitar	   os	   efeitos	   nocivos	   resultantes	   da	   acumulação	  de	  restos	  proteicos	  potencialmente	  tóxicos.	  	   O	  controlo	  de	  qualidade	  é	  mantido	  no	  citoplasma	  principalmente	  por	  dois	  tipos	  de	  proteínas:	  chaperones	  associadas	  ao	  ribosoma	  e	  chaperones	  que	  foram	  primeiro	   identificadas	   por	   serem	   induzidas	   em	   resposta	   a	   uma	   elevação	   de	  temperatura,	   sendo	  por	   isso	  chamadas	  de	  Hsps	  (do	   inglês	  heat	   shock	  proteins).	  Estas	   chaperones	   são	   de	   diferentes	   famílias,	   com	   atividades	   específicas	   e	   cujo	  nome	  resultou	  da	  sua	  massa	  molecular	  (em	  kiloDalton):	  Hsp100,	  Hsp90,	  Hsp70,	  Hsp60,	   Hsp40	   e	   as	   pequenas	  Hsps	   ou	   sHsps	   (s	   =	   small).	   No	   caso	   de	   proteínas	  destinadas	   para	   a	   via	   secretora,	   o	   seu	   processamento	   ocorre	   no	   retículo	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endoplasmático	   (RE),	   um	   dos	   organitos	   celulares.	   Neste	   caso,	   existem	   vias	   de	  controlo	   de	   qualidade	   específicas,	   reguladas	   por	   chaperones	   próprias	   que	   só	  “autorizam”	  a	  saída	  da	  proteína	  para	  ser	  secretada	  quando	  esta	  tiver	  adquirido	  a	  respetiva	   conformação	   nativa.	   Caso	   contrário,	   é	   marcada	   para	   degradação	   e	  retro-­‐translocada	  para	  o	  citoplasma,	  onde	  é	  destruída	  no	  proteasoma.	  Em	  alguns	  casos,	   proteínas	   com	   mutações	   que	   retêm	   alguma	   função	   mas	   têm	   um	  processamento	   alterado,	   como	   p.	   ex.	   a	   proteína	   CFTR,	   são	   prematuramente	  degradadas	  por	  este	  mecanismo,	  conduzindo	  a	  doenças	  como	  a	  Fibrose	  Quística.	  	   Muitos	   factores	   podem	   contribuir	   para	   a	   acumulação	   de	   resíduos	   de	  proteínas	   com	   processamento	   alterado	   na	   célula.	   Estes	   podem	   ser	   ambientais,	  como	  a	  exposição	  a	  temperaturas	  elevadas	  ou	  metais	  pesados,	  mudanças	  de	  pH,	  infecções	  virais,	  etc.,	  ou	  intrínsecas,	  como	  a	  expressão	  de	  proteínas	  mutadas	  ou	  erros	   de	   tradução.	   Para	   responder	   a	   estes	   insultos,	   também	   denominados	   de	  “stress”,	   as	   células	   desenvolveram	  um	   conjunto	  de	  mecanismos	  protetivos	   que	  rapidamente	   induzem	  a	  expressão	  de	  chaperones	  e	  promovem	  a	  sobrevivência	  celular.	  Os	  principais	  mecanismos	  de	   resposta	   ao	   stress	   são	   a	  HSR	   (heat	   shock	  
response),	   o	   UPR	   (unfolded	   protein	   response)	   do	   RE	   ou	   do	   mitocôndrio	   e	   a	  resposta	   ao	   stress	   oxidativo.	   Apesar	   de	   serem	   mecanisticamente	   diferentes,	  todos	  estes	  sistemas	  de	  controlo	  de	  qualidade	  e	  resposta	  ao	  stress	  celular	  atuam	  em	   conjunto	   e	   tentam	   manter	   a	   célula	   num	   estado	   saudável.	   No	   entanto,	   em	  alguns	   casos	   isso	   não	   é	   possível,	   e	   surgem	   doenças	   relacionadas	   com	  conformação	  proteica.	  	   As	  doenças	  de	  conformação	  proteica	  podem	  ser	  de	  dois	  tipos:	  o	  primeiro	  são	  as	  de	  "perda	  de	   função"	  de	  uma	  proteína	  mutada,	  resultante	  em	  alterações	  da	  sua	  conformação	  ("misfolding")	  e	  a	  uma	  degradação	  prematura,	  como	  é	  o	  caso	  da	  já	  referida	  Fibrose	  Quística	  e	  da	  doença	  de	  Gaucher,	  resultante	  de	  defeitos	  no	  armazenamento	  de	  proteínas	  nos	  lisossomas.	  O	  segundo	  tipo	  são	  as	  doenças	  em	  que	   há	   "ganho	   de	   função"	   p.	   ex.	   pelo	   produto	   proteico	   ser	   tóxico,	   devido	   a	  interações	  erróneas	  na	  estrutura	  da	  proteína	   ("misfolding"),	   conduzindo	  a	  uma	  propensão	   para	   agregação,	   o	   que	   tem	   consequências	   nocivas	   para	   a	   célula	   e	  doença	  associada.	  Alguns	  exemplos	  notórios	  são	  as	  chamadas	  amiloidoses,	  como	  a	   paramiloidose	   (conhecida	   por	   "doença	   dos	   pezinhos")	   ou	   as	   doenças	   de	  Alzheimer,	   Parkinson	   ou	   ainda	   a	   esclerose	   lateral	   amiotrófica	   (ALS).	  Um	  outro	  
	   xi	  
grupo	  de	  doenças	  neurodegenerativas	  que	  resultam	  da	  acumulação	  de	  amilóide	  são	  conhecidas	  como	  doenças	  de	  poliglutamina	  (PolyQ),	  e	  ocorrem	  por	  expansão	  de	  uma	   repetição	  de	   resíduos	  de	   glutamina	  nas	  proteínas	   afetadas.	   Este	   grupo	  inclui	   a	   doença	   de	   Huntington	   e	   ataxias	   espinocerebelares,	   como	   a	   doença	   de	  Machado-­‐Joseph.	  	   Todas	  estas	  doenças	  podem	  ser	  vistas	  como	  uma	  perda	  na	  regulação	  da	  "homeostase	   proteica"	   ou	   proteostase.	   Ao	   longo	   da	   vida,	   este	   mecanismo	  mantém	  a	  resposta	  celular	  aos	  vários	   insultos	  a	  que	  é	  submetida,	  até	  um	  certo	  limite	  em	  que	  a	  proteção	  começa	  a	  falhar	  e	  dá-­‐se	  o	  envelhecimento	  ou,	  em	  casos	  de	  mutações	   e/ou	  misfolding	   proteico	  marcante,	   um	   estado	   de	   doença.	  Muitos	  trabalhos	   de	   investigação	   têm	   contribuído	   para	   uma	   melhor	   compreensão	   da	  rede	   de	   proteínas	   que	   constituem	   a	   proteostase,	   que	   são	   as	   que	   estão	  essencialmente	   envolvidas	   nos	   vários	  mecanismos	   de	   controlo	   de	   qualidade	   e	  resposta	   ao	   stress.	   Igualmente,	   vários	   esforços	   recentes	   têm	   sido	   feitos	   para	  desenvolver	   compostos	   químicos	   que	   permitam	   aumentar	   a	   capacidade	   da	  proteostase,	   quer	   mimetizando	   os	   efeitos	   das	   chaperones	   moleculares	  (chaperones	   químicas	   ou	   farmacológicas)	   quer	   aumentando	   a	   quantidade	   de	  chaperones	   na	   célula	   e	   permitindo	   uma	   melhor	   resposta	   aos	   fatores	   nocivos,	  tóxicos	  para	  o	  ambiente	  celular.	  Muitos	  destes	  contributos	  resultaram	  de	  screens	  de	  alto	  rendimento	  ou	  HTS	  (do	  inglês	  high	  throughput	  screens),	  onde	  milhares	  de	  novos	   compostos	   podem	   ser	   testados	   e	   selecionados	   num	   tempo	   reduzido,	  aumentando	   a	   probabilidade	   de	   encontrar	   compostos	   positivos	   para	   a	   função	  testada.	   Em	  muitos	   destes	   trabalhos	   há	   também	   uma	   componente	   de	   química	  medicinal,	   i.e.,	   produção	   de	   análogos	   químicos	   semelhantes	   aos	   originalmente	  descritos,	   para	   testar	   se	   pequenas	   alterações	   na	   sua	   estrutura	   produzem	  melhores	  resultados,	  otimizando	  assim	  a	  ação	  do	  composto	  líder.	  	   O	   objectivo	   geral	   deste	   trabalho	   foi	   o	   de	   contribuir	   para	   o	  desenvolvimento	   de	   novos	   compostos	   químicos	   com	   potencial	   aplicação	   para	  doenças	  de	  conformação	  proteica.	  	   O	   nosso	   estudo	   iniciou-­‐se	   assim	   (Capítulo	   III)	   pela	   otimização	   dum	  composto	   líder	   anteriormente	   identificado.	   O	   nosso	   ponto	   de	   partida	   foi	   uma	  pequena	  molécula	  (small	  molecule)	  previamente	  descrita	  como	  sendo	  ativadora	  da	   via	   de	   stress	   HSR	   (heat	   shock	   response),	   denominada	   F1/SKM-­‐4,	   e	   que	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também	  tinha	  demonstrado	  capacidade	  de	  atenuar	  fenótipos	  de	  agregação	  com	  baixa	   toxicidade	   em	  modelos	   de	   cultura	   celular	   e	   no	   nemátode	  Caenorhabditis	  
elegans	  (C.	  elegans).	  Utilizando	  esta	  molécula	  como	  referência,	  realizámos	  assim	  um	  estudo	  de	  comparação	  de	  estrutura-­‐função,	  através	  da	  aplicação	  de	  análogos	  estruturais	   de	   F1/SKM-­‐4,	   e	   descobrimos	  que	   a	  molécula	   de	   referência	   já	   era	   a	  que	   produzia	  melhores	   resultados	   para	   a	   ativação	   da	  HSR,	   quando	   também	   se	  tinha	  em	  conta	  a	   toxicidade	  de	  cada	  composto.	  Para	  além	  disto,	   comparámos	  a	  ativação	   de	   outras	   vias	   de	   stress	   entre	   o	   composto	   inicial	   e	   alguns	   dos	   seus	  análogos,	   e	   descobrimos	   que	   é	   possível	   manipular	   a	   estrutura	   química	   nesta	  classe	  de	  pequenas	  moléculas	  de	  modo	  a	  obter	  uma	  ativação	  diferencial	  de	  vias	  como	   a	   UPR	   do	   RE	   ou	   do	   mitocôndrio.	   Testámos	   dois	   destes	   análogos	   num	  modelo	  de	  agregação	  proteica	  em	  C.	  elegans,	  que	  expressa	  uma	  repetição	  de	  35	  poliglutaminas	  (poly-­‐Q35,	  ou	  Q35)	  resultante	  no	  aparecimento	  de	  agregados	  nas	  células	   musculares	   dos	   animais,	   acompanhados	   de	   uma	   crescente	   toxicidade	  (evidenciada	  por	  defeitos	  de	  locomoção	  nestes	  nemátodes,	  a	  partir	  do	  sexto	  dia	  de	   vida).	   Esta	   experiência	  mostrou	  que	   apesar	   de	   os	   2	   análogos	   ativarem	   com	  maior	   intensidade	   outras	   vias	   de	   stress	   celular,	   não	   eram	   mais	   eficazes	   no	  tratamento	   dos	   fenótipos	   de	   doença	   em	   C.	   elegans.	   Estes	   resultados	   foram	  também	  apoiados	  pela	  nossa	  descoberta	  que	  em	  F1/SKM-­‐4,	  apesar	  de	  várias	  vias	  de	  stress	  serem	  activadas,	  apenas	  a	  ativação	  da	  HSR	  mostrou	  ser	  necessária	  para	  que	   F1/SKM-­‐4	   reduzisse	   o	   número	   de	   agregados	   nos	   nemátodes	   Q35.	   Este	  resultado	  foi	  obtido	  utilizando	  técnicas	  de	  RNAi,	  que	  permitem	  reduzir	  os	  níveis	  de	  expressão	  de	  genes	  específicos,	  e	  observar	  efeito	  dessa	  redução.	  Neste	  caso,	  reduzimos	   selectivamente	   o	   nível	   de	   factores	   de	   transcrição	   que	   controlam	   as	  diferentes	   vias	   de	   stress,	   e	   só	   com	   a	   redução	   nos	   níveis	   de	   HSF1	   (heat	   shock	  
factor	  1)	  se	  perdeu	  o	  efeito	  do	  composto	  F1/SKM-­‐4.	  Também	  mostrámos	  que	  o	  composto	   F1/SKM-­‐4	   é	   funcional	   na	   melhoria	   de	   modelos	   relevantes	   para	  doenças	  neurológicas,	  como	  foi	  o	  caso	  dos	  modelos	  neuronais	  em	  C.	  elegans	  Q67,	  relacionado	  com	  doenças	  de	  poliglutaminas,	  e	  AT3q130,	  modelo	  para	  a	  doença	  de	   Machado-­‐Joseph.	   Esta	   descoberta	   foi	   sustentada	   pela	   elevada	   eficiência	  revelada	  por	  F1/SKM-­‐4	  na	  protecção	  de	  neurónios	  em	  experiências	  com	  células	  primárias	   de	   rato.	   Neste	   caso,	   F1/SKM-­‐4	   mostrou	   ser	   protetivo	   contra	   a	  expressão	   de	   um	   fragmento	   proteico,	   encontrado	   em	   pacientes	   da	   doença	   de	  
	   xiii	  
Huntington,	   em	  cérebros	  de	   rato.	  Todas	   estas	  descobertas	   fazem	  de	  F1/SKM-­‐4	  um	  composto	  com	  potencial	  para	  estudos	  mais	  avançados,	  e	  eventualmente	  para	  ensaios	  clínicos.	  	   No	  Capítulo	  IV,	  descreve-­‐se	  um	  novo	  screen	  que	  realizámos	  em	  condições	  de	  HTS	  para	  a	  identificação	  de	  novos	  compostos	  reguladores	  da	  HSR,	  que	  levem	  a	   uma	   melhoria	   da	   proteostase.	   A	   optimização	   e	   realização	   deste	   screen,	  juntamente	   com	  uma	  cuidada	  seleção	  dos	  melhores	   compostos	  daí	   resultantes,	  resultou	   em	   três	   novas	   pequenas	   moléculas	   com	   diferentes	   efeitos	   na	   HSR.	   O	  novo	  composto	  A731	  ativa	  uma	  HSR	  geral	  e	  dependente	  da	  presença	  de	  HSF1,	  e	  já	   demonstrou	   a	   capacidade	  de	  melhorar	  modelos	  de	  doenças	  de	   conformação	  proteica	   em	  nemátodes	  C.	   elegans.	   Também	   identificámos	  um	   inibidor	  da	  HSR,	  que	   apesar	   de	   não	   ter	   mostrado	   elevada	   eficiência,	   apresentou	   uma	   reduzida	  toxicidade,	   podendo	   ser	   usado	   no	   futuro	   para	   desenvolver	   novos	   compostos	  análogos	   nesta	   classe,	   por	   um	   estudo	   comparativo	   de	   estrutura	   e	   atividade.	  Finalmente,	   identificámos	   um	   composto	   numa	   classe	   pouco	   descrita,	   de	   co-­‐ativadores	   de	   uma	   HSR,	   dependente	   da	   presença	   de	   MG132	   (um	   conhecido	  ativador	  desta	  via).	  O	  co-­‐ativador	  C732	  tem	  uma	  estrutura	  química	  semelhante	  à	  do	  ativador	  A731,	  embora	  não	  resulte	  em	  HSR	  por	  si	  próprio.	  Este	  facto	  leva-­‐nos	  a	   questionar	   se	   os	   dois	   compostos	   actuaram	   por	   uma	   mesmo	   mecanismo	   de	  acção,	  um	  ponto	  que	  queremos	  explorar	  no	  futuro.	  	   Na	   sua	   globalidade,	   o	   trabalho	   descrito	   nesta	   tese	   contribui	   para	   a	  aplicação	   de	   pequenas	   moléculas	   químicas	   para	   a	   regulação	   de	   vias	   de	   stress	  celular,	   demonstrando	   como	   podem	   ter	   um	   efeito	   benéfico	   em	   modelos	  relevantes	   para	   doenças	   de	   conformação	   proteica	   e,	   potencialmente,	   no	   seu	  tratamento.	   Com	   o	   trabalho	   futuro,	   para	   seguimento	   dos	   estudos	   aqui	  apresentados,	  propomos	  a	  continuação	  da	  caraterização	  destas	  moléculas.	  Com	  efeito,	  esperamos	  que	  estes	  compostos	  possam	  vir	  a	  ser	  utilizados,	  na	  sua	  forma	  atual,	  ou	  após	  otimização	  da	  sua	  estrutura,	  no	  tratamento	  de	  doenças	  que	  afetam	  a	  população	  humana.	  Caso	  tal	  não	  se	  concretize,	  serão	  pelo	  menos	   importantes	  ferramentas	   para	   compreender	  melhor	   os	  mecanismos	   que	   defendem	   o	   nosso	  organismo,	  mantendo-­‐o	  num	  estado	  homeostático	  e	  saudável.	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RLU	  	   	   relative	  light	  units	  
ROS	   	   reactive	  oxygen	  species	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S.E.M.	   	  	   standard	  error	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  mean	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  dismutase	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   transcription	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UPR	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  protein	  response	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  system	  
wt	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   yellow	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  binding	  protein	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I – General Introduction 	  	  
1.	  Protein	  Folding	  Proteins	  are	  a	  major	  component	  of	  all	  cells	  and	  are	  responsible	  for	  most	  cellular	   functions.	   The	   processes	   involved	   in	   protein	   biogenesis,	   namely	  synthesis,	   folding,	   transport	   and	   degradation,	   constitute	   a	   constant	   challenge	  that	  must	  be	  accomplished	  efficiently	  in	  order	  to	  maintain	  cellular	  health.	  	   Folding	  is	  the	  process	  by	  which	  a	  linear	  polypeptide	  chain	  transitions	  into	  a	  three-­‐dimensional	  structure	  (2),	  mostly	  with	  the	  information	  contained	  by	  the	  sequence	   of	   amino	   acids,	   particularly	   the	   attractive	   or	   repulsive	   forces	   that	  neighboring	  amino	  acids	  exert	  on	  each	  other.	  An	  efficient	  folding	  process	  can	  be	  seen	  as	  an	  energy	  landscape,	  where	  the	  unfolded	  protein	  represents	  the	  state	  of	  maximum	  energy,	  and	  the	   folded	  state	  corresponds	   to	   the	  protein	  at	   its	   lowest	  energy	   level,	   which	   is	   also	   where	   thermodynamic	   stability	   is	   maximized.	   In	  addition,	   folding	   intermediates	   and	   misfolded	   peptides	   have	   intermediary	  energy	  states	  ((3),	  (4),	  (5),	  (6)).	  Protein	  folding	  is	  particularly	  demanding	  in	  the	  crowded	  intra-­‐cellular	  environment	  (7)	  (8).	  It	  is	  commonly	  accepted	  that,	  for	  the	  majority	  of	  polypeptides	  in	  living	  cells,	  the	  intricate	  folding	  process	  is	  assisted	  by	  auxiliary	  factors	  that	  include	  folding	  enzymes	  and	  molecular	  chaperones	  (9).	  	  
	  	  
Figure	   1.	   Hypothetical	   folding	   energy	  
landscape	   for	   a	   polypeptide.	   Energy	   is	  lowered	  from	  the	  unfolded	  (U)	  state	  to	  the	  native	   functional	   protein	   (F).	   Folding	  intermediates	   or	   misfolded	   peptides	   (M)	  have	  medium	  energy	  levels.	  Adapted	  from	  (1)	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2.	  Molecular	  chaperones	  and	  quality	  control	  	   The	   main	   function	   of	   molecular	   chaperones	   is	   to	   maintain	   proteome	  integrity,	   which	   consists	   in	   maintaining	   proteins	   in	   their	   functional,	   native	  conformation.	  This	  is	  regulated	  by	  constitutively	  expressed	  chaperones	  that	  span	  all	   cellular	   compartments	   and	   also,	   under	  more	   extreme	   conditions	   (like	   heat	  shock	  and	  other	  forms	  of	  cellular	  stress),	  by	  inducible	  ones.	  In	  addition	  to	  their	  role	  in	  protein	  folding,	  molecular	  chaperones	  also	  have	  functions	  in	  assembling	  and	   regulating	   macromolecular	   complexes,	   in	   trafficking	   proteins	   between	  different	   cell	   compartments	   or	   to	   the	   cell	   membrane,	   and	   also	   in	   targeting	  proteins	   for	   degradation	   (10),	   (11),	   (12),	   (13).	   Since	  molecular	   chaperones	   are	  the	  main	   components	   in	   pathways	   ranging	   from	   protein	   biogenesis	   to	   protein	  degradation,	   they	   make	   up	   the	   core	   of	   the	   cellular	   protein	   quality	   control	  machinery,	   which	   is	   essential	   for	   maintaining	   protein	   homeostasis	  (proteostasis).	  	   The	   protein	   quality	   control	   machinery	   is	   composed	   of	   many	  molecular	  chaperones	   that	   can	   act	   either	   ubiquitously	   or	   at	   specific	   cellular	   locations.	  Chaperones	  thus	  constitute	  a	  surveillance	  system	  with	  conformational	  requisites	  that	   proteins	   must	   fulfill	   in	   order	   to	   reach	   their	   native	   functional	   state	   and	  optimal	   cellular	   localization.	   Failure	   to	   do	   so	   can	   result	   in	   refolding	   of	   the	  polypeptide,	   or,	  when	   refolding	   fails,	   in	   protein	  degradation,	   thus	   avoiding	   the	  detrimental	  effects	  caused	  by	  the	  accumulation	  of	  misfolded	  and	  potentially	  toxic	  proteins.	   Hence,	   protein	   quality	   control	   coordinates	   gene	   transcription	   and	  protein	   synthesis	  with	   the	  post-­‐translational	  machineries	  of	   folding,	   trafficking	  and	  repair/degradation,	  and	  is	  therefore	  integral	  to	  cellular	  health	  (14).	  	  
2.1.	  Cytoplasmic	  molecular	  chaperones	  	   Many	   of	   the	   firstly	   described	  molecular	   chaperones	  were	   inducible,	   i.e.,	  proteins	   that	   are	   up-­‐regulated	   in	   response	   to	   elevated	   temperatures.	   As	   a	  consequence,	   these	   chaperones	   are	   often	   named	   Heat	   Shock	   Proteins	   (Hsps).	  Different	   classes	   of	   Hsps	  were	   initially	   separated	   according	   to	   their	  molecular	  weights	   (KDa)	   and	   sequence	   homology:	  Hsp100,	  Hsp90,	   Hsp70,	   Hsp60,	   Hsp40	  and	  the	  small	  Hsps	  or	  sHsps	  (15)	  (Figure	  2).	  Each	  chaperone	  family	  differs	  in	  the	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number	   of	   members,	   substrate	   specificity,	   cellular	   localization	   and	   identity	   of	  associated	   co-­‐chaperones	   that	   assist	   in	   their	   function.	   Therefore,	   it	   is	   not	  surprising	   that	   chaperone	   expression	  differs	   amongst	   cell	   types	   and	   correlates	  with	  the	  specific	  demands	  of	  each	  cell	  (16).	  
	   	  
Figure	   2.	   Different	   families	   of	   chaperones	   and	   co-­chaperones	   are	   involved	   in	   protein	  
folding.	  Adapted	  from	  (17).	  	   	  	   In	  the	  cytosol,	  two	  main	  groups	  of	  molecular	  chaperones	  facilitate	  protein	  folding:	  ribosome-­‐associated	  chaperones	  that	  stabilize	  nascent	  chains	  and	  allow	  the	  initial	  steps	  in	  protein	  folding,	  and	  a	  second	  group	  of	  chaperones	  that	  assist	  in	   the	   later	  steps	  of	   the	   folding	  and	  targeting	  processes	  (18).	  The	   first	  group	   is	  comprised	   of	   the	   trigger	   factor	   in	   bacteria	   and	   by	   the	   ribosome-­‐associated	  complex	   (RAC)	   and	   the	  nascent	   chain-­‐associated	   complex	   (NAC)	   in	   eukaryotes	  (3);	  the	  second	  group	  includes	  many	  of	  the	  aforementioned	  Hsps,	  which	  we	  will	  describe	  in	  more	  detail.	  	   Hsp70s	  (heat	  shock	  proteins	  of	   the	  70kDa	  size)	  are	   involved	   in	  both	  co-­‐	  and	  post-­‐translational	  protein	  folding	  in	  an	  ATP-­‐dependent	  manner,	  by	  cycles	  of	  substrate	   binding	   and	   release.	   The	   Hsp70	   machinery	   is	   assisted	   by	   co-­‐chaperones	  and	  also	  nucleotide	  exchange	  factors	  (NEFs)	   like	  Bag-­‐1,	  which	  help	  increase	  the	  efficiency	  of	  substrate	  binding	  and	  release.	  These	  factors	  also	  confer	  
(Hsp40)	  
	  	  	  (Hsp60)	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specificity,	  by	  modulating	  multiple	   steps	  of	   the	  ATPase	  cycle	  and	  by	   regulating	  the	  interactions	  with	  other	  components	  of	  the	  quality	  control	  network	  (3)	  (16).	  	   The	  members	  of	  the	  Hsp40	  family	  are	  chaperones	  that	  contain	  a	  signature	  J	   domain	   and	   are	   comparable	   to	   (and	   named	   after)	   the	  DnaJ	   protein	   in	  E.	   coli	  (19).	   They	   are	   mainly	   Hsp70	   co-­‐chaperones	   that	   function	   in	   stimulating	   ATP	  hydrolysis	  and	  in	  stabilizing	  the	  binding	  of	  Hsp70	  to	  its	  substrates	  (20).	  Some	  J-­‐domain	   proteins	   have	   the	   ability	   to	   participate	   in	   folding	   independently	   of	  Hsp70,	  binding	  to	  unfolded	  polypeptides	  and	  preventing	  their	  aggregation.	  It	  has	  been	  proposed	  that	  most	  unfolded	  substrates	  first	  bind	  to	  an	  Hsp40,	  which	  then	  transfers	  them	  to	  Hsp70	  for	  correct	  folding	  (16).	  	   The	   Hsp60	   proteins	   (also	   known	   as	   Chaperonins)	   are	   large	  multimeric	  complexes	   that	   form	  a	  double	  ring	  structure.	  Well-­‐known	  examples	  are	  Hsp60,	  GroEL	   (from	   E.	   coli),	   and	   the	   TRiC	   (TCP-­‐1	   ring	   complex)	   complex	   (21).	   These	  chaperone	   machines	   form	   cage-­‐like	   structures	   that	   encapsulate	   the	   protein	  substrates	  and	  accelerate	  their	  rate	  of	  folding,	  in	  an	  ATP-­‐dependent	  manner	  (22)	  (23).	  	  	   Hsp90	  family	  members	  are	  essential	  for	  the	  regulation	  and	  maturation	  of	  client	  proteins	  that	  are	  involved	  in	  signaling	  pathways	  and	  in	  control	  of	  the	  cell	  cycle.	  Some	  of	  these	  “client”	  proteins	  are	  various	  transcription	  factors,	  hormone	  receptors	   and	   serine-­‐threonine	   kinases	   (12).	   The	   folding	   intermediates	  recognized	   by	   Hsp90	   have	   near-­‐native	   structures;	   accordingly,	   Hsp90	   was	  proposed	  to	  act	  following	  Hsp70	  in	  the	  protein	  folding	  pathway	  (24).	  	   Hsp100s	  are	  members	  of	  a	  larger	  family	  of	  AAA+	  (ATPase	  associated	  with	  diverse	  activities)	  proteins	  with	  a	  conserved	  ATPase	  unit	   that	  contains	  at	   least	  one	  nucleotide	  binding	  domain.	  Monomers	  of	  Hsp100	  form	  functional	  hexameric	  rings	   that	  provide	   chaperone	  activity.	  Most	  of	   these	   chaperones	  associate	  with	  proteases	   to	   participate	   in	   protein	   degradation.	   However,	   some	   Hsp100s	   like	  ClpB	  of	  E.	  coli	  or	  Hsp104	  of	  S.	  cerevisiae	  associate	  with	  Hsp70	  to	  promote	  protein	  disaggregation.	   (25).	   Interestingly,	   mammals	   do	   not	   possess	   an	   Hsp104	  homologue.	   In	   fact,	   it	   was	   recently	   found	   that	   the	   mammalian	   “disaggregase”	  machinery	  is	  the	  result	  of	  a	  synergetic	  activity	  of	  an	  Hsp110	  (Apg-­‐2)	  with	  Hsp70	  (Hsc70	  or	  Hsp70)	  and	  Hsp40	  (Hdj1).	  All	  of	  these	  chaperones	  were	  necessary	  and	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sufficient	  for	  dissolving	  disordered	  aggregates	  and	  recovering	  the	  native	  folded	  state	  of	  proteins	  (26).	  	   Finally,	   sHsps	   are	   chaperones	  with	   a	   conserved	   α-­‐cystallin	   domain	   and	  with	   low	  molecular	  weights	  between	  15	  and	  40kDa.	  They	  are	  distinct	   from	  the	  other	  Hsp	  families	  in	  that	  they	  do	  not	  require	  ATP	  for	  prevention	  of	  aggregation.	  Under	   stress	   conditions,	   sHsps	   form	   dimers	   or	   larger	   multimers	   that	   bind	  misfolding	  proteins	  in	  order	  to	  prevent	  them	  from	  aggregating	  (27)	  (28).	  These	  small	  Hsps	  cannot	  promote	  folding	  alone,	  but	  they	  act	  as	  “holders”	  that	  present	  the	  client	  proteins	  to	  the	  Hsp70	  machinery	  for	  ATP-­‐dependent	  refolding	  (29).	  	  
2.2.	  Quality	  control	  in	  the	  endoplasmic	  reticulum	  	   The	   ER	   is	   the	   site	   of	   folding	   for	   proteins	   that	   are	   destined	   for	   the	  secretory	   pathway.	   The	   environment	   in	   the	   ER	   is	   unique	   and	   differs	   from	   the	  cytoplasm	  in	   ion	  concentrations,	   redox	  conditions,	  and	  chaperone	  composition.	  This	   creates	   an	   optimal	   environment	   for	   formation	   of	   disulphide	   bonds,	  assembly	  of	  multi-­‐domain,	  complex	  proteins	  and	  higher	  folding	  efficiencies	  (30)	  (31).	   	  The	  most	   important	   chaperones	  with	   function	   in	   the	  ER	   include	  BiP	  and	  Grp170,	   members	   of	   the	   Hsp70	   family;	   Hsp40	   family	   members	   like	   ERdj1-­‐5;	  Grp94,	  belonging	  to	  the	  Hsp90	  family;	  and	  two	  important	  lectin	  chaperones	  that	  aid	  in	  the	  folding	  of	  proteins	  with	  monoglucosylated	  N-­‐linked	  glycans	  -­‐	  calnexin	  (CNX)	   in	   the	   ER	   membrane	   and	   calreticulin	   (CRT)	   in	   the	   ER	   lumen.	   Besides	  chaperones	   mechanically	   involved	   in	   protein	   folding,	   enzymes	   important	   for	  catalyzing	   isomerization,	   oxidation	   and	   reduction	   of	   disulfide	   bonds	   such	   as	  thiol-­‐disulphide	   oxidoreductases	   and	  peptidyl-­‐prolyl	   isomerases	   (PPIases)	   also	  contribute	  to	  protein	  homeostasis	  in	  the	  ER	  (32)	  (30).	  	   ER	   chaperones	   like	   BiP,	   CNX	   and	   CRT	   have	   the	   ability	   to	   work	   as	  “retention	  anchors”,	  thereby	  suppressing	  the	  secretion	  of	  incompletely	  folded	  or	  misfolded	   proteins.	  When	   an	   ER	   resident	   protein	   is	   permanently	  misfolded	   or	  associated	   with	   ER	   chaperones	   for	   an	   extended	   period,	   it	   is	   targeted	   for	  degradation	  via	  ER	  associated	  degradation	  (ERAD).	  During	  ERAD,	  the	  misfolded	  client	  is	  retro-­‐translocated	  to	  the	  cytosol	  where	  it	  is	  degraded	  by	  the	  proteasome	  (30),	  (31),	  (33).	  While	  some	  proteins	  are	  ER-­‐resident	  and	  have	  an	  ER	  retention	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signal	   in	   their	   sequence,	   many	   others	   are	   exported	   via	   vesicles	   to	   the	   Golgi	  complex	   and	   the	   secretion	   pathway.	   Alterations	   in	   ERAD	   are	   particularly	  problematic	   for	  mutant	  proteins	  that	  are	  partly	   functional	  but	  are	  still	  signaled	  for	  degradation,	  leading	  to	  diseases	  such	  as	  Cystic	  Fibrosis	  (33).	  	  
2.3.	  Protein	  degradation	  	   There	   are	   two	  major	   systems	   for	   degradation	   of	   proteins	   in	   eukaryotic	  cells:	   the	  ubiquitin-­‐proteasome	   system	   (UPS)	   and	   the	   lysosomal	   system.	  These	  are	  important	  not	  only	  for	  clearing	  misfolded,	  damaged	  and	  mutant	  proteins,	  but	  also	   for	  maintaining	   protein	   synthesis	   by	   renewing	   the	   reserves	   of	   free	   amino	  acids	   in	   the	   cell	   (34)	   (35).	   	   Both	   proteolysis	   systems	   share	   a	   common	  mechanism:	   cargo	   to	   be	   degraded	   is	   selected	   and	   tagged,	   then	   recognized	   and	  delivered	  to	  the	  proteolytic	  system,	  where	  it	  undergoes	  proteolysis.	  	  
	  
Figure	  3.	   Chaperones	   are	   involved	   in	  protein	   clearance.	   	   Chaperones	   perform	   functions	   in	  folding	  new	  proteins	  (A),	  unfolding/refolding	   for	   trafficking	   into	  cellular	  compartment	  (B)	  and	  refolding	   associated	   with	   protein	   damage	   (C).	   When	   these	   mechanisms	   fail,	   unfolded	   or	  misfolded	  proteins	   can	  be	  degraded	  by	   a	   proteolytic	   system:	   the	   ubiquitin-­‐proteasome	   system	  (UPS)	  (D)	  or	  autophagy	  (E).	  Adapted	  from	  (35).	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   Conjugation	  of	  lysine	  48	  linked	  ubiquitin	  chains	  to	  proteins	  targets	  them	  for	  degradation	  via	  the	  proteasome	  (Figure	  3D)	  (36).	  Three	  types	  of	  enzymes	  act	  in	  succession	  to	  coordinate	  this	  process:	  an	  ubiquitin-­‐activating	  enzyme	  (E1),	  an	  ubiquitin-­‐conjugating	  enzyme	   (E2)	  and	  an	  ubiquitin-­‐ligase	   (E3).	  Recognition	  of	  misfolded	  substrates	  by	  E3	  ligases	  occurs	  in	  collaboration	  with	  Hsp70	  or	  Hsp90	  chaperones.	  Ubiquitylated	  clients	  are	  then	  targeted	  by	  chaperone/co-­‐chaperone	  complexes	   to	   the	  26S	  proteasome,	  a	  highly	  conserved	  ATP-­‐dependent	  protease	  complex	  with	  multi-­‐catalytic	  capabilities.	  Substrates	  are	  recognized	  by	  ubiquitin	  receptors,	  de-­‐ubiquinated	  by	  specific	  enzymes	  named	  de-­‐ubiquitinases	   (DUBs),	  and	   unfolded	   in	   order	   to	   fit	   the	   barrel-­‐like	   proteolytic	   chamber	   of	   the	  proteasome	  (34)	  (35).	  	   Lysosomal	   degradation	   is	   the	   final	   stage	   of	   the	   autophagy	   pathway	  (Figure	   3E).	   Lysosomes	   are	   single-­‐membrane	   vesicles	   that	   incorporate	  proteases,	   lipases,	  glycases	  and	  nucleotidases.	   Inside,	  unfolding	  of	  proteins	  and	  their	   proteolysis	   is	   helped	   by	   an	   acidic	   lumen	   environment.	   Autophagy	   is	  responsible	   for	   the	   degradation	   of	   large	   organelles	   such	   as	   the	   mitochondria	  (mitophagy),	   aggregated	   proteins	   (macroautophagy),	   and	   individual	   misfolded	  proteins	  (chaperone-­‐mediated	  autophagy),	  under	  basal	  or	  stress	  conditions.	  The	  more	   specialized	   chaperone-­‐mediated	   autophagy	   (CMA)	   of	   cytosolic	   proteins	  requires	   chaperones	   for	   recognition	  of	   the	   target	   proteins,	   their	   unfolding	   and	  targeting	  to	  the	  lysosome	  via	  surface	  receptors,	  usually	  in	  response	  to	  stress	  (34)	  (35).	  	   Dysregulation	  of	  the	  UPS	  and	  autophagy	  has	  been	  related	  to	  many	  protein	  folding	  diseases.	  In	  some	  conformational	  disorders,	  the	  QC	  and	  protein	  clearance	  apparatuses	   are	   unable	   to	   handle	   the	   chronic	   expression	   of	   misfolding	   and	  aggregation-­‐prone	   proteins.	   As	   an	   example,	   some	   proteins	   related	   to	  neurodegenerative	   diseases	   have	   been	   shown	   to	   present	   a	   direct	   inhibitory	  effect	   in	   the	   proteasome	   26S.	   This	   was	   observed	   for	   tau	   in	   the	   brains	   of	  Alzheimer’s	  disease	  patients	   (37),	   polyQ	   stretches	   (38)	   in	  Huntington’s	  models	  and	   α-­‐synuclein	   both	   in	   vitro	   and	   in	   vivo	   (39).	   This	   results	   in	   a	   deleterious	  accumulation	   of	   insoluble	   and	   sometimes	   toxic	   oligomeric	   species.	   Genetic	   or	  pharmacological	   mechanisms	   to	   cope	   with	   these	   chronic	   conditions	   are	  therefore	  of	  the	  utmost	  importance.	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3.	  Cellular	  Stress	  Pathways	  	   Exposure	   to	   acute	   cellular	   stress	   (elevated	   temperature,	   changes	   in	   pH,	  heavy	  metals,	  viral	  infection)	  can	  result	  in	  an	  accumulation	  of	  misfolded	  proteins	  that	   over-­‐whelms	   the	   constitutive	   chaperone	   network	   (40).	   Furthermore,	  protein	  homeostasis	   is	   challenged	  by	  errors	   in	   translation	  or	   the	  expression	  of	  mutant	  proteins,	  either	  of	  which	  can	  cause	  chronic	  stress	  	  	   In	  order	  to	  maintain	  proteome	  integrity	   in	  response	  to	  stress,	  cells	  have	  developed	   a	   number	   of	   cytoprotective	   pathways	   that	   rapidly	   up-­‐regulate	  chaperones	   and	   promote	   cell	   survival.	   These	   stress	   responses	   protect	   all	  compartments	   of	   the	   cell	   by	   enhancing	   the	   recognition	   and	   refolding	   of	  misfolded	   proteins,	   and	   preventing	   protein	   aggregation,	   both	   of	   which	   can	   be	  deleterious	   to	   cells	   (3).	  The	  major	   cellular	   stress	   responses	   are	   the	  heat	   shock	  response	  (HSR),	  the	  unfolded	  protein	  responses	  (UPR)	  of	  the	  ER	  (ER	  UPR)	  and	  of	  the	  mitochondria	  (UPRmt),	  and	  the	  oxidative	  stress	  response	  (41).	  	  
3.1.	  The	  heat	  shock	  response	  	  	   The	   heat	   shock	   response	   was	   first	   reported	   in	   the	   fruit	   fly	   Drosophila	  
buschii,	  by	  the	  appearance	  of	  a	  puffing	  pattern	  in	  its	  polytene	  chromosomes	  upon	  heat	  shock	  (42).	  This	  was	  later	  associated	  with	  an	  up-­‐regulation	  of	  HSR	  proteins	  (15).	   The	  heat	   shock	   factor	   family	   (HSF)	  has	  multiple	  members	   in	   vertebrates,	  but	  only	  one	  (HSF1)	  in	  the	  commonly	  used	  models	  S.	  cerevisiae,	  D.	  melanogaster	  and	  C.	  elegans.	  HSFs	  are	  transcription	  factors	  that	  promote	  chaperone	  expression	  under	   both	   basal	   and	   stress	   conditions	   (43)	   (44).	   Most	   tissues	   and	   cell	   types	  constitutively	  express	  HSF1,	  the	  main	  regulator	  of	  chaperone	  expression	  and	  the	  only	  HSF	  that	  is	  known	  to	  be	  active	  during	  stress	  (43)	  (45).	  	   Under	   non-­‐stress	   conditions,	   localization	   of	  HSF1	   is	  mainly	   cytoplasmic	  where	   it	   remains	   as	   an	   inactive	   monomer.	   It	   is	   widely	   accepted	   that	   weak	  interactions	  of	  HSF1	  with	  the	  molecular	  chaperones	  Hsp70	  and	  Hsp90	  keep	  it	  in	  this	   repressed	   monomeric	   state	   (46)	   (47).	   Whenever	   there	   is	   a	   stress	   signal,	  Hsp70	   and	   Hsp90	   are	   recruited	   to	   the	   misfolding	   proteins	   in	   the	   cytoplasm	  leaving	   HSF1	   free	   to	   translocate	   into	   the	   nucleus	   (Figure	   4b).	   In	   the	   nucleus,	  HSF1	   trimerizes	   and	   becomes	   an	   active	   transcription	   factor	   (TF)	   that	   binds	   to	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consensus	   sequences,	   named	   heat	   shock	   elements	   (HSEs),	   in	   the	   promoter	  regions	   of	   heat	   shock	   genes.	   This	   facilitates	   a	   rapid	   increase	   in	   the	   levels	   of	  chaperones	   such	   as	   HSP70,	   HSP40,	   and	   HSP25	   (48)	   (49).	   HSF1	   activity	   is	  extensively	   regulated	  by	  post-­‐translational	  modifications	   (Figure	  4a);	  however,	  it	   is	   not	   fully	   established	   whether	   these	   occur	   prior	   to,	   during,	   or	   after	   HSF1	  binds	  to	  DNA,	  but	  they	  are	  required	  for	  the	  transcriptional	  activity	  of	  HSF1	  and	  also	  for	  its	  later	  repression.	  Besides	  post-­‐translational	  modifications,	  attenuation	  of	   HSF1	   activity	   is	   also	   achieved	   by	   a	   feedback	   loop	   involving	   the	   Hsps	  themselves,	   whereby	   at	   elevated	   concentrations	   HSP70	   and	   HSP40	   inhibit	   the	  transactivational	  capacity	  of	  HSF1	  (49).	  	  	  
	  
Figure	  4.	  (a)	  Structure	  of	  HSF1	  showing	  examples	  of	  post-­translational	  modification,	  such	  as	  acetylation	  (A),	  phosphorylation	  (P)	  and	  sumoylation	  (S).	  (b)	  Representative	  scheme	  of	  the	  
HSF1	   cycle.	   HSF1	   undergoes	   activation	   by	   stress,	   trimerization,	   activity	   in	   transcriptional	  activation	   and	   attenuation	   by	   feedback	   loop	   from	   the	   Hsps	   or	   as	   a	   consequence	   of	   the	   post-­‐translational	  modifications.	  	  
3.2.	  The	  unfolded	  protein	  response	  in	  the	  ER	  and	  in	  the	  mitochondria	  	   The	  most	  studied	  compartmental	  stress	  response	  is	  the	  ER	  UPR,	  a	  stress	  response	  activated	  by	   the	  accumulation	  of	  unfolded	  or	  misfolded	  protein	   in	   its	  lumen.	  Given	  its	  organellar	  localization,	  the	  ER	  UPR	  requires	  signal	  transduction	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pathways	  that	  communicate	  the	  proteotoxicity	  status	  from	  the	  ER	  to	  the	  nucleus,	  for	   the	   expression	   of	   ER-­‐specific	   chaperones	   (50)	   (51).	   This	   response	   can	   be	  activated	   by	   differences	   in	   the	   folding	   environment,	   increase	   in	   the	   load	   of	  secreted	  proteins	  or	  by	  different	  physiological	  states.	  	   The	   ER	   UPR	   contains	   three	   major	   branches	   that	   form	   a	   coordinated	  response	  and	  are	  regulated	  by	  three	  ER	  transmembrane	  signal	  transducers:	  IRE1	  (inositol-­‐requiring	  protein	  1),	  PERK	  (PKR-­‐like	  ER	  kinase)	  and	  ATF6	  (activating	  transcription	   factor	   6)	   (Figure	   5).	   IRE1	   is	   the	   most	   conserved	   transduction	  pathway	   of	   the	   ER.	   It	   is	   believed	   that	   in	   physiological	   conditions	   BiP	   binds	   to	  IRE1	  in	  the	  lumen	  of	  the	  ER	  to	  keep	  it	  inactive.	  Activation	  of	  stress	  sends	  BiP	  to	  its	  target	  proteins,	  thus	  releasing	  IRE1,	  which	  oligomerizes	  and	  becomes	  active.	  Alternatively,	   IRE1	   might	   also	   become	   active	   through	   direct	   interaction	   of	   its	  stress-­‐sensing	  domain	  with	  unfolded	  proteins	  (52)	  (53).	  When	  IRE1	  is	  activated,	  it	  causes	  splicing	  of	  an	   intron	  in	  a	  major	  UPR	  transcription	  factor,	  XBP1	  (X-­‐box	  binding	  protein	  1).	  This	  splicing	  event	  is	  needed	  for	  XBP1	  to	  be	  functional	  and	  its	  spliced	   form	   then	  migrates	   into	   the	   nucleus	   to	   activate	   transcription	   of	   genes	  involved	   in	   ER	   protein	   quality	   control	   (54).	   In	   parallel	   with	   IRE1,	   the	   PERK	  kinase	   responds	   to	   ER	   stress	   through	   dimerization	   and	   autophosphorylation.	  There	   is	   phosphorylation	   of	   the	   elongation-­‐initiation	   factor	   2α	   (eIF2α),	   which	  results	   in	   a	   general	   repression	   of	   translation	   and	   protein	   synthesis.	   This	  contributes	   to	   a	   relaxation	   of	   ER	   stress	   and	   also	   the	   up-­‐regulation	   of	   ATF4	  (activating	   transcription	   factor	   4),	   which	   then	   induces	   a	   more	   specific	   up-­‐regulation	   of	   UPR	   genes	   (55).	   ATF6,	   the	   third	   UPR	   transmembrane	   signal	  transducer,	   is	   also	   linked	   to	   BiP.	   Upon	   ER	   stress,	   ATF6	   is	   released	   by	   BiP	   and	  transported	  to	  the	  Golgi	  apparatus	   in	  a	  COPII	  (coat	  protein	  complex	  II)	  vesicle-­‐dependent	  manner.	   In	   the	  Golgi,	  ATF6	   is	  enzymatically	   cleaved,	  which	  releases	  the	  DNA-­‐binding	  and	  transcriptional	  activation	  domain	  which	  then	  translocates	  to	  the	  nucleus	  where	   it	  activates	  gene	  expression	  (50).	  The	  accumulation	  of	  ER	  stress	  and	   failure	  of	   the	  UPR	   to	  alleviate	   it	   can	  ultimately	   lead	   to	   cell	  death	  by	  apoptosis,	   so	   that	   the	  whole	   tissue	   or	   organism	   is	   protected	   from	   proteotoxic	  effects	  of	  increasing	  misfolded	  protein	  in	  individual	  cells	  (54)	  (50).	   	  	   Although	   poorly	   described	   in	   comparison,	   another	   UPR	  mechanism	   has	  been	   described	   for	   the	   mitochondria.	   Most	   of	   the	   studies	   performed	   on	   the	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mtUPR	   have	   been	   performed	   in	   C.	   elegans,	   where	   it	   has	   been	   shown	   that	   the	  mitochondrial	  Hsp70	  family	  member	  (mitoHsp70,	  coded	  by	  hsp-­6	   in	  C.	  elegans)	  and	  also	  Hsp60	  are	   induced	  by	  perturbations	   in	  protein	  folding	  and	  processing	  inside	   the	   mitochondria.	   mitoHsp70	   and	   Hsp-­‐60	   have	   functions	   in	   importing,	  folding	  and	  assembling	  multi-­‐protein	  complexes	  in	  the	  mitochondrial	  matrix	  and	  on	  the	  matrix	  side	  of	   the	   inner	  mitochondrial	  membrane	  (56).	  These	  genes	  are	  also	   induced	   by	   the	   accumulation	   of	   reactive	   oxygen	   species,	   but	   not	   by	  perturbations	   in	  metabolism	  or	  ATP	  synthesis	  pathways.	  This	  points	   to	  a	  more	  specific	   (rather	   than	   general)	   organellar	   response.	   (41)	   (57).	   Recently,	   several	  proteins	  were	  identified	  that	  are	  required	  for	  signaling	  the	  mtUPR	  and	  activating	  mtHsp70	  and	  Hsp60.	  It	  was	  found	  that	  there	  were	  two	  parallel	  branches	  of	  the	  mtUPR.	  In	  the	  first	  one,	  HAF-­‐1	  is	  activated	  by	  stress	  in	  the	  mitochondria,	  leading	  to	  activation	  of	  ATFS-­‐1	  (activating	  transcription	  factor	  associated	  with	  stress	  1),	  which	   in	   turn	   activates	   gene	   induction	   of	   mitochondrial	   chaperones.	   In	   the	  second	  arm	  of	  mtUPR,	  the	  GCN-­‐2	  kinase	  is	  activated	  by	  stress.	  This	  leads	  to	  GCN-­‐2-­‐mediated	   phosphorylation	   of	   eIF2a,	   resulting	   in	   a	   general	   attenuation	   of	  protein	  translation	  that	  is	  protective	  to	  the	  mitochondria	  (58).	  	  
	  
Figure	  5.	  The	  unfolded	  protein	  response	  (UPR)	  of	   the	  ER	   is	  regulated	  by	  3	   transmembrane	  signal	  transducers:	  IRE1,	  PERK	  and	  ATF6.	  These	  3	  branches	  act	  through	  different	  pathways,	  but	  result	   in	   a	   coordinated	   stress	   response	   to	   activate	   transcription	   of	   UPR-­‐responsive	   genes.	  Adapted	  from	  (59).	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3.3.	  Oxidative	  stress	  response	  	   Living	   in	   an	   oxygenated	   environment	   requires	   an	   effective	   cellular	  strategy	   for	   the	   detection	   and	   detoxification	   of	   metabolites	   resulting	   from	  oxidation	  of	  molecules	  such	  as	  carbonylated	  proteins,	  lipids	  and	  DNA.	  In	  order	  to	  maintain	   the	   redox	   state	   of	   a	   cell,	   reactive	   oxygen	   species	   (ROS)	   have	   to	   be	  maintained	   at	   physiological	   levels.	   Production	   of	   ROS	   results	   from	   diverse	  metabolic	  pathways	  and	  cytosolic	  enzymes,	  but	  the	  most	  important	  source	  is	  the	  mitochondrial	  electron	  transport	  chain	  (60).	  	  Another	  significant	  source	  of	  these	  species	   is	   the	   lumen	   of	   the	   ER,	   where	   disulfide	   bond	   creation	   during	   protein	  folding	  uses	  molecular	  oxygen	  as	   the	   terminal	  electron	  acceptor,	   thus	  resulting	  in	  ROS	  production	  (61)	  (62).	  Additional	  ROS	  result	  from	  perturbations	  of	  the	  cell	  redox	   state,	   such	   as	   chemotherapeutic	   agents,	   UV	   radiation,	   hyperthermia	   and	  growth	  factors.	  	   Under	   a	   certain	   threshold,	   ROS	   are	   important	   for	   defense	   against	  infection,	   control	   of	   cell	   proliferation	   and	   signaling	   of	   metabolic	   stress.	   When	  ROS	  levels	  become	  detrimental,	  leakage	  of	  Ca2+	  ions	  from	  the	  ER	  lumen	  increases	  mitochondrial	   permeability,	   stimulates	   cytochrome	   C	   release,	   and	   disrupts	   the	  respiratory	   chain.	   In	   extreme	   situations,	   this	   can	   lead	   to	   apoptosis	   (60).	   To	  protect	   against	   cell	   death	   from	   increased	  ROS,	   the	   oxidative	   stress	   response	   is	  activated.	   The	   oxidative	   stress	   response	   involves	   activation	   of	   JNK	   (c-­‐Jun	   N-­‐terminal	   kinase),	   MAPK	   (p38	   mitogen-­‐activated	   protein	   kinase),	   ERK	  (extracellular	   signal-­‐regulated	   kinase),	   the	   NF-­‐κB	   nuclear	   factor	   and	   p53	  signaling	  cascades.	   It	   is	  also	  mediated	  by	  a	  concerted	  activation	  of	   the	  HSR.	  All	  these	  pathways	   lead	   to	   expression	  of	   the	  antioxidant	   enzyme	  SOD	   (superoxide	  dismutase),	   the	   thioredoxin	   reductase	   GPX	   (glutathione	   peroxidase),	   catalase	  and	  peroxiredoxins	  (61)	  (60).	  	   In	   the	  nematode	  C.	   elegans,	   the	   transcription	   factor	  SKN-­‐1,	  orhologue	  of	  the	  human	  Nrf	   (NF-­‐E2-­‐related	   factor)	   family	  proteins,	   regulates	   the	  expression	  of	   oxidative	   stress	   response	   genes	   such	   as	   SOD,	   GSTs	   (glutathione	   S-­‐transferases),	  catalase	  and	  cytochrome	  P450.	  It	  is	  also	  involved	  in	  the	  regulation	  of	  Hsps	  expression.	  In	  the	  absence	  of	  stress,	  SKN-­‐1	  up-­‐regulates	  numerous	  genes	  with	  functions	  in	  detoxification	  and	  cellular	  repair,	  while	  down-­‐regulating	  genes	  that	   promote	   stress	   resistance	   and	   lifespan.	   However,	   upon	   oxidative	   stress,	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SKN-­‐1	   induces	   the	   activation	   of	   stress	   responsive	   genes	   and	   shows	   a	   different	  activation	  program,	  showing	  a	  remarkable	  capability	   in	  adapting	  to	  the	  cellular	  challenges	  at	  hand	  (63)	  (64).	  	   	  	   All	   the	   cellular	   mechanisms	   of	   QC	   and	   stress	   responses	   act	   in	   a	  coordinated	   way,	   constantly	   attempting	   to	   maintain	   the	   cell	   in	   a	   healthy,	  homeostatic	  state.	  However,	  in	  some	  cases,	  the	  cell	  responses	  are	  insufficient	  to	  deal	   with	   accumulated	   toxicity	   that	   results	   from	   acute	   or	   chronic	   challenges.	  When	  this	  happens,	  diseases	  related	  to	  protein	  misfolding	  can	  occur.	  	  
4.	  Protein	  conformational	  disorders	  	   The	   chronic	   expression	   of	   misfolded	   proteins	   is	   a	   common	   cause	   of	  human	  disease.	  Protein	   conformational	  diseases	  occur	   through	   loss-­‐of-­‐function	  mutations	   that	   cause	   conformational	   changes	   and	   promote	   premature	   protein	  degradation;	  and	  gain-­‐of-­‐function	  disorders,	  which	  are	  caused	  by	  aberrant	  inter	  and	  intra-­‐protein	  interactions	  causing	  cell	  damage	  and	  dysfunction.	  	  
4.1.	  Loss-­of-­function	  protein	  folding	  diseases	  	   Loss-­‐of-­‐function	   conformational	   disorders	   characteristically	   derive	   from	  inherited	  mutations	   that	   lead	   to	   deficient	   folding	   of	   the	   resulting	   protein.	   This	  class	  of	   genetic	  diseases	   typically	   includes	  proteins	  processed	  by	   the	   secretory	  pathway.	  When	  mutated,	   these	   fold	   slowly,	   have	   defects	   in	   trafficking	   and	   are	  recognized	  by	  the	  cellular	  clearance	  mechanisms,	  namely	  the	  ER	  quality	  control	  (65)	   (66).	   As	   a	   consequence,	   such	   proteins	   are	   prematurely	   degraded,	   even	  though	  they	  might	  retain	  partial	  function.	  	   A	  commonly	  recognized	  loss-­‐of-­‐function	  disorder	  is	  Cystic	  Fibrosis	  (CF),	  a	  prevalent	   recessive	   genetic	   disease	  manifested	   in	   epithelial	   tissues	   of	  multiple	  organs	  and	  mostly	  connected	  to	  chronic	  lung	  disease.	  CF	  is	  caused	  by	  mutations	  in	   the	   CF	   transmembrane	   conductance	   regulator	   (CFTR),	   which	   disrupts	  trafficking	   from	   the	   ER	   to	   the	   apical	   membrane	   in	   epithelial	   tissues,	   where	   it	  normally	   functions	   as	   a	   cAMP-­‐regulated	   chloride	   channel	   (67)	   (68).	   Many	  different	  mutations	   in	  CFTR	  can	  result	   in	  CF;	  however,	  a	  single	  point	  mutation,	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the	   deletion	   of	   phenylalanine	   in	   position	   508	   of	   the	   polypeptide	   (F508del),	   is	  present	  in	  over	  90%	  of	  CF	  patients	  and	  leads	  to	  a	  severe	  form	  of	  the	  disease.	  The	  folding	  of	  F508del-­‐CFTR	  is	  kinetically	  impaired,	  causing	  retention	  at	  the	  ER	  and	  excessive	   degradation	   by	   ERAD.	   Nevertheless,	   this	  mutant	   protein	   still	   retains	  some	   function.	   Therefore,	   increasing	   the	   expression	   of	   molecular	   chaperones	  that	   help	   F508del-­‐CFTR	   reach	   the	   membrane,	   either	   genetically	   or	  pharmacologically,	  could	  be	  of	  therapeutic	  interest	  (69)	  (70).	  	   Lysosomal	   storage	   disorders,	   of	   which	   the	   most	   common	   is	   Gaucher’s	  disease,	  are	  caused	  by	  the	  excessive	  ER-­‐associated	  degradation	  of	  mutated	  and	  destabilized	   lysosomal	  enzymes	  (β-­‐glucocerebrosidase	   in	  Gaucher’s).	  Pathology	  results	  from	  an	  accumulation	  of	  the	  substrates	  of	  these	  enzymes.	  As	  in	  CF,	  these	  variant	  enzymes	  retain	  partial	  function,	  and	  efforts	  have	  been	  made	  to	  stabilize	  them	  sufficiently	  for	  proper	  cellular	  localization	  to	  be	  achieved	  (71)	  (1).	  	  
4.2.	  Gain-­of	  -­function	  protein	  folding	  disorders	  	   Protein	  misfolding	   is	   the	   central	   cause	   of	   gain-­‐of-­‐function	   diseases	   that	  lead	   to	   cellular	   dysfunction.	   When	   misfolded	   proteins	   are	   not	   promptly	  recognized	   for	   degradation,	   they	   can	   form	   protein	   aggregates	   in	   a	   time-­‐	   and	  concentration-­‐dependent	   manner.	   Various	   species	   of	   aggregate	   exist	   and,	   in	  particular,	  highly	  ordered,	  fibrilar	  β-­‐structures	  known	  as	  amyloid	  are	  a	  hallmark	  of	   many	   protein	   folding	   disorders	   (6)	   (72).	   Many	   neurodegenerative	   diseases,	  such	   as	   Alzheimer’s	   disease	   (AD),	   amyotrophic	   lateral	   sclerosis	   (ALS)	   and	  Parkinson’s	  disease	  (PD),	  are	  termed	  amyloidoses	  and	  share	  similar	  pathological	  mechanisms	  despite	  different	  causative	  proteins.	  Amyloidoses	  commonly	  feature	  genetically	   inherited	  mutations,	  a	   late	  onset	   that	  correlates	  with	  aging,	  and	   the	  loss	  of	  neuronal	  function	  by	  apoptosis	  or	  programmed	  cell	  death	  (73).	  Amyloid	  formation	  is	  also	  a	  feature	  of	  another	  set	  of	  neurodegenerative	  disorders,	  known	  as	  Polyglutamine	   (PolyQ)	  diseases,	  which	  occur	  due	   to	   the	   expansion	  of	   polyQ	  repeats	   in	   the	   causative	   proteins.	   These	   include	   Huntington’s	   disease	   (HD),	  spinocerebellar	   ataxias	   (SCA)	   and	   Kennedy	   disease	   (SBMA).	   The	   causative	  proteins	  in	  these	  disorders	  do	  not	  share	  sequence	  similarity	  and	  yet	  share	  many	  features	   of	   disease	   progression	   (74)	   (75).	   Despite	   the	   sequence	   diversity	   of	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polyglutamine	  disease	  proteins	  (besides	  the	  polyQ	  tract),	  protein	  aggregation	  is	  an	  early	  event	  that	  correlates	  with	  the	  onset	  of	  symptoms	  in	  all	  polyQ	  disorders,	  a	  characteristic	  that	  is	  shared	  with	  the	  amyloidoses.	  	   PolyQ	  length	  is	  highly	  polymorphic	  and	  expansion	  of	  the	  CAG	  (glutamine)	  tract	  above	  a	  certain	  length,	  considered	  between	  35-­‐50	  repeats	  in	  most	  diseases,	  is	   extremely	   toxic.	  Whenever	   that	   threshold	   is	   reached,	   an	   inverse	   correlation	  can	  be	  observed	  between	  the	  polyQ	  length	  and	  the	  age	  of	  disease	  onset	  (Figure	  6)	  (76).	  However,	  variation	  in	  the	  age	  of	  onset	  and	  severity	  of	  the	  disorder	  for	  a	  defined	   Q	   length	   suggests	   that	   genetic	   and	   environmental	   factors	   also	   modify	  disease	  progression	  (77).	  
	  
Figure	  6.	  The	  age	  of	  onset	  of	  PolyQ	  neurodegenerative	  diseases	  correlates	  with	  the	  length	  
of	   the	   CAG	   tract.	   Age	   of	   onset	   usually	   occurs	   at	   Q	   >	   35,	   except	   for	   SCA7.	   The	   disorders	  represented	  are	  Huntington’s	  disease	  (HD),	  Kennedy’s	  disease	  (SBMA),	  different	  spinocerebellar	  ataxias	  (SCAs)	  and	  dentatorubral-­‐pallidoluysian	  atrophy	  (DRPLA).	  The	  +	  signs	  represent	  the	  age	  of	   onset	   for	   individual	   patients	  with	   a	   certain	   Q	   length;	   circles	   represent	   the	   age	   of	   onset	   for	  homozygous	  patients,	  plotted	  against	  their	  highest	  Q	  length.	  Adapted	  from	  (76).	  	   	  	   Even	   though	   aggregates	   are	   a	   common	   feature	   of	   gain-­‐of-­‐function	  neurodegenerative	  diseases,	  it	  is	  still	  not	  fully	  understood	  whether	  they	  are	  the	  principal	   cause	   of	   pathogenesis	   (75),	   a	   benign	   consequence	   or	   even	   beneficial.	  Aggregates	  tend	  to	  be	  detrimental	  to	  cells	  by	  exhausting	  the	  free	  pool	  of	  usable	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amino	  acids,	  forming	  structures	  that	  disrupt	  cellular	  functions	  and	  sequestering	  molecular	   chaperones	   and	   other	   vital	   proteins,	   which	   leads	   to	   impairment	   of	  proteostasis	   (78).	   This	   is	   particularly	   detrimental	   for	  metastable	   proteins	   that	  are	   constantly	   in	   danger	   of	   misfolding,	   but	   would	   acquire	   their	   native	  conformation	  if	  properly	  assisted	  by	  the	  folding	  machineries	  (79).	  Despite	  these	  negative	   effects,	   it	   has	   been	   proposed	   that	   soluble	   oligomeric	   species	   are	   the	  main	  source	  of	  toxicity,	  and	  that	  further	  enhancement	  of	  their	  aggregation	  could	  be	   a	   cellular	   attempt	   to	   avoid	   additional	   toxic	   effects	   (80).	   In	   support	   of	   this	  theory,	   it	   has	   been	   shown	   that	   the	   localization	   of	   aggregates	   does	   not	   always	  match	  the	  focus	  of	  pathology	  in	  several	  aggregation-­‐related	  disorders	  (81)	  (82)	  (83)	  (84)	  (85).	  One	  possible	  explanation	  for	  these	  observations	  is	  that	  different	  species	  –	  monomers,	  soluble	  oligomeric	  intermediates	  and	  insoluble	  aggregates	  –	  all	  have	  harmful	  effects	  to	  the	  neuronal	  function,	  acting	  in	  different	  phases	  of	  the	  disease	  pathogenesis.	  	  
5.	  Proteostasis,	  disease	  and	  aging	  	   In	  the	  last	  five	  years,	  a	  better	  understanding	  of	  the	  folding	  challenges	  that	  affect	  the	  proteome	  in	  the	  crowded	  environment	  of	  a	  cell	  gave	  rise	  to	  a	  unified	  view	  of	  the	  chemistry	  of	  protein	  (mis)folding,	  together	  with	  regulated	  networks	  described	   for	   synthesis,	   folding,	   trafficking,	   disaggregation	   and	   degradation.	  These	   interacting	   and	   sometimes	   competing	   biological	   pathways	   maintain	  proteostasis	   (protein	   homeostasis),	   either	   alone	   or	   collectively	   (86).	  Transcriptional	   and	   translational	   changes	   act	   together	   to	   control	   the	  concentration,	  conformation,	  interactions	  and	  location	  of	  the	  individual	  proteins	  that	   compose	   the	  proteome.	  As	  a	   consequence,	   the	   innate	  biology	  of	   the	   cell	   is	  readapted.	  Maintenance	  of	  proteostasis	  is	  essential	  throughout	  development	  and	  aging,	   as	   multiple	   factors	   of	   stress	   accumulate	   in	   an	   organism	   either	   from	   an	  intrinsic	  propensity	  for	  misfolding	  or	  from	  diverse	  environmental	  insults.	  In	  fact,	  the	  gradual	  collapse	  of	  proteostasis	  is	  an	  early	  event	  in	  aging	  (87).	  	   In	   the	   face	   of	   all	   the	   challenges	   described	   above,	   it	   is	   the	   role	   of	   the	  proteostasis	  network	  (PN)	  to	  help	  keep	  organismal	  homeostasis.	  This	  network	  is	  composed	  of	  over	  1,000	  general	   and	   specialized	  molecular	   chaperones,	   folding	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enzymes,	  trafficking	  and	  degradation	  components	  (Figure	  7).	  For	  the	  control	  of	  the	   PN,	  many	   stress	   sensors	   and	   signaling	   pathways	   are	   necessary	   to	   regulate	  the	  concentration,	  distribution	  and	  activities	  of	   these	  components.	  By	  doing	  so,	  they	  also	  control	   the	  relative	  activities	  of	   the	  different	  biological	  pathways	  that	  make	  up	  the	  network	  (1).	  The	  PN	  is	  composed	  of	  proteins	  involved	  in	  the	  above-­‐described	  HSR,	   ER	   and	  mitochondrial	  UPR,	   oxidative	   stress	   response	   and	  UPS,	  but	   also	   in	   other	   stress	   pathways	   like	   caloric	   restriction	   and	   inflammatory	  signaling.	  
	  
Figure	  7.	  The	  proteostasis	  network	  (PN)	  influences	  the	  fate	  of	  folded	  proteins.	  An	  unfolded	  polypeptide	  chain	  can	  have	  different	  destinations,	  assisted	  by	  cellular	  proteostasis.	  The	  various	  pathways	   (red	   arrows)	   composing	   the	   PN	   interact	   and	   compete	   and	   can	   be	   assisted	   by	  proteostasis	  regulators	  (magenta	  circles).	  These	  regulators	  can	  manipulate	  the	  network	  and	  alter	  the	   outcome	   of	   loss-­‐	   and	   gain-­‐of-­‐function	   conformational	   diseases.	   Some	   steps	   of	   folding	   and	  trafficking	   can	   also	   be	   assisted	   by	   pharmacological	   chaperones	   (green	   squares).	   Adapted	   from	  (86).	  	   	  	   Like	   the	   proteome	   making	   up	   individual	   cells,	   maintenance	   of	  proteostasis	  seems	  to	  vary	  across	  different	  cells	  and	  tissues.	  Some	  cell	  types,	  like	  neurons,	   are	   more	   sensitive	   to	   the	   toxicity	   of	   misfolding	   and	   aggregating	  proteins,	   thus	   displaying	   specific	   needs	   for	   their	   proteostasis.	   This	   provides	   a	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good	   explanation	   for	   the	   late	   onset	   of	  most	   neurodegenerative	   diseases,	  when	  the	   PN	   capacity	   is	   diminished.	   Recently,	   there	   have	   been	   promising	   efforts	   to	  restore	   and/or	   increase	   the	   efficiency	   of	   the	   PN	   network	   for	   the	   treatment	   of	  protein	  conformational	  diseases,	  aiming	  at	  the	  prevention,	  delay	  or	  alteration	  of	  their	   clinical	   course	   (86)	   (88).	   These	   are	   based	   on	   a	   concept	   of	   “proteostasis	  boundary”	   (1),	   that	   assumes	   there	   is	   a	   borderline	   for	   the	   folding	   energetics	  needed	   to	   achieve	   proper	   folding	   of	   a	   protein,	   assisted	   by	   a	   quantified	  proteostasis	  capacity.	  Three	  main	  factors	  can	  alter	  the	  proteostasis	  boundary,	  at	  a	   given	   state	   of	   homeostasis	   in	   the	   cell	   and	   for	   each	   protein:	   the	   folding	   rate	  kinetics,	  the	  unfolding	  rate	  kinetics	  and	  the	  innate	  thermodynamical	  stability	  of	  that	   protein.	   The	   fact	   that	   this	   is	   a	   product	   of	  multiple	   variables	   helps	   explain	  how	   sometimes	   proteostasis	   capacity	   is	   overwhelmed	   and	   conformational	  diseases	  ensue.	  	  
5.1.	  Small	  molecules	  affecting	  proteostasis	  	   Genetic	   approaches	   have	   demonstrated	   that	   increasing	   levels	   of	  chaperones,	   either	   alone	   or	   in	   combination,	   are	   beneficial	   to	   many	   protein	  folding	  disorders.	  However,	  for	  these	  findings	  to	  translate	  to	  the	  clinic	  we	  must	  develop	   small	   molecules	   that	   can	   enhance	   proteostasis	   by	   mimicking	   the	  function	   of	  molecular	   chaperones.	   Two	  kinds	   of	   small	  molecule	   pharmacologic	  agents	   have	   been	   described	   in	   the	   literature	   that	   can	   improve	   proteostasis.	  Pharmacological	   chaperones	   (PCs)	   have	   the	   ability	   to	   increase	   stability	   of	   a	  specific	  protein,	  whereas	  proteostasis	  regulators	  (PRs)	  have	  a	  broader	  effect	  on	  moving	   the	  proteostasis	  boundary	   itself,	   allowing	   for	   inclusion	  of	   an	   in-­‐danger	  protein	  back	  into	  the	  proper	  folding	  and	  higher	  stability	  environment	  (Figure	  7)	  (1).	   In	   this	   context	   of	   the	   proteostasis	   boundary,	   loss-­‐	   or	   gain-­‐of-­‐function	  conformational	  diseases	  can	  be	  seen	  as	  the	  result	  of	  proteins	  that	  have	  an	  altered	  folding	  energetics,	  causing	  them	  to	  be	  excluded	  from	  the	  proteostasis	  boundary	  (Figure	  8A).	  	   Pharmacological	   chaperones	   or	   PCs	   will	   bind	   to	   a	   protein	   and	   directly	  affect	  their	  folding	  energetics,	  either	  by	  increasing	  its	  folding	  rate,	  decreasing	  its	  misfolding	  rate	  or	  by	  enhancing	  its	  stability	  (the	  most	  common	  mechanism).	  This	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way,	   the	   at-­‐risk	   protein	   is	   brought	   back	   into	   a	   homeostasis	   environment	   and	  allowed	   to	   function	   (Figure	   8B).	   	   The	   effect	   of	   PCs	   should	   be	   effective	   in	   the	  context	   of	   most	   proteostasis	   networks,	   since	   it	   represents	   an	   effect	   on	   the	  problematic	  protein	  itself	  (1).	  
	  
Figure	   8.	   Proteostasis	   boundary	   in	   diseases	   of	   protein	   conformation.	   In	   the	   cellular	  environment,	  most	  proteins	  (green	  nodes)	  possess	  enough	  stability	  (red	  axis),	  a	  fast	  folding	  rate	  (green	  axis)	  and	  a	  slow	  misfolding	  rate	  (blue	  axis)	  that	  allow	  them	  to	  stay	  within	  the	  proteostasis	  boundary	  (in	  purple).	  (A)	  Aggregation	  prone	  proteins	  with	  gain-­‐of-­‐toxic-­‐function	  (black	  node)	  or	  mutated	  proteins	  that	  result	  in	  loss-­‐of-­‐function	  diseases	  (red	  node)	  fall	  outside	  the	  boundary.	  (B)	  Pharmacological	   chaperones	   (PCs)	   generally	   bind	   to	   an	   at-­‐risk	   protein	   to	   improve	   stability,	  folding	   rate	   or	   misfolding	   rate,	   bringing	   it	   inside	   the	   proteostasis	   boundary.	   (C)	   Proteostasis	  regulators	  (PRs)	  can	  extend	  the	  proteostasis	  boundary	  and	  help	   include	  defective	  proteins	  that	  were	   not	   included;	   other	   PRs	   could	   constrict	   the	   boundary,	   by	   favoring	   PN	   components	   that	  activate	  misfolding	  and/or	  degradation.	  	   	  	   PCs	  have	  been	  shown	  to	  provide	  exciting	  results	   in	   the	   treatment	  of	   the	  F508del-­‐CFTR	  mutant.	  An	  example	  are	  polyaromatic	  compounds	  identified	   in	  a	  high-­‐throughput	   screen	   (HTS)	   for	   the	   improvement	   of	   chloride	   current	   in	  epithelial	   cells	   expressing	   F508del-­‐CFTR	   (89).	   Some	   of	   these	   compounds,	   like	  corr-­‐2b	   or	   corr-­‐4a,	   have	   been	   shown	   to	   stabilize	   the	   mutant	   CFTR	   at	   the	   ER,	  allowing	   for	  a	  more	  efficient	   transport	   into	   the	  membrane,	  where	   it	  will	   retain	  some	   function	  (90).	  This	   is	   similar	   to	   the	  example	  shown	   in	  Figure	  8B,	  moving	  the	  red	  node	  along	  the	  stable	  end	  of	   the	  red	  axis.	  For	  Gaucher’s	  disease,	   it	  was	  demonstrated	  that	  stabilization	  of	  β-­‐glucocerebrosidase	  could	  be	  achieved	  by	  N-­‐(n-­‐nonyl)deoxynojirimycin	  (NN-­‐DNJ).	  Stabilization	  allowed	  improved	  trafficking	  into	   the	   lysosome	  and	  some	   function,	  albeit	  with	  reduced	  specific	  activity	  (91).	  Pharmacological	   chaperones	   were	   also	   shown	   to	   improve	   gain-­‐of-­‐function	  diseases.	  This	  is	  the	  case	  of	  transthyretin	  (TTR)	  kinetic	  stabilizers	  that	  favor	  the	  non-­‐amyloidogenic	   native	   state	   (a	   tetramer)	   over	   the	   misfolding-­‐prone	  transition	  state	  of	  mutant	  TTR	  (the	  monomer),	   slowing	  down	  or	  preventing	   its	  aggregation	  and	  ameliorating	  the	  TTR	  amyloidoses	  (92)	  (93).	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   The	   advantage	   of	   PRs	   is	   that	   by	   promoting	   adjustments	   in	   the	  proteostasis	   boundary	   itself,	   they	   might	   be	   functional	   for	   a	   group	   of	  conformational	   diseases	   that	   share	   a	   similar	   PN,	   for	   example	   for	   affecting	   the	  same	   tissue,	   the	   same	   cellular	   organelle	   or	   function	   (86).	   PRs	   described	   until	  now	   favor	   the	   expansion	   of	   the	   proteostasis	   boundary,	   which	   helps	   to	   rescue	  misfolding	   proteins	   that	   were	   previously	   excluded	   from	   it.	   The	   accepted	  hypothesis	   is	   that	   boundary	   expansion	   occurs	   mainly	   by	   changing	   the	   levels,	  activity	  or	  distribution	  of	  the	  core	  PN	  chaperones,	  for	  example	  Hsp70	  or	  Hsp90.	  This	  can	  happen	  as	  a	  result	  of	  HSR	  or	  UPR	  induction,	  both	  of	  which	  result	  in	  an	  increase	  of	  PN	  capacity	  (61)	  (50).	  When	  a	  more	  localized	  or	  focused	  adjustment	  of	  the	  proteostasis	  boundary	  would	  be	  favored	  over	  a	  global	  PN	  alteration,	  PRs	  that	   directly	   target	   co-­‐chaperones	   could	   be	   used.	   These	   would	   induce	   more	  selective,	  rather	  than	  general,	  alterations	  in	  the	  core	  QC	  machineries	  (1).	  	   Several	  PRs	  have	  been	  described	   that	   activate	   the	  HSR	  and	  other	   stress	  responses.	   One	   notable	   example	   is	   the	   quinone	   methide	   triterpene	   celastrol,	  initially	  identified	  in	  a	  screen	  for	  neuroprotection	  in	  Huntigton’s	  disease	  models	  (94).	   It	   is	  believed	  that	  celastrol	   is	   thiol-­‐reactive	  and	  acts	   through	   formation	  of	  disulfide	   bonds	   in	   free	   thiol	   groups	   of	   target	   proteins,	   activating	   not	   only	  HSR	  but	   also	   the	   antioxidant	   response	   (95).	   Recently,	   a	   HTS	   of	   ≈	   900,000	   small	  molecules	   uncovered	   new	   classes	   of	   PRs	   that	   activated	   the	   HSR.	   These	   new	  compounds	  rescued	  protein	  aggregation	  phenotypes,	  across	  multiple	  models	  of	  conformational	  diseases	  and	  acted	  by	  mechanisms	  distinct	   from	  the	  previously	  described	  activators	  of	  the	  HSR.	  In	  particular,	  the	  small	  molecule	  F1,	  identified	  in	  that	  screen,	  showed	  the	  remarkable	  ability	  to	   improve	  aggregation	  and	  toxicity	  phenotypes	   in	   cytosolic	   and	  ER	  models	  of	  misfolding.	  This	   constitutes	   the	   first	  characterized	  small	  molecule	  that	  enhances	  correct	   folding	  in	  two	  different	  cell	  compartments	   (96)	   and	   motivated	   the	   studies	   described	   in	   chapter	   2	   of	   this	  thesis.	  	   In	  addition	  to	  modulation	  of	  the	  classical	  stress	  pathways,	  some	  PRs	  have	  been	  identified	  that	  act	  on	  other	  targets,	  but	  have	  similar	  effects	  in	  the	  rescue	  of	  misfolding	  toxicity.	  AGK2	  was	  identified	  as	  a	  potent	  inhibitor	  of	  SIRT2,	  a	  member	  of	  the	  histone	  deacetylases	  family.	  Activity	  of	  AGK2	  resulted	  in	  the	  rescue	  of	  α-­‐synuclein	  induced	  toxicity	  and	  also	  in	  modification	  of	  the	  inclusion	  morphology	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in	   a	   cell-­‐based	   model	   of	   Parkinson’s	   disease	   (97).	   Even	   though	   the	   molecular	  mechanisms	  of	  this	  compound	  were	  not	  fully	  clear,	  it	  supported	  the	  finding	  that	  SIRT2-­‐dependent	   inhibition	   of	   histone	   acetylation	   was	   associated	   with	   an	  increase	  of	  neurotoxicity	  (98).	  	   A	  link	  from	  molecular	  chaperones	  to	  cancer	  has	  also	  been	  established.	  In	  a	  wide	   range	  of	   tumor	   types,	   the	   levels	  of	  Hsps	  were	   found	   to	  be	  upregulated.	  This	   was	   observed	   for	   members	   of	   the	   Hsp70	   family	   (99)	   (100)	   (101)	   (102),	  Hsp90	   (103)	   (104),	  or	  other	   families	   (105).	  However,	   it	   remains	  unclear	   if	  Hsp	  up-­‐regulation	   is	   a	   cause	   or	   effect	   in	   tumorigenesis	   (106).	   Cancer	   cells	   exhibit	  high	   rates	   of	   protein	   synthesis	   due	   to	   an	   unregulated	   cell	   division	   control,	  leading	   to	   a	   higher	   load	  of	  misfolded	  proteins	   (107).	   Theoretically,	   contracting	  the	  proteostasis	  boundary	  in	  these	  cells	  could	  lead	  to	  loss	  of	  function	  of	  various	  proteins	   that	  were	   in	   its	  edge	  due	   to	   their	   folding	  energetics.	  This	  strategy	  has	  the	   potential	   to	   lead	   to	   the	   exclusive	   cell	   death	   of	   the	   cancer	   cells,	   without	  significant	   effect	   in	   the	   normal	   cell	   physiology,	   and	  would	   be	   of	   great	  medical	  interest	  (1).	  	  
5.2.	  Chemical	  genetics	  efforts	  to	  ameliorate	  proteostasis	  	   In	   the	   pipeline	   of	   small	   molecule	   development,	   many	   studies	   turn	   to	  structure-­‐activity	   relationship	   (SAR)	   as	   a	   way	   to	   uncover	   the	   mechanism	   of	  action	   of	   these	   compounds,	   or	   even	   to	   perfect	   previously	   described	   chemicals	  into	  drugs	  applicable	  for	  human	  disease	  treatment.	  	   Celastrol	  analogues	  have	  been	  designed	  as	  a	  tool	  to	  create	  suitable	  affinity	  tools	  that	  allowed	  identifying	  its	  binding	  partners	  in	  the	  cell	  as	  Annexin	  2,	  eEF1A	  (eukaryotic	   translation	  elongation	   factor	  1A)	   and	   tubulin.	  The	   same	   study	  also	  created	  a	  structural	  map	  of	  how	  alterations	  in	  the	  structure	  of	  celastrol	  impacted	  the	  activation	  of	  the	  HSR	  and	  the	  oxidative	  stress	  response	  (108).	  The	  design	  of	  analogues	  for	  previously	  described	  small	  molecules	  was	  also	  successfully	  used	  to	  create	  a	  new	   lead	   series	   scaffold	   for	   improving	   inhibition	  of	   the	  SIRT2	  histone	  deacetylase.	   In	   this	   case,	   compound	   AGK2	   showed	   a	   10-­‐fold	   improvement	   in	  potency	   over	   compound	   B2.	   AGK2	   was	   then	   shown	   to	   rescue	   α-­‐synuclein-­‐mediated	  toxicity	  and	  improve	  aggregation	  phenotypes	  in	  models	  of	  Parkinson’s	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disease	   (97).	   A	   different	   study	   used	   chemical	   modifications	   of	   arylsulfanyl	  pyrazolone	   (ASP),	   previously	   described	   to	   ameliorate	   ALS	  models	   by	   blocking	  SOD1	   cytotoxicity	   and	   protein	   aggregation,	   to	   create	   derivative	   analogues	   that	  showed	  efficacy	  in	  an	  ALS	  mouse	  model,	  creating	  a	  new	  therapeutic	  lead	  for	  the	  treatment	   of	   this	   neurodegenerative	   disease	   (109).	   The	   same	   laboratory	   also	  identified	   barbiturate-­‐like	   derivatives	   of	   pyrimidine-­‐2,4,6-­‐trione	   as	   a	   chemical	  scaffold	   with	   the	   potential	   to	   become	   new	   drug	   candidates	   for	   use	   in	   clinical	  trials	   for	   ALS	   (110).	   Interestingly,	   this	   is	   the	   chemical	   group	   of	   the	   F-­‐class	  compounds	   identified	   by	   Calamini	   and	   colleagues	   (96).	   Another	   clue	   to	   the	  importance	  of	  chemical	  genetics	  efforts	  in	  treating	  proteostasis-­‐related	  diseases	  came	  from	  the	  barbiturate-­‐like	  small	  molecule	  thiopental,	  which	  was	  reported	  to	  protect	   human	   T	   Lymphocytes	   from	   apoptosis.	   In	   an	   apparent	   link	   with	   the	  proteostasis	   network,	   this	   protection	   mechanism	   was	   linked	   with	   HSF1-­‐dependent	   up-­‐regulation	   of	   Hsp70.	   In	   addition,	   this	   activation	   proved	   to	   be	  specific	  to	  the	  chemistry	  of	  thiopental,	  as	  the	  related	  analogue	  pentobarbital	  lost	  the	   capability	   of	   inducing	   HSR	   (111).	   All	   these	   findings	   are	   examples	   of	   the	  usefulness	  of	  adapting	  chemistry	  of	  small	  molecules	   for	  a	  better	  understanding	  of	  their	  mechanism	  of	  action.	  	  
5.3.	  C.	  elegans	  as	  a	  model	  for	  understanding	  proteostasis	  and	  disease	  	  As	   a	   model	   system,	   the	   nematode	   Caenorhabditis	   elegans	   serves	   as	   a	  bridge	   between	   the	   complexity	   of	   vertebrate	   models	   like	   the	   mouse	   and	   the	  simplicity	   of	   unicellular	   models	   such	   as	   bacteria	   or	   yeast.	   Worms	   have	   been	  widely	   used	   to	   develop	  models	   of	   protein	   aggregation,	   resulting	   in	   invaluable	  tools	   for	   a	  better	   comprehension	  of	   proteostasis	   and	   conformational	  disorders	  that	  affect	  the	  human	  population.	  Some	  examples	  are	  the	  PolyQ	  worm	  models	  in	  which	   polyglutamine	   fused	   to	   YFP	   is	   expressed	   in	   muscle	   cells	   (112)	   and	  neuronal	  cells	  (113);	  a	  neuronal	  SOD1-­‐G85R	  model	  for	  ALS	  (114);	  a	  beta-­‐amyloid	  expressed	   in	  muscle	   cells	   for	  Alzheimer’s	  disease	   (115);	   a	  Parkinson’s	  disease-­‐related	  α-­‐synuclein	  expressed	  in	  muscle	  cells	  (116);	  or	  a	  full-­‐length	  ataxin-­‐3,	  the	  protein	   involved	   in	   Machado-­‐Joseph	   disease,	   in	   neurons	   (117).	   Among	   other	  uses,	   these	   models	   have	   proved	   invaluable	   in	   adding	   to	   our	   knowledge	   of	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molecular	  chaperones,	  quality	  control	  mechanisms,	  cellular	  stress	  responses	  and	  genetic	  or	  pharmacological	  maintenance	  of	  proteostasis	  (96).	  
C.	  elegans	  is	  a	  free	  living,	  non-­‐pathogenic	  and	  soil	  living	  nematode,	  widely	  employed	  as	  a	  laboratory	  model	  organism.	  It	  feeds	  essentially	  on	  bacteria	  and,	  in	  optimal	   conditions,	   its	   life	   cycle	   has	   approximately	   3	   days,	   with	   an	   average	  lifespan	  of	  2-­‐3	  weeks	  (118).	  Initial	  studies	  with	  C.	  elegans	  were	  made	  by	  Sidney	  Brenner	   in	   1963	   (119)	   and,	   as	   of	   today,	   it	   is	   the	   most	   meticulously	   studied	  multicellular	   organism.	   In	   addition,	   C.	   elegans	   was	   also	   the	   first	   metazoan	  organism	  to	  have	  its	  genome	  fully	  sequenced	  (C.	  elegans	  Sequencing	  Consortium,	  1998).	  Both	  forward	  and	  reverse	  genetics	  are	  easy	  to	  perform	  with	  C.	  elegans,	  as	  well	   as	   the	   production	   of	   transgenic	   lines;	   also,	   many	   phenotypes	   can	   be	  observed	  directly	  by	  visualization	  since	  its	  body	  is	  transparent	  (Figure	  9)	  (120).	  
	  
Figure	  9.	  Anatomy	  of	  an	  adult	  hermaphrodite	  C.	  elegans	  nematode.	  (A)	  DIC	  image	  of	  the	  left	  lateral	   side,	  next	   to	  2	  eggs.	  The	  organs	  of	   the	  animal	  are	  visible,	  due	   to	   the	   transparency	  of	   its	  body.	  (B)	  Scheme	  of	  prominent	  anatomical	  structures	  in	  the	  body	  of	  a	  worm.	  Image	  taken	  from	  the	  WormAtlas.	  (http://www.wormatlas.org).	  	  
6.	   Using	   HTP	   and	   chemical	   genetics	   for	   new	   treatments	   of	  
neurodegenerative	  diseases	  	   In	   the	  wake	   of	   astonishing	  progresses	   in	  medicine,	   nutrition	   and	  public	  health,	  the	  average	  human	  lifespan	  has	  almost	  doubled	  since	  the	  early	  1900s.	  For	  example,	   the	  median	   life	  expectancy	   is	  now	  of	  78.49	   for	   the	  U.S.A.	  and	  78.7	   for	  Portugal	   (https://www.cia.gov/library/publications/the-­‐world-­‐factbook/,	   The	  CIA	   World	   Factbook).	   In	   fact,	   most	   people	   from	   developed	   countries	   are	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expected	   to	   live	   beyond	   their	   70s	   and	   life	   expectancy	  might	   exceed	   85	   by	   the	  year	   2050	   (121).	   However,	   as	   the	   number	   of	   aged	   individuals	   increases,	   so	   to	  does	   the	   prevalence	   of	   age-­‐associated	   diseases.	   With	   the	   tendencies	   set	   to	  remain	  the	  same,	  a	  better	  understanding	  of	  neurodegenerative	  diseases	  and	  the	  discovery	  of	  new	   treatments	  are	  of	   crucial	   importance.	  Furthermore,	   the	  aging	  process	   has	   been	   associated	   with	   a	   failure	   to	   maintain	   protein	   QC	   and	   lower	  capacity	  of	  the	  HSR	  and	  UPR,	  which	  may	  explain	  the	  increased	  misfolding	  events	  and	   accumulation	   of	   misfolded	   proteins	   that	   accompany	   aging	   (57)	   (87).	   This	  provides	  another	  important	  link	  between	  aging,	  protein	  conformational	  diseases	  and	  maintenance	  of	  proteostasis.	  	   High-­‐throughput	  screens	  (HTS)	  have	  been	  successfully	  used	  for	  revealing	  key	  components	  of	  proteostasis	  at	  the	  genetic	  level	  (122)	  (123).	  Other	  HTS	  led	  to	  the	   discovery	   of	   small	   molecules	   with	   potential	   applications	   for	  neurodegenerative	  diseases	  (109)	  (110)	  (96).	  	  	   	  
7.	  Aims	  of	  the	  present	  work	  	   The	   overall	   aim	   of	   the	   current	   study	   is	   to	   contribute	   to	   a	   better	  understanding	  of	  how	  chemical	  manipulation	  of	  the	  proteostasis	  network	  can	  be	  used	   for	   potential	   therapeutics	   for	   human	   diseases	   of	   protein	   conformation,	  namely	  neurodegenerative	  disorders	  and	  loss-­‐of-­‐function	  diseases	  such	  as	  cystic	  fibrosis.	  	  	   The	  specific	  objectives	  of	  the	  current	  work	  are:	  1. To	  further	  develop	  a	  previously	  described	  and	  promising	  small	  molecule	  hit,	  F1	   (96),	  by	  understanding	   its	   chemical	   features,	   effects	  on	  proteostasis	  and	  its	  mechanism	  of	  action	  (Chapter	  III).	  2. To	   screen	   a	   new	   chemical	   library,	   designed	   to	   be	   skeletally	   diverse,	   to	  identify	   new	   small	   molecule	   regulators	   of	   the	   HSR	   in	   three	   classes	   –	  activators,	   inhibitors	   and	   co-­‐activators	   –,	   with	   the	   goal	   of	   making	   them	  applicable	   for	   the	   study,	   or	   even	   treatment,	   of	   loss-­‐	   or	   gain-­‐of-­‐function	  conformational	  diseases	  (Chapter	  IV).	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II – Materials and Methods 	  	  
1.	  Compounds	  The	  barbiturate-­‐like	  small	  molecules	  used	  in	  this	  work	  were	  synthesized	  by	  Dr.	  Soosung	  Kang	  in	  the	  Silverman	  Laboratory,	  Northwestern	  University	  and	  purified	   by	   HPLC.	   F1	   was	   also	   synthesized	   and	   is	   comparable	   to	   the	  commercially	   available	   5-­‐[3-­‐(4-­‐Methoxyphenyl)-­‐2-­‐propen-­‐1-­‐ylidene]-­‐2,4,6(1H,3H,5H)-­‐Pyrimidinetrione,	   CAS	   100872-­‐83-­‐1,	   ChemBridge	   5772104,	  which	  was	   only	   used	   in	   the	   rat	   brain	   slices	   and	   co-­‐culture	   experiments.	   Other	  barbiturates	   were	   previously	   not	   described.	   All	   new	   small	   molecules	   were	  prepared	  as	  10mM	  stocks	  in	  100%	  DMSO.	  17-­‐N-­‐Allylamino-­‐17-­‐demethoxygeldanamycin	   (17-­‐AAG,	   A.G.	   Scientific,	  Inc.,	   San	   Diego,	   CA,	   USA),	   a	   derivative	   of	   Geldanamycin	   and	   an	   inhibitor	   of	  HSP90,	  was	  used	  as	  a	  positive	  control	  for	  activation	  of	  the	  heat-­‐shock	  response	  in	   nematodes	   (96).	   MG132	   (AG	   Scientific,	   San	   Diego,	   CA,	   USA),	   a	   proteasome	  inhibitor,	   and	   CdCl2	   (Sigma,	   St.	   Louis,	   MO,	   USA),	   inducer	   of	   the	   heavy	   metal	  stress	  response,	  were	  used	  as	  positive	  control	   for	  activation	  of	   the	  HSR	  for	  cell	  based	   assays.	   Triptolide	   (AG	   Scientific),	   a	   diterpene	   triepoxide	   extracted	   from	  the	  plant	  Triptergium	  wilfordii,	  was	  used	  as	   a	   control	   for	   inhibition	  of	   the	  HSR	  (124).	   Tunicamycin	   (EMD	   Millipore,	   Darmstadt,	   Germany)	   was	   the	   substance	  used	  as	  a	  reference	  for	  activation	  of	  the	  unfolded	  protein	  response	  (UPR).	  Compounds	  for	  the	  HTP	  screen	  were	  from	  the	  Kozmin	  Laboratory	  library	  and	   are	   the	   property	   of	   the	   Chicago	   Tri-­‐Institutional	   Center	   for	   Chemical	  Methods	  and	  Library	  Development	  (CTCMLD)	  as	  described	  in	  (125).	  	  
2.	  Cell	  cultures	  Mammalian	   cell	   lines	   used	   in	   this	   study	   were:	   HeLa-­‐luc	   cells,	   a	   stable	  HeLa	   cell	   line	   that	   contains	   a	   heat	   shock–inducible	   reporter	   construct	   derived	  from	  the	  Hsp70.1	  promoter	   sequence,	   fused	   to	  a	   luciferase	   reporter	   (126);	  WT	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and	   hsf-­1-­/-­	   MEF	   cells	   (127);	   Neuro2A	   neuroblastoma	   cells	   (128);	   C2C12	  myoblast	  cells	  (129).	  Neuro2A,	   C2C12	   and	   HeLa-­‐luc	   cells	   were	   maintained	   in	   Dulbecco’s	  modified	   Eagle’s	   medium	   (DMEM,	   Invitrogen,	   Carlsbad,	   CA)	   with	   phenol	   red	  buffered	  with	  HEPES	  and	  supplemented	  with	  10%	  v/v	  fetal	  bovine	  serum	  (FBS),	  1%	  L-­‐glutamine,	  and	  100	  U/ml	  penicillin/streptomycin.	  HeLa-­‐luc	  cells	  were	  also	  supplemented	   with	   100	   μg/ml	   of	   G418.	   MEF	   cells	   were	  maintained	   in	   DMEM	  supplemented	   with	   10%	   FBS,	   0.1	   mM	   nonessential	   amino	   acids,	   100	   U/ml	  penicillin/streptomycin	  and	  55	  μM	  2-­‐	  mercaptoethanol.	  All	  cells	  were	  cultured	  at	  37°C	  with	  a	  5%	  CO2	  atmosphere.	  	  
3.	  C.	  elegans	  strains	  Nematode	  worms	  were	  maintained	  at	  20°C	  on	  Nematode	  Growth	  Media	  (NGM)	  plates	  seeded	  with	  OP50	  E.	  coli	  bacteria	  as	  a	  food	  source,	  according	  to	  the	  standard	  methods	   described	   by	   Sidney	   Brenner	   (119).	   The	   wild-­‐type	   (wt)	   N2	  Bristol	   strain	   was	   obtained	   from	   the	   C.	   elegans	   Genetic	   Center	   (CGC).	   The	  polyglutamine	   strain	   that	   expresses	   a	   stretch	  of	  35	  CAG	   repeats	   in	   fusion	  with	  the	  Yellow	  Fluorescence	  Protein	  (YFP)	  in	  muscle	  cells	  (Q35::YFP,	  rmIs132[Punc-­
54::q35::yfp]I)	   was	   described	   in	   (112)	   (CGC	   strain	   AM140)	   and	   the	   strain	  expressing	   67	   CAG	   repeats	   in	   fusion	  with	   YFP	   in	   neurons	   (Q67::YFP,	   rmIs282	  [PF25B3.3::q67::yfp])	   in	   (113)	   (AM714).	   The	   worms	   expressing	   the	   full	   human	  ataxin-­‐3	  gene	  with	  130	  CAG	  repeats,	  or	  AT3q130,	  in	  fusion	  with	  YFP,	  in	  neuron	  cells	  (rmls263[PF25B3.3::AT3v1-­‐1q130::yfp),	  were	  described	  in	  (117)	  (AM685),	  as	  were	  the	  nematodes	  with	  the	  same	  construct	  but	  only	  14	  CAG	  repeats:	  AT3q14	  (rmls227[PF25B3.3::AT3v1-­‐1q14::yfp,	  AM509).	  	  
4.	  Cell-­based	  determination	  of	  small	  molecule	  activity	  This	   assay	  was	   adapted	   from	   (96)	   and	   performed	   in	   the	   384-­‐well	   plate	  format.	   HeLa-­‐luc	   cells	   with	   a	   heat	   shock–inducible	   reporter	   construct	   derived	  from	  the	  Hsp70.1	  promoter	  sequence,	   fused	  to	  a	   luciferase	  reporter	  (Figure	  1),	  were	  dispensed	  into	  white	  tissue	  culture	  treated	  384-­‐well	  plates	  at	  a	  density	  of	  1750	   cells/well,	   in	   25μl	   assay	   medium	   using	   a	   ViaFILL	   automated	   dispenser	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Figure	  1.	   (A)	  HeLa	   luc	  reporter	  cells	  have	  a	  heat	  shock-­inducible	  construct	  derived	   from	  
the	  Hsp70	  promoter	  sequence,	   fused	  to	   luciferase	  (adapted	  from	  (126)	  );	  (B)	  Conversion	  
of	   D-­luciferin	   into	   Oxyluciferin,	   by	   the	   action	   of	   luciferase,	   originates	   a	   luminescence	  
signal	  in	  the	  reporter	  assay	  (image	  from	  Perkin	  Elmer).	  	  
5.	  Cytoxicity	  Assays	  In	   parallel	   with	   the	   determination	   of	   activity,	   we	   performed	   cytoxicity	  assays	   for	   the	   same	   compoundsm	   using	   the	   Calcein	   AM	   method	   (Invitrogen).	  Calcein	   AM	   is	   a	   cell-­‐permeant	   dye	   used	   to	   determine	   cell	   viability.	   In	   live	  eukaryotic	   cellsm,	   the	   nonfluorescent	   calcein	   AM	   is	   converted	   to	   a	   green-­‐fluorescent	   calcein	   after	   acetoxymethyl	   ester	   hydrolysis	   by	   intracellular	  
!"
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esterases	   (Figure	   2).	   HeLa-­‐luc	   cells	  were	   prepared	   in	   the	   same	  manner	   as	   the	  previous	  section,	  but	  plated	  in	  black,	  transparent	  bottom,	  384-­‐well	  plates.	  After	  compound	   addition	   and	   incubation,	   cells	   were	   washed	   2x	   with	   50μl	   PBS	   and	  then	  50μl	  of	  a	  solution	  of	  1μg/ml	  if	  calcein	  AM	  was	  added	  to	  each	  well,	  using	  a	  Biomek	   FX	   automated	   liquid	   handler	   with	   a	   multichannel	   head	   (Beckman	  Coulter	   Inc.).	   Assay	   plates	   were	   incubated	   for	   30min	   at	   37°C,	   5%	   CO2	   and	  fluorescence	   was	   measured	   in	   a	   Synergy	   4	   multimode	   plate	   reader	   (BioTek	  Instruments,	   Inc.,	   Winooski,	   VT,	   USA).	   Percent	   cytotoxicity	   was	   calculated	  relative	   to	  wells	   that	  were	   added	  DMSO	   only	   (100%	   or	   survival).	   The	  median	  lethal	  dose	  (LD50)	  of	  each	  small	  molecule	  was	  calculated	  using	  Prism.	  	  
	  
Figure	   2.	   The	   non	   fluorescent	   dye	   Calcein	   AM	   is	   converted	   into	   fluorescent	   Calcein	   by	  
intracellular	   esterases.	   Calcein	   only	   remains	   in	   the	   cytosol	   of	   cells	   with	   intact	   membranes,	  constituting	   a	   method	   for	   performing	   cytotoxicity	   assays	   (image	   from	  http://bio530.wikispaces.com/Calcein+AM).	  	  
6.	  RNA	  extraction	  in	  cells	  and	  semi-­quantitative	  RT-­PCR	  For	   treatment	   with	   compounds	   and	   RNA	   extraction,	   MEF,	   C2C12	   and	  Neuro2A	  cells	  were	  plated	  into	  24-­‐well	  plates	  at	  a	  density	  of	  40000	  cells/well,	  in	  400μl	   assay	  medium.	  The	  multi-­‐well	   plates	  were	   incubated	   at	   37°C	  with	   a	   5%	  CO2	  atmosphere	  for	  24h.	  The	  small	  molecules	  were	  prepared	  to	  100x	  of	  the	  final	  concentration	  desired	  and	  4μl	  of	  each	  were	  added	  to	  each	  assay	  well.	  The	  cells	  were	   incubated	   with	   the	   compounds	   for	   4h.	   Alternatively,	   in	   cases	   where	  inhibitors	  or	  co-­‐activators	  of	   the	  HSR	  were	  being	   tested,	  compounds	  were	   first	  added	  to	   the	  cells	   for	  1h,	  after	  which	   the	  agonist	   (known	  activator	  of	   the	  HSR)	  was	   added.	   Compounds	   where	   then	   allowed	   to	   incubate	   with	   the	   cells	   for	   4h	  further.	   Then,	   in	  both	   experimental	   settings,	   the	  media	  was	   removed	   and	   cells	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washed	  2x	  with	  400μl	  PBS.	  Finally,	  300μl	  of	  the	  RLT	  lysis	  buffer	  (Qiagen	  RNeasy	  Micro	  Kit,	  Qiagen,	  Valencia,	  CA,	  USA)	  were	  added	  to	  the	  cells	  for	  15min	  at	  room	  temperature.	   Each	   sample	  was	   then	  mixed	  with	   the	  micropipette,	   collected	   to	  eppendorf	   tubes,	   flash	   frozen	   in	   liquid	   N2	   and	   places	   at	   -­‐80°C	   until	   RNA	  extraction.	  RNA	   extraction	   was	   done	   with	   the	   RNeasy	   Micro	   Kit	   (Qiagen),	   mostly	  according	   to	   the	   instructions	   of	   the	  manufacturer.	   First,	   the	   cell	   lysate	   in	   RLT	  buffer	  was	  added	  to	  G	  columns	  and	  centrifuged	  at	  13500g	  for	  15sec.	  The	  DNA-­‐free	  flowthrough	  was	  carefully	  mixed	  with	  an	  equal	  volume	  of	  70%	  (v/v)	  ethanol	  and	  added	  to	  an	  RNeasy	  MinElute	  Spin	  Column.	  The	  columns	  were	  centrifuged	  at	  13500g	   for	   15	   sec,	   followed	   by	   washes	   with	   500μl	   of	   buffers	   RW1	   and	   RPE.	  500μl	   of	   80%	  ethanol	  were	   added	   to	   each	   column,	   followed	  by	   centrifuging	   at	  13500g	   for	   2min.	   Columns	   were	   placed	   in	   new	   collection	   tubes,	   opened,	   and	  centrifuged	  again	  at	  16000g	  for	  5minutes	  to	  completely	  dry	  the	  ethanol.	  14μl	  of	  RNase-­‐Free	  water	  were	  placed	  in	  the	  center	  of	  each	  column	  and	  centrifuged	  into	  new	   collection	   tubes.	   The	   concentration	   of	   the	   RNA	   solution	   was	   determined	  with	  a	  NanoVue	  spectrophotometer	  (GE	  Healthcare	  LifeSciences,	  Pittsburgh,	  PA,	  USA)	   and	   400ng	   of	   each	   RNA	   were	   reverse	   transcribed	   into	   cDNA	   using	   the	  iScript	   kit	   (Bio-­‐Rad,	   Hercules,	   CA,	   USA).	   The	   resulting	   cDNA	   solutions	   were	  diluted	  1:15	  in	  RNase-­‐Free	  water	  and	  arrayed	  in	  a	  96-­‐well	  plate	  format,	  so	  that	  RT-­‐PCRs	  could	  be	  performed	  using	  liquid	  handling	  High-­‐Throughput	  devices.	  Preparation	   of	   the	   semi-­‐quantitative	   PCR	   plates	  was	   performed	   using	   a	  Mosquito	  nanoliter	  liquid	  handler	  with	  an	  8-­‐channel	  head	  and	  a	  5-­‐position	  deck	  (TTP	   Labtech,	   Melbourn,	   United	   Kingdom),	   pipetting	   1.2μl	   of	   IQ	   SYBR	   Green	  Supermix	   (Bio-­‐Rad)	   mixed	   with	   primers	   and	   1.2μl	   of	   each	   cDNA	   per	   reaction	  well.	  PCRs	  were	  run	  in	  a	  CFX384	  real	  time	  PCR	  machine	  (with	  5	  channels)	  (Bio-­‐Rad)	   and	  measurements	  were	  made	   to	   determine	   activation	   of	   the	   heat	   shock	  response	   (Hsp70	  and	  Hsp40),	   the	  ER	  unfolded	  protein	  response	  (UPR,	  BiP	  and	  CHOP),	   the	   mitochondrial	   UPR	   (Hsp60	   and	   HspA9	   or	   mitoHsp70)	   and	   the	  oxidative	   stress	   response	   (HO1	   and	   GCLM).	   For	   determining	   which	   stress	  pathways	  were	  activated	  by	  the	  small	  molecules	  of	  the	  new	  HTP	  screen,	  we	  also	  tested	  additional	  HSR	  genes,	  Hsp25	  and	  Hsp110.	  GAPDH	  was	  used	  as	  an	  internal	  control.	  The	  following	  primers	  were	  used:	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mGAPDH.F	  5'-­‐TGCACCACCAACTGCTTAG-­‐3'	  mGAPDH.R	  5'-­‐GGATGCAGGGATGATGTTC-­‐3'	  mHsp70.1.F	  5'-­‐AGGTGCTGGACAAGTGCCAG-­‐3'	  mHsp70.1.R	  	  5'-­‐AACTCCTCCTTGTCGGCCA-­‐3'	  mHsp40.F	  	  5'-­‐ACCGCTATGGAGAGGAAGG-­‐3'	  mHps40.R	  5'-­‐GAGGTACCATTAGCACCACCA-­‐3'	  mBiP.F	  	  5’-­‐ACTCCGGCGTGAGGTAGAAA-­‐3’	  mBiP.R	  5’-­‐AGAGCGGAACAGGTCCATGT-­‐3’	  mCHOP.F	  5’-­‐TGCCTTTCACCTTGGAGAC-­‐3’	  mCHOP.R	  5’-­‐CGTTTCCTGGGGATGAGATA-­‐3’	  mHsp60.F	  5’-­‐TATTGAACAGAGTTGGGGAAGTCC-­‐3’	  mHsp60.R	  5’-­‐GCTCATCATTCAGGGTTTTTCCATC-­‐3’	  mHspA9.F	  5’-­‐AATTACTTGGGCCACACAGC-­‐3’	  mHspA9.R	  5’-­‐TCCAGACCGTAAGCTAGAGCA-­‐3’	  mHO1.F	  5’-­‐GCCACCAAGGAGGTACACAT-­‐3’	  mHO1.R	  5’-­‐GCTTGTTGCGCTCTATCTCC-­‐3’	  mGCLM.F	  5’-­‐TGTTTTGGAATGCACCATGT-­‐3’	  mGCLM.R	  5’-­‐GCCATGATCACAGAGTCCAG-­‐3’	  mHsp25.F	  5'-­‐CACTGGCAAGCACGAAGAAAG-­‐3'	  mHsp25.R	  5'-­‐GCGTGTATTTCCGGGTGAAG-­‐3'	  mHsp110.F	  5’-­‐ACGCTCAATGCAGACGAAG-­‐3’	  mHsp110.R	  5’-­‐CCGGAGAAAGAATTGCACAC-­‐3’	  	  
7.	   C.	   elegans	   liquid	   culture	   assay	   for	   assessment	   of	   rescue	   of	  
aggregation	  and	  motility	  defects	  Liquid	   media	   growth	   of	   C.	   elegans	   for	   drug	   assays	   was	   adapted	   from	  (130).	  Worms	  were	   first	   age	   synchronized	  by	  bleaching	   a	  population	  of	   gravid	  adults	  with	  a	  NaOCl	  solution	  [250mM	  NaOH	  and	  1:4	  (v/v)	  dilution	  of	  commercial	  bleach)].	   Eggs	  were	   allowed	   to	   hatch	   overnight	   at	   20°C	   in	  M9	   buffer	   and	   then	  transferred	   to	   NGM	   plates	  with	   OP50	   bacteria	   for	   16-­‐18	   hours	   so	   they	  would	  develop	   from	   the	   first	   larval	   stage	   (L1)	   into	   the	   second	   (L2),	   since	   some	  RNAi	  constructs	  could	  affect	  development	  at	  this	  stage.	  Nematodes	  were	  then	  washed	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off	   the	   plates	   with	   M9	   and	   resuspended	   in	   S-­‐medium	   complete	   (S-­‐Basal	  supplemented	   with	   3	   mM	   MgSO4,	   3	   mM	   CaCl2,	   10	   mM	   KCitrate,	   100	   mg/ml	  Ampicillin	   and	   1	   mM	   IPTG).	   The	   number	   of	   worms	   per	   30	   μl	   of	   media	   was	  adjusted	  to	  have	  25-­‐30	  in	  each	  experimental	  well.	  The	  empty	  vector	  control	  (EV)	  L4440,	  hsf-­1,	   skn-­1,	  atf-­6,	  daf-­16	  RNAi	  bacteria	  were	  from	  the	  commercial	  RNAi	  library,	  GeneServiceTM,	  USA	  (131)	  (132).	  The	  atfs-­1	  construct	  was	  from	  the	  Vidal	  RNAi	   library	  (133)	  (Thermo	  Fisher	  Scientific,	  Hudson,	  NH).	  RNAi	  bacteria	  were	  grown	   overnight	   in	   LB	  media	   supplemented	  with	   50μg/ml	   ampicillin	   at	   37°C;	  expression	  of	  the	  RNAi	  construct	  was	  induced	  with	  1mM	  (IPTG)	  for	  2.5	  hours	  at	  37°C.	   The	   bacteria	   was	   then	   pelleted	   and	   resuspended	   is	   the	   same	   S-­‐medium	  complete,	  adjusting	   the	  OD595	   to	  0.9	   in	   the	  microtiter	  plate.	  30μl	  of	  worms	  and	  30μl	  of	  bacteria	  were	  pipetted	  to	  96-­‐well	  plates.	  Compounds	  were	  dissolved	  and	  also	   diluted	   in	   100%	   DMSO	   to	   a	   60x	   concentration	   and	   then	   1μl	   of	   each	   was	  added	   to	   each	   well	   (so	   that	   the	   final	   DMSO	   concentration	   would	   not	   exceed	  1.67%	   and	   cause	   solvent-­‐specific	   defects	   and/or	   toxicity).	   Each	   condition	  was	  performed	   in	   triplicate.	   The	   compound	   17-­‐N-­‐Allylamino-­‐17-­‐demethoxygeldanamycin	   (17-­‐AAG,	  Biomol,	   Plymouth	  Meeting,	   PA)	  was	  used	  at	  50μM	   as	   a	   positive	   control	   for	   induction	   of	   the	   HSR	   (96).	   The	   plates	   were	  incubated	  at	  20°C	  until	  the	  worms	  were	  day-­‐3	  adults	  (or	  6	  day	  animals).	  At	  this	  time,	  worms	  were	   removed	   from	   the	  96-­‐well	   plates	   into	  NGM	  plates	  prepared	  with	  a	  thinner	  layer	  of	  OP50	  E.	  coli,	  allowed	  to	  equilibrate	  during	  1h	  at	  20°C	  and	  the	  motility	  assay	  was	  performed.	  For	  this	  assay,	  30sec	  movies	  were	  performed	  for	   each	   plate	   to	   record	   the	  movement	   of	   the	   animals,	   using	   a	   Leica	  M205	   FA	  microscope	   with	   a	   Hamamatsu	   digital	   camera	   C10600-­‐10B	   (Orca-­‐R2,	   Leica	  Microsystems,	   Switzerland)	   and	   the	   Hamamatsu	   Simple	   PCI	   imaging	   software.	  Each	  condition	  was	  assayed	  at	  least	  3	  times.	  The	  obtained	  movies	  were	  exported	  into	   *.avi	   format	   and	   then	   opened	   with	   ImageJ	   software	   (134).	   Image	   was	  improved	   by	   subtracting	   the	   constant	   background	   and	   converted	   to	   binary	  format	  using	  a	  Maximum	  Entropy	  thresholding.	  The	  resulting	  binary	  objects	  that	  represented	   the	  movement	  of	   nematodes	  were	   tracked	  with	   the	   ImageJ	  plugin	  wrMTrck	  (96)	  and	  the	  measured	  output	  was	  the	  average	  speed	  of	  each	  animal,	  represented	  by	  the	  length	  of	  each	  track	  divided	  by	  the	  body	  length	  of	  each	  object	  (body	   length	   per	   second,	   or	   BLPS).	   The	   measurements	   are	   shown	   as	   a	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percentage	  to	  the	  motility	  of	  the	  wild	  type	  N2	  control	  strain.	  wrMTrck	  plugin	  and	  scripts	   for	   automated	   analysis	   are	   open-­‐source	   and	   publicly	   available	   at	  http://www.phage.dk/plugins.	   Scoring	   for	   changes	   in	   aggregation	   was	  performed	  with	  the	  same	  animals,	  5	  per	  plate	  (15	  per	  condition	  in	  each	  day	  the	  experiment	   was	   performed),	   in	   blind	   assays.	   Aggregates	   were	   defined	   as	  fluorescent	  foci	  that	  are	  brighter	  than	  the	  background	  fluorescence	  in	  the	  same	  worm	  and	  were	  scored	  using	  the	  stereomicroscope	  Leica	  MZ16FA	  equipped	  for	  epifluorescence	   (Leica	  Microsystems).	   For	   fluorescence	  microscopy,	  we	   picked	  assayed	  worms	  into	  glass	  slides	  coated	  with	  2%	  agarose	  in	  M9	  media	  and	  a	  drop	  of	   2mM	   levamisole	   (prepared	   in	   water)	   to	   immobilize	   the	   animals.	   YFP	  fluorescence	   and	   bright	   field	   pictures	   (as	   a	   control	   to	   allow	   visualizing	   the	  identical	  development	  of	  the	  worms	  in	  the	  different	  conditions)	  were	  taken	  with	  an	  Axiovert	  200	  inverted	  microscope	  equipped	  with	  a	  Hamamatsu	  digital	  camera	  C4742-­‐98	  (Carl	  Zeiss,	  Germany)	  When	   the	   liquid	   culture	   assays	   with	   small	   molecules	   were	   performed	  without	  RNAi	  bacteria,	  some	  changes	  were	  made	  to	  the	  assay.	  OP50	  bacteria	  and	  worms	  were	  resuspended	  in	  S-­‐complete	  media	  the	  day	  after	  synchronization	  and	  the	  media	  was	  supplemented	  with	  streptomycin,	  penicillin	  and	  nystatin	  (Sigma)	  instead	   of	   ampicillin	   and	   IPTG.	   Then,	   16-­‐18h	   later	   (at	   the	   L2	   stage),	   the	  compounds	  were	  added.	  	  
8.	  Locomotion	  deficiency	  assay	  	   Worms	  were	   age-­‐synchronized	   as	   in	   the	   section	   before	   and	   plated	   into	  96-­‐well	   plates	   with	   S-­‐medium	   complete	   media,	   for	   growing	   in	   liquid	   culture.	  Growth	   and	   assay	   were	   performed	   as	   previously	   described	   (79)	   (117).	  Compounds	  were	   added	   to	   the	  media	   for	   4	   days,	   from	   the	   egg	   stage	   until	   the	  nematodes	   were	   day-­‐1	   adults.	   At	   that	   stage,	   5	   to	   10	   animals	   were	   placed	  simultaneously	   in	   the	   middle	   of	   a	   freshly	   seeded	   plate	   equilibrated	   at	   20°C.	  Animals	   remaining	   inside	   a	   1cm	   circle	   after	   1min	  were	   scored	   as	   locomotion-­‐defective.	  At	  least	  three	  independent	  assays	  were	  performed	  for	  each	  strain,	  with	  a	  total	  of	  at	  least	  150	  animals	  tested	  per	  condition.	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9.	  RNA	  extraction	  of	  nematodes	  and	  semi-­quantitative	  RT-­PCR	  40	   animals	   from	   each	   treatment	  were	   picked	   into	  M9,	   flash	   frozen	   and	  stored	   at	   -­‐80°C.	   Later,	   samples	  were	   resuspended	   in	   250μl	   Trizol	   (Invitrogen,	  Carlsbad,	   CA,	   USA)	   and	   homogenized	   by	   vortexing	   for	   20min	   at	   4°C.	   	   50μl	   of	  chloroform	  were	  added	  and	  the	  samples	  were	  mixed	  by	  hand	  during	  30sec,	  left	  at	  room	  temperature	  for	  3min	  and	  then	  centrifuged	  at	  13500g	  for	  15min	  at	  4°C.	  The	   aqueous	   (top)	   layer	   was	   collected	   and	   thoroughly	   mixed	   with	   an	   equal	  volume	  of	  70%	  (v/v)	  ethanol.	  This	  mix	  was	  added	  to	  an	  RNeasy	  MinElute	  Spin	  Column	  (Qiagen)	  and	  spun	  for	  15sec	  at	  13500g.	   	  The	  column	  was	  washed	  with	  250μl	  buffer	  RW1,	  centrifuged,	  and	  then	  treated	  for	  30-­‐40min	  with	  DNase	  I	  from	  the	  RNase-­‐Free	  DNase	  Set	   (Qiagen)	  mixed	  with	  buffer	  RDD.	  After	   that,	  another	  wash	  with	  buffer	  RW1	  was	  performed.	  Following	  one	  more	  wash	  with	  500μl	  of	  buffer	   RPE,	   500μl	   of	   80%	   ethanol	   were	   added	   to	   each	   column,	   followed	   by	  centrifuging	  at	  13500g	   for	  2min.	  Columns	  were	  placed	   in	  new	  collection	  tubes,	  opened,	   and	   centrifuged	   again	   at	   16000g	   for	   5minutes	   to	   completely	   dry	   the	  ethanol.	  14μl	  of	  RNase-­‐Free	  water	  were	  placed	  in	  the	  center	  of	  each	  column	  and	  centrifuged	  into	  new	  collection	  tubes.	  10μl	  of	   the	  resulting	  RNA	  solutions	  were	  reverse	   transcribed	   into	   cDNA	  using	   the	   iScript	   kit	   (Bio-­‐Rad).	   Prepared	   cDNAs	  were	   diluted	   1:5	   in	   RNase-­‐Free	  water	   and	   2.5μl	   of	   this	   dilution	  were	   used	   for	  each	   real-­‐time	   PCR	   amplification,	   using	   IQ	   SYBR	  Green	   Supermix	   (Bio-­‐Rad),	   in	  the	   iCycler	   system	   (Bio-­‐Rad).	   For	   detecting	   the	   activation	   of	   different	   stress	  responses	  by	  the	  small	  molecules,	  PCR	  measurements	  were	  performed	  for	  HSP-­‐70	  (C12C8.1),	  the	  ER	  HSP-­‐70	  (hsp-­4),	  the	  mitochondrial	  chaperone	  hsp-­6	  and	  the	  oxidative	   stress	  genes	   sod-­1	   and	   sod-­3.	  act-­1	  was	  used	  as	  a	  housekeeping	  gene	  for	  an	  internal	  control.	  To	  determine	  whether	  certain	  transcription	  factors	  (TFs)	  were	   downregulated	   by	  RNAi,	   PCRs	  were	   performed	   for	   the	  main	   regulator	   of	  the	  heat	  shock	  response	  (hsf-­1),	  one	  of	  the	  main	  controllers	  of	  the	  UPR	  (atf-­6),	  a	  TF	   that	   regulates	   both	   heat	   shock	   and	   oxidative	   stress	   responses	   (daf-­16),	   the	  main	   regulator	   of	   the	   oxidative	   stress	   response	   (skn-­1)	   and	   the	   TF	   for	  mitochondrial	  stress	  (atfs-­1).	  The	  following	  primers	  were	  used:	  act-­‐1.fw	  5’-­‐ATCACCGCTCTTGCCCCATC-­‐3’;	  act-­‐1.rev	  5’-­‐GGCCGGACTCGTCGTATTCTTG;	  C12C8.1.fw	  5’-­‐ACTCATGTGTCGGTATTTATCA-­‐3’;	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C12C8.1.rev	  5’-­‐ACGGGCTTTCCTTGTTTT-­‐3’;	  hsp-­‐4.fw	  5’-­‐GCAGATGATCAAGCCCAAAAAG-­‐3’;	  hsp-­‐4.rev	  5’-­‐GGAGACGATTGGTTGAACAACAG-­‐3’;	  hsp-­‐6.fw	  5’-­‐CAGGCCGTTACCAACTCTGC-­‐3’;	  hsp-­‐6.rev	  5’-­‐GCAGTTTCCTTCATCTTCATC-­‐3’;	  sod-­‐1.fw	  5’-­‐GGACTTACTCCCGGTCTTCATG-­‐3’;	  sod-­‐1.rev	  5’-­‐GTAAAGCGTGACGAGCGTGTCG-­‐3’;	  sod-­‐3.fw	  5’-­‐CCAACTTGGCTAAGGATGGT-­‐3’	  sod-­‐3.rev	  5’-­‐GAGCCTTGAACCGCAATAGT-­‐3’	  YFP.fw	  5’-­‐ACGTAAACGGCCACAAGTTC-­‐3’	  YFP.rev	  5’-­‐AAGTCGTGCTGCTTCATGTG-­‐3’	  hsf-­‐1.fw	  5’-­‐TGTACAAGGACGTCCCGAAT-­‐3’	  hsf-­‐1.rev	  5’-­‐TCCAAATTTTGTTGCGTCTG-­‐3’	  skn-­‐1.fw	  5’-­‐GTTCCCAACATCCAACTACG-­‐3’	  skn-­‐1.rev	  5’-­‐TGGAGTCTGACCAGTGGATT-­‐3’	  daf-­‐16.fw	  5’-­‐TCGTCGTCTCGTGTTTCTCCA-­‐3’	  daf-­‐16.rev	  5’-­‐TTCCATAGGCACCCGGTAGTG-­‐3’	  atf-­‐6.fw	  5’-­‐CAGAATGCTGGATTTCGCTCAAG-­‐3’	  atf-­‐6.rev	  5’-­‐CACTTCGTCGTCCTGATATGGAG-­‐3’	  atfs-­‐1.fw	  5’-­‐AGAAGAAACGAGCCGAGAAG-­‐3’	  atfs-­‐1.rev	  5’-­‐TCACGCTTTAGTTGACGTTCT-­‐3’	  	  
10.	  Rat	  brain	  slice	  and	  neuronal	  co-­culture	  assays	  (Lo	  Lab)	  	   The	  brain	  slice	  method	  was	  performed	   in	  the	  Lo	  Lab	  at	  Duke	  University	  by	  Dr.	  Barbara	  Calamini	  and	  Denise	  Dunn,	  according	  to	  the	  method	  described	  in	  (135).	   Rat	   brain	   slices	  were	   prepared	   from	  pup	   brains.	   The	   slices	  were	   plated	  with	   culture	   support	   provided	   by	   culture	  media	   set	   in	   a	   low	   concentration	   of	  agarose.	   This	   culture	   support	   contained	   either	   only	   the	   DMSO	   vehicle	   (as	   a	  negative	  control),	  a	  combination	  of	  compounds	  KW6002	  and	  SP600125	  used	  as	  a	  positive	  control	  for	  neuroprotection	  or	  F1	  at	  different	  concentrations	  of	  0.1,	  1	  and	   10μM.	   The	   brain	   slices	   were	   then	   transfected	   with	   YFP	   alone	   or	   with	   a	  Huntingtin	   fragment	   in	   fusion	   with	   a	   polyQ	   stretch	   of	   73	   CAG	   repeats	   (Htt-­‐
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N90Q73).	   Brain	   slices	   were	   maintained	   for	   4	   days	   at	   32°C,	   after	   which	   the	  number	  of	  healthy	   cortical	  neurons	  was	   counted.	  12	  brain	   slices	  were	  assayed	  for	  each	  different	  condition.	  	   For	   the	   neuronal	   co-­‐culture	   protection	   assay	   (also	   performed	   in	   the	   Lo	  Lab	   at	   Duke	   University),	   primary	   striatal	   and	   cortical	   neuronal	   cultures	   were	  prepared	  from	  E18	  embryonic	  rat	  brains.	  Cells	  were	  transfected	  separately	  with	  either	   Htt-­‐N90Q73	   and	   YFP	   for	   the	   cortical	   neurons,	   or	   Htt-­‐N90Q73	   and	  mCherry	  for	  the	  striatal	  neurons.	  The	  fluorescent	  proteins	  were	  used	  in	  order	  to	  be	  able	  to	  distinguish	  the	  2	  types	  of	  neurons	  at	  the	  microscope.	  The	  two	  neuron	  types	   were	   combined	   together	   and	   then	   plated.	   On	   day	   4	   of	   culturing,	  compounds	  were	  added	  to	  the	  culture	  media	  and	  endoxifene	  was	  used	  to	  induce	  expression	  of	  the	  Htt-­‐N90Q73.	  The	  negative	  control	  was	  just	  the	  DMSO	  vehicle	  at	  1.2%	  and	  positive	  control	  was	  30ng/mol	  of	   the	  neurotrophin	  BDNF.	  One	  week	  later	  (on	  day	  11),	  cells	  were	   fixed	  and	   images	  were	  captured	  using	  a	  Cellomics	  Arrayscan	  VTI	   (Thermo	  Fisher	  Scientific).	  The	   images	  were	  analyzed	  using	   the	  Cellomics	   Target	   Activation	   algorithm,	   optimized	   to	   identify	   specific	   neuronal	  cells	   bodies.	   Representative	   fluorescence	   pictures	   were	   taken	   with	   a	  StereoLumar	  fluorescence	  microscope	  (Carl	  Zeiss).	  Each	  condition	  was	  scored	  6	  times.	  	  
11.	  Cell-­based	  High-­Throughput	  Assays	  We	   performed	   two	   High-­‐Throughput	   screens	   in	   parallel:	   one	   for	  identifying	  novel	  activators	  of	  the	  HSR	  and	  another	  for	  uncovering	  inhibitors	  and	  co-­‐activators	   of	   the	   same	   stress	   response.	   The	   protocols	   were	   developed	   by	  adapting	  the	  screens	  described	  in	  (96),	  to	  the	  instruments	  available	  at	  the	  High-­‐Throughput	   Facility	   of	   Northwestern	   University.	   Before	   starting	   the	   HTP	  screens,	   a	   Z’-­‐value	   (136)	   for	   each	   screen	   was	   calculated.	   Using	   DMSO	   as	   a	  negative	  control	  and	  30μM	  MG132	  (AG	  Scientific)	  as	  a	  positive	  control,	  a	  Z’-­‐value	  of	   0.59	   was	   obtained	   for	   the	   Activator	   screen.	   For	   the	   inhibitor	   screen,	   with	  DMSO	   and	   20μM	   MG132	   as	   a	   negative	   control	   and	   50nM	   Triptolide	   +	   20μM	  MG132	   as	   a	   positive	   control,	   the	   Z’-­‐value	   obtained	  was	   0.79.	   For	  more	   on	   the	  optimization	   of	   the	   screens,	   see	   chapter	   3.	   HeLa-­‐luc	   cells	  were	   dispensed	   into	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white	   tissue	   culture	   treated	   384-­‐well	   plates	   at	   a	   density	   of	   7500	   cells/well,	   in	  25μl	  assay	  medium	  using	  a	  ViaFILL	  automated	  dispenser	  (Integra	  Biosciences).	  The	  assay	  plates	  were	  incubated	  for	  4h	  at	  37°C	  and	  5%	  CO2.	  Then,	  the	  library	  of	  compounds	  was	  added	  to	  half	  of	  the	  plates	  for	  the	  Inhibitor/Co-­‐Activator	  screen,	  using	  an	  Echo	  acoustic	  liquid	  handler	  (Labcyte	  Inc.),	  from	  5mM	  DMSO	  stocks,	  to	  a	   final	   concentration	   of	   10μM.	   75nl	   of	   DMSO	  were	   added	   to	   16	   wells	   in	   each	  assay	  plate,	  as	  a	  negative	  control	  (0.3%	  DMSO)	  and	  Triptolide	  (124)	  was	  added	  to	  50nM	  as	  a	  positive	  control	  of	  HSR	  inhibition.	  These	  plates	  were	  incubated	  for	  1h	   and	   then	   MG132	   was	   added	   to	   20μM	   to	   every	   well,	   as	   an	   antagonist	   that	  would	   induce	   the	   HSR.	   For	   the	   Activator	   screen,	   the	   library	  was	   added	   to	   the	  other	   half	   of	   assay	   plates,	   with	   0.2%	   DMSO	   as	   a	   negative	   control	   and	   30μM	  MG132	  as	  a	  positive	  control.	  After	  16-­‐18h	  of	  incubation	  with	  the	  compounds,	  the	  plates	  were	  equilibrated	  at	  room	  temperature	  and	  a	  Biomek	  FX	  automated	  liquid	  handler	  with	  a	  multichannel	  head	  (Beckman	  Coulter	  Inc.)	  was	  used	  to	  dispense	  25μl	  of	  the	  Steadylite	  HTS	  reagent	  (Perkin	  Elmer).	  After	  an	  incubation	  of	  6min	  at	  room	   temperature,	   luciferase	   activity	   was	   quantified	   using	   a	   multimode	  luminometer	  plate	  reader	  Analyst	  GT	  (Molecular	  Devices.	  The	  assay	  was	  run	  in	  20	  plates	  for	  each	  screen.	  We	  defined	  a	  positive	  hit	  for	  Activation	  of	  the	  HSR	  as	  a	  compound	   that	   showed	   luciferase	   activity	   of	   3-­‐fold	   or	   higher	   than	   the	   DMSO	  negative	   control.	   Primary	   hits	   for	   Inhibition	   of	   the	   HSR	  were	   compounds	   that	  lowered	  the	  luciferase	  signal	  of	  20μM	  MG132	  by	  50%	  or	  more.	  The	  third	  class	  of	  compounds	  was	  unexpected	  upon	  the	  beginning	  of	  the	  screens	  and	  resulted	  from	  compounds	  that	  further	  enhanced	  (2-­‐fold	  or	  higher)	  the	  activation	  of	  the	  HSR	  by	  20μM	  MG132.	  We	  defined	   this	   class	  of	   compounds	  as	  Co-­‐Activators	  of	  MG132-­‐induced	  HSR.	  A	   movie	   of	   the	   different	   steps	   performed	   during	   a	   run	   of	   the	   HTS	   is	  included	  as	  Appendix	  2	  in	  the	  CD-­‐ROM	  that	  accompanies	  this	  thesis.	  	  
12.	  Western	  Blot	  analysis	  	   For	   compound	   treatment	   and	   Western	   Blot	   analysis,	   MEF	   cells	   were	  plated	   in	   6-­‐well	   plates	   at	   a	   density	   of	   160,000	   cells	   per	   well.	   The	   cells	   were	  incubated	  for	  24h	  at	  37°C	  and	  5%	  CO2.	  At	  that	  time,	  compounds	  were	  added	  and	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left	   to	   incubate	   for	  8h.	  The	  negative	   control	  was	  DMSO	  at	  1%	  and	   the	  positive	  control	  was	   the	   known	   activator	   of	   HSR	  MG132	   at	   30μM.	   Activator	   A731	  was	  assayed	   at	   20μM	   to	   check	   for	   upregulation	   of	   HSR	   genes	   at	   the	   protein	   level.	  After	  compound	  incubation,	  cells	  were	  washed	  twice	  with	  PBS,	  trypsinized	  and	  collected	  to	  eppendorf	  tubes.	  The	  resulting	  pellets	  were	  flash	  frozen	  and	  placed	  at	   -­‐80°C.	   Later,	   2	   volumes	   of	   Radio-­‐immunoprecipitation	   assay	   (RIPA)	   were	  added	  to	   the	  cell	  pellets	  and	  cells	   lysed	  mechanically	  by	  pippeting,	   then	   left	  on	  ice	  for	  20min,	  to	  improve	  lysis.	  Samples	  were	  centrifuged	  at	  13,000g	  for	  15min	  at	  4°C	  and	  the	  supernatant	  was	  retained.	  Protein	  concentration	  was	  determined	  for	   each	   sample	   using	   the	   bicinchoninic	   acid	   (BCA)	   assay	   (Thermo	   Fisher	  Scientific)	   as	   per	   manufacturer’s	   instructions.	   20μg	   of	   protein	   of	   each	   sample	  were	   separated	   by	   SDS-­‐PAGE	   and	   transferred	   to	   a	   nitrocellulose	   membrane	  using	   standard	   techniques.	   After	   transfer,	   membranes	   were	   blocked	   for	  unspecific	  binding	  with	  5%	  milk	  in	  PBS	  (w/v)	  for	  1h.	  Blots	  were	  incubated	  with	  primary	   antibody	   for	   90min	   at	   room	   temperature,	   then	   washed	   3	   times	   with	  0.2%	  PBS-­‐Tween	  (v/v),	  followed	  by	  incubation	  with	  HRP-­‐conjugated	  secondary	  antibodies	  (1	  in	  10,000)	  for	  1h	  at	  room	  temperature.	  Blots	  were	  again	  washed	  3	  times	  (as	  above)	  and	  signal	  was	  developed	  using	  Amersham	  ECL	  Plus	  detection	  reagent	  (GE	  Healtchare	  LifeSciences).	  Primary	  antibodies	  for	  Hsp	  proteins	  were	  purchased	   from	   Enzo	   Life	   Sciences	   (Farmingdale,	   NY,	   USA)	   and	   used	   at	   the	  following	   dilutions	   -­‐	   SPA810	   (for	   Hsp70,	   1:1000);	   SPA801	   (Hsp25,	   1:1000);	  SPA400	   (Hsp40,	   1:2500).	   Tubulin	   antibody	   (T5168,	   1:2500,	   from	   Sigma)	   was	  used	  to	  verify	  equal	  sample	  loading.	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III – Mechanism of the Proteostasis 
Regulation by the Barbiturate-like Small 
Molecule F1 	  	  
1.	  Background	  The	   small	   molecule	   5-­‐[3-­‐(4-­‐Methoxyphenyl)-­‐2-­‐propen-­‐1-­‐ylidene]-­‐2,4,6	  (1H,3H,5H)-­‐Pyrimidinetrione,	   also	   known	   as	   F1,	   is	   a	   barbiturate-­‐like	   chemical	  that	  activates	  several	  stress	  response	  pathways	  (heat	  shock	  response,	  oxidative	  stress	  and	  unfolded	  protein	  response)	  and	  restores	  proteostasis.	  F1	  was	  shown	  to	   suppress	   aggregation	   and	   toxicity	   phenotypes	   in	  mammalian	   and	  C.	   elegans	  models	  of	  protein	  misfolding	  (96).	  The	  properties	  of	  F1	  and	  its	  effect	   in	  a	  wide	  range	   of	   disease	  models	   point	   to	   the	   importance	   of	   further	   understanding	   the	  mechanism	  of	  action	  (MoA)	  by	  which	  the	  compound	  operates.	  	  
1.1.	  Structure/function	  studies	  of	  F1	  Previous	   studies	   have	   pointed	   to	   the	   existence	   of	   potentially	   reactive	  regions	   in	   the	   structure	   of	   F1,	   mainly	   in	   the	   allylidene	   double	   linker	   and	   the	  barbiturate	   ring	   (Figure1)	   (96).	   To	   precisely	   define	   the	   chemical	  moieties	   that	  mediate	  F1	  activity,	  and	  ascertain	  how,	  if	  at	  all,	  F1	  can	  be	  chemically	  optimized,	  we	   performed	   structure-­‐activity	   relationship	   (SAR)	   studies	   in	   a	   HeLa	   cell	  luciferase	   reporter	   system.	   In	   collaboration	   with	   Dr.	   Soosung	   Kang,	   and	   Dr.	  Richard	   Silverman,	   at	   Northwestern	   University,	   we	   designed	   and	   synthesized	  analogues	  of	  F1	  in	  which	  different	  structural	  regions	  were	  systematically	  altered.	  We	  then	  measured	  the	  potency	  with	  which	  our	  F1	  analogues	  induced	  luciferase	  activity	   in	   a	   HeLa	   cell	   reporter	   system	   for	   the	   heat	   shock	   response	   (HSR)	  (pHsp70::luciferase).	  Analogue	   purity	   was	   assessed	   by	   high	   performance	   liquid	  chromatography	  (HPLC)	  at	  the	  Silverman	  laboratory	  and	  compounds	  were	  then	  diluted	   in	   DMSO	   to	   a	   stock	   concentration	   of	   10mM.	   Using	   the	   instruments	  available	  at	  the	  High	  Throughput	  Facility	  (see	  “Cell-­‐based	  determination	  of	  small	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molecule	   activity”	   and	   “Cytotoxicity	   Assays”	   sections	   in	   the	   Materials	   and	  Methods	  chapter),	  we	  tested	  activity	  and	  toxicity	  of	  all	  F1	  analogues	  in	  parallel.	  In	  addition,	  F1	  (which	  we	  re-­‐named	  SKM-­‐4)	  was	  re-­‐synthesized	  in	  parallel	  with	  our	   analogues.	   This	   facilitated	   a	   comparative	   study	   of	   how	   each	   chemical	  alteration	   impacted	   both	   function	   and	   toxicity	   of	   SKM-­‐4/F1	   (our	   reference	  compound).	  
	  
Figure	   1.	   F1/SKM-­4	   has	   three	   sub-­regions	   that	   were	   altered	   to	   generate	   analogues	   for	  
structure/function	  studies.	  These	  regions	  are	  an	  aromatic	  ring	  with	  a	  methoxy	  side	  group	  (1),	  an	   allylidene	   double	   linker	   (2)	   and	   a	   barbiturate	   group	   (3).	   Each	   of	   these	   was	   systematically	  altered	  to	  create	  an	  extensive	  set	  of	  analogues	  that	  could	  help	  define	  the	  chemical	  features	  of	  F1	  that	   are	   essential	   for	   efficacy.	   Some	   examples	   are	   SKM-­‐2,	   where	   the	  methoxy	   side	   group	  was	  removed	   from	  the	  aromatic	  ring	  region;	  SKM-­‐9,	  where	   the	  double	   linker	  was	   fully	  saturated	   to	  single	   bonds;	   and	   SKM-­‐3,	   a	   methylation	   of	   the	   2	   amide	   groups	   that	   compose	   the	   barbiturate,	  decreasing	  the	  steric	  interactions	  in	  this	  substructure.	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2.	  Results	  
2.1.	  Activity	  and	  toxicity	  of	  SKM-­4	  when	  compared	  to	  F1	  	   SKM-­‐4/F1	  exhibited	  dose-­‐dependent	  curves	  for	  both	  activity	  and	  toxicity	  in	  these	  HeLa	  cells	  (Figure	  2B).	  Furthermore,	  the	  activity	  and	  toxicity	  profiles	  of	  SKM-­‐4	  were	  highly	  comparable	  to	  those	  previously	  reported	  for	  F1	  (Figure	  2A)	  (96).	  In	  both	  cases,	  there	  was	  measurable	  activity	  starting	  at	  5μM	  and	  peaking	  at	  12.5μM;	   also,	   both	   compounds	   showed	   similar	   toxicity	   with	   the	   lower	  concentrations	   not	   showing	   much	   cell	   death	   and	   with	   around	   40%	   of	   cells	  surviving	   at	   12.5μM	   (Figure	   2B).	   For	   concentrations	   of	   25μM	   and	   higher,	   the	  decrease	   in	   activity	   correlates	   with	   lower	   cell	   survival	   (less	   than	   20%).	  Interestingly,	   SKM-­‐4	   showed	   higher	   fold	   activation	   of	   the	   HeLa-­‐luc	   reporter	  compared	   to	  DMSO	   treated	   samples	   than	   commercial	   F1.	   This	   could	  be	  due	   to	  variations	   in	   methodology	   (the	   original	   F1	   experiments	   were	   performed	   with	  96-­‐well	  plates	  and	  a	  different	  number	  of	  cells	  per	  well,	  while	  we	  performed	  our	  assays	   in	   384-­‐well	   plates	   to	   be	   able	   to	   use	   HTP	   conditions	   in	   testing	   the	  analogues	  and	  in	  only	  in	  a	  few	  plates	  –	  always	  containing	  SKM-­‐4	  as	  a	  reference)	  or	   differences	   in	   small	   molecule	   purity.	   	   Importantly,	   the	   dynamic	   range	   of	  activity	  for	  SKM-­‐4	  is	  wider	  than	  previously	  reported	  for	  F1	  (SKM-­‐4	  activity	  peaks	  at	   80.5	   fold	   of	   the	   HeLa-­‐luc	   signal	   of	   the	   negative	   control,	   DMSO),	   thereby	  allowing	   a	   more	   thorough	   analysis	   of	   analogue	   activity	   without	   interference	  from	  background	  signal.	  
	  
Figure	  2.	  Activity	  and	  toxicity	  profiles	  of	  commercial	  F1	  (adapted	  from	  (96))	  (A)	  and	  the	  
newly	  synthesized	  SKM-­4	  (B).	  Cells	  were	   incubated	   for	  24h	  with	  the	  compounds,	  after	  which	  activity	  was	  determined	  by	  measuring	  luciferase	  activity	  with	  the	  Steadylite	  HTS	  reagent	  (Perkin	  Elmer).	   In	  parallel,	   toxicity	  was	  assessed	  using	  Calcein	  AM	  (Invitrogen).	  Both	  compounds	  show	  the	  same	  trends	  along	  the	  dose-­‐dependent	  curves	  and	  share	  similar	  parameters	  of	  activity	  and	  toxicity.	   This	   demonstrates	   that	   SKM-­‐4	   behaves	   as	   expected	   and	   can	   be	   used	   as	   the	   basis	   of	  comparison	  for	  new	  structural	  analogues.	  
SKM-4 (F1)









Activity  (Fold of DMSO)
Survival (% of DMSO)A B
Concentration (µM)
adapted from Calamini et al., 2012
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   F1	  can	  be	  divided	  into	  three	  distinct	  substructures:	  an	  aromatic	  ring	  with	  a	   methoxy	   side	   chain,	   a	   barbiturate-­‐like	   ring	   and	   an	   allylidene	   linker	   region	  (Figure	   1).	   	   New	   SKM-­‐4/F1	   analogues	  were	   designed	   to	   contain	   alterations	   in	  each	  one	  of,	  or	  a	  combination	  of,	  these	  regions,	  thereby	  allowing	  us	  to	  pinpoint	  which	  aspects	  of	  F1	  chemistry	  are	  required	  for	  activation	  of	  the	  HSR	  and	  which	  moieties	  could	  be	  manipulated	  to	  minimize	  toxicity.	  	  
2.2.	  Effect	  of	  structural	  changes	  on	  SKM-­4/F1	  function	  and	  toxicity	  	   Upon	  determining	  dose-­‐dependent	  curves	  of	  activity	  and	  toxicity	   for	  the	  full	  set	  of	  SKM-­‐4/F1	  analogues	  (Appendix	  1),	  GraphPad	  Prism	  software	  was	  used	  to	  calculate	  the	  median	  effective	  concentration	  (EC50),	  median	  lethal	  dose	  (LD50)	  and	   the	   therapeutic	   index	   (Ti	   =	   LD50/EC50,	   a	   parameter	   that	   compares	   the	  amount	  of	  a	  compound	  causing	  an	  effect	  with	   the	  amount	  resulting	   in	   toxicity)	  for	  each	  analogue	  (137).	  Table	  1	  features	  the	  structures	  of	  SKM-­‐4/F1	  and	  the	  63	  analogues	  that	  were	  studied,	  along	  with	  their	  corresponding	  molecular	  weights,	  modified	  regions,	  dose	  response	  parameters,	  and	  maximum	  reporter	  activation,	  relative	   to	   F1.	   A	   figure	   containing	   all	   activation/toxicity	   profiles	   for	   each	  compound	  is	  included	  as	  Appendix	  1	  at	  the	  end	  of	  this	  thesis	  and	  in	  the	  CD-­‐ROM	  that	  accompanies	  this	  thesis.	  
2.2.1.	  Allylidene	  modifications	  	  A	   striking	   observation	   is	   that	   any	  modification	   of	   the	   allylidene	   region	  (Figure	  1,	   region	  2)	  diminishes	   SKM-­‐4/F1	  activity.	   Firstly,	   saturating	   either,	   or	  both,	   carbon-­‐carbon	   double	   bonds	   in	   this	   linker	   yielded	   chemicals	   that	   were	  either	  chemically	  unstable	  (SKM-­‐1)	  and	  therefore	  could	  not	  be	  purified	  enough	  to	   enable	   testing	   or	   were	   tested	   but	   proved	   unable	   to	   activate	   the	   luciferase	  reporter	  (SKM-­‐6,	  SKM-­‐9).	  	  In	  addition,	  these	  compounds	  also	  showed	  no	  toxicity,	  even	  at	  concentrations	  as	  high	  as	  100μM.	  
Table	  1.	  (next	  page)	  Structures	  of	  SKM-­4/F1	  analogues	  and	  their	  dose	  response	  parameters	  of	  HeLa-­luc	  
reporter	   activation.	   Small	  molecules	   are	   ordered	   by	   the	   region	   that	  was	  modified.	  We	   calculated	   the	   half	  maximal	  effective	  concentration	  (EC50)	  and	  the	  median	  lethal	  dose	  (LD50)	  for	  each	  compound,	  which	  allowed	  us	  to	  determine	  their	  therapeutic	  index	  (Ti	  =	  LD50/EC50).	  Analyzing	  the	  Ti	  together	  with	  the	  maximum	  reporter	  activation	  for	  all	  chemicals,	  we	  concluded	  that	  no	  analogues	  were	  better	  compounds	  than	  the	  original	  F1,	  but	  the	  group	  of	  tested	  analogues	  provided	  significant	  information	  as	  to	  what	  are	  the	  reactive	  moieties	  of	  F1.	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   This	  might	  suggest	  that	  small	  molecules	  with	  saturated	  allylidene	  regions	  are	  simply	  unable	  to	  penetrate	  the	  HeLa	  cells	  used	  in	  the	  assay.	  We	  did	  not	  test	  this	   hypothesis,	   since	   our	   primary	   goal	   was	   to	   identify	   the	   moieties	   in	   F1	  required	  for	  its	  therapeutic	  effects.	  Therefore,	  analogues	  SKM1,	  SKM6,	  and	  SKM9	  were	  not	  studied	  further.	  	  Secondly,	  the	  length	  of	  the	  allylidene	  region	  seems	  to	  be	   optimal	   in	   F1.	   A	   smaller	   linker	   (SKM-­‐12)	   proved	   to	   be	   non-­‐functional,	  whereas	   increased	   linker	   length	   (SKM-­‐33)	   reduced	   the	   maximal	   activation	   of	  SKM-­‐4/F1	   by	   approximately	   75%.	   This	   also	   coincided	   with	   reduced	   toxicity,	  pointing	   to	   reduced	   cellular	   penetration	   by	   the	   compound.	   Some	   of	   the	   side	  groups	  that	  were	  added	  to	  this	  linker	  in	  order	  to	  determine	  if	  this	  was	  a	  possible	  location	   to	  place	   tags	  on	  F1	   (a	  phenyl	  group	   in	  SKM-­‐17,	  a	  methyl	   in	  SKM-­‐66A)	  were	  tolerated	  but	  affected	  the	  dose	  response	  parameters.	  Taken	  together,	  these	  data	  demonstrate	   that	   the	  allylidene	  region	  and	   its	   length	  are	  critical	   for	  SKM-­‐
Table	  1.	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4/F1	  activity.	  Prior	  to	  modification,	  the	  allylidene	  region	  confers	  a	  planar	  shape	  on	   SKM-­‐4/F1.	   However,	   addition	   of	   side	   chains	   to	   the	   linker	   imposes	   a	   three-­‐dimensional	   structure	   to	   SKM-­‐4/F1,	   indicating	   that	   the	   compound	   functions	  optimally	  as	  a	  two-­‐dimensional	  molecule.	  This	  suggests	  that	  the	  conformation	  of	  F1	  is	  critical	  for	  cellular	  uptake,	  perhaps	  hinting	  at	  the	  mode	  by	  which	  F1	  enters	  HeLa	  cells.	  
2.2.2.	  Aromatic	  ring	  analogues	  By	  altering	  the	  aromatic	  ring	  of	  SKM-­‐4/F1	  we	  wanted	  to	  see	  if	  side	  groups	  causing	  electron	  shift	  to	  the	  aromatic	  region	  (Figure	  1,	  region	  1),	  like	  the	  amine	  analogue	  SKM-­‐16,	  the	  alcohol	  analogue	  SKM-­‐18	  and	  the	  rotations	  of	  the	  methoxy	  group	   of	   SKM-­‐8	   and	   SKM-­‐43,	   versus	   other	   side	   groups	   that	   promote	   electron	  withdrawal	  from	  this	  substructure	  (the	  nitro	  analogues	  SKM-­‐14	  and	  SKM-­‐15	  or	  the	  many	  chloride	  and	  bromide	  analogues)	  showed	  an	  evident	  direction	  (either	  decrease	  or	   increase)	   for	  alteration	  of	  activity.	  To	   investigate	  these	  aspects,	  we	  synthesized	  analogues	  in	  which	  the	  aromatic	  ring	  side	  chains	  were	  modified.	  All	  the	  alterations	  failed	  to	  clearly	  improve	  SKM-­‐4/F1.	  In	  some	  cases,	  as	  for	  example	  in	  the	  elimination	  of	  the	  methoxy	  side	  group	  in	  SKM-­‐2,	  a	  nitro	  side	  group	  in	  the	  
ortho	  position	  in	  SKM-­‐15,	  addition	  of	  two	  chlorides	  in	  the	  ortho	  position	  in	  SKM-­‐69A	  (trans	  isomer)	  and	  SKM-­‐69C	  (cis	  isomer	  of	  SKM-­‐69A),	  the	  Ti	  was	  improved	  (from	  8%	  in	  SKM-­‐2	  to	  almost	  60%	  in	  SKM-­‐15)	  but	  at	  the	  cost	  of	  lower	  reporter	  activation.	   Conversely,	   the	   aromatic	   ring	   analogue	   SKM-­‐8	   (a	   rotation	   of	   the	  methoxy	  side	  chain	  from	  the	  para-­	  to	  the	  ortho-­	  position)	  slightly	  improved	  the	  maximum	  activation	  of	  the	  reporter	  (by	  11%),	  but	  had	  a	  lower	  Ti.	  Alterations	  in	  this	   substructure	   did	   not	   show	   any	   significant	   changes	   in	   dose	   response	  parameters,	  with	  the	  exception	  of	  SKM-­‐16	  that	  was	  non-­‐functional.	  Because	  both	   groups	  of	  modifications	   (causing	   electron	   shift	   to	   or	   from	  the	  aromatic	  region)	  failed	  to	  improve	  SKM-­‐4/F1,	  we	  were	  able	  to	  conclude	  that	  the	   steric	   effects	   in	   the	   aromatic	   ring	   of	   F1	   are	   already	   at	   a	   balance,	   which	  worsens	  with	  changes	  in	  either	  direction.	  
2.2.3.	  Barbiturate	  substructure	  substitutions	  Our	  initial	  effort	  was	  to	  methylate	  one	  (SKM-­‐5)	  or	  both	  (SKM-­‐3)	  amides,	  since	   these	  are	   the	   locations	  of	   the	  barbiturate	  region	  (Figure	  1,	   region	  3)	   that	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can	  be	  donors	  of	  hydrogen	  to	  the	  carbonyl	  groups	  in	  the	  ring,	  altering	  its	  steric	  effects.	   These	   modifications	   increased	   EC50	   2-­‐fold	   and	   lowered	   the	   maximum	  reporter	   activation	   (with	   a	   cumulative	   effect)	   by	   21%	   when	   methylating	   one	  amide	   group	   (SKM-­‐5),	   and	   by	   40%	   when	   methylating	   both	   (SKM-­‐3).	   This	  demonstrates	   the	   importance	   of	   the	   existing	   steric	   interactions	   inside	   this	  substructure	  for	  SKM-­‐4/F1	  activity.	  Nevertheless,	  the	  fact	  that	  these	  compounds	  were	   still	   functional	   showed	   that	   different	   side	   groups	   could	   be	   substituted	   in	  those	  positions	   in	  order	   to	  derive	   improved	  SKM-­‐4/F1	   function.	  Therefore,	  we	  tested	   different	   chains	   and	   rings	   that	   are	   commonly	   found	   in	   small	  molecules	  with	  proven	  therapeutic	  effects	   in	  those	  positions	  and	  the	  best	  substituent	  was	  an	  ethane	  chain	  in	  one	  of	  the	  amides	  (SKM-­‐27).	  This	  analogue	  maintained	  the	  Ti	  while	   improving	  maximum	  activation	  by	  13%.	  We	  also	  attempted	   to	  substitute	  one	   of	   the	   carbonyl	   groups	  with	   a	   sulfide	   group	   (SKM-­‐39)	   expecting	   that	   this	  could	   improve	  HSR	  activation,	   as	   it	   has	  been	  published	   that	   only	   thiopental	   (a	  barbiturate	   small	   molecule	   that	   contains	   a	   sulfide)	   but	   not	   pentobarbital	   (an	  analogue	  with	  carbonyl	  in	  the	  same	  position),	  activates	  the	  HSR	  (111).	  However,	  even	  though	  this	  analogue	  showed	  an	  improved	  Ti	  (0.93	  to	  0.77	  in	  SKM-­‐4)	  both	  EC50	   and	   maximum	   activation	   (lowered	   by	   more	   than	   30%)	   were	   severely	  worsened.	   	  
2.2.4.	  Additional	  analogues	  Combinations	  of	  modifications	  in	  more	  than	  one	  region	  were	  also	  tested.	  Allylidene	   and	   barbiturate	   analogues	   were	   non-­‐functional,	   either	   because	  function	  was	  already	  impaired	  solely	  with	  an	  allylidene	  substitution	  (from	  SKM-­‐54A	   to	   SKM-­‐54B,	   both	   non-­‐functional)	   or	   because	   both	   modifications	   were	  somewhat	  deleterious	  and	  when	  combined	  completely	  abolished	  function:	  SKM-­‐66A,	   which	   has	   a	   methyl	   addition	   in	   the	   allylidene	   linker,	   had	   a	   vestigial	  activation	  of	  8%	  when	  compared	  to	  SKM-­‐4/F1,	  but	  this	  completely	  disappeared	  in	  SKM-­‐66B,	  which	  in	  addition	  to	  an	  allylidene	  methyl	  addition,	  also	  has	  methyl	  groups	  in	  the	  amides	  of	  the	  barbiturate	  region.	  The	  arrangement	  of	  alterations	  in	  both	   the	   aromatic	   and	   the	   barbiturate	   rings	   showed	   differential	   effects	   and	  produced	   the	   only	   analogues	   that	   improved	   both	   the	   Ti	   and	   the	   maximum	  activation	   of	   the	   reporter.	   These	   are	   a	   rotation	   from	   the	   para-­	   to	   the	  meta-­	  
	   55	  
position	  of	  the	  methoxy	  side	  chain	  of	  the	  aromatic	  ring,	  coupled	  with	  one	  methyl	  addition	   at	   one	   of	   the	   amides	   of	   the	   barbiturate	   substructure.	   We	   tested	   this	  analogue	  in	  two	  forms,	  a	  1/1	  cis/trans	  mixture	  (SKM-­‐49)	  and	  a	  73/27	  trans/cis	  (SKM-­‐70).	  Because	  SKM-­‐70	   showed	  a	  better	  Ti	   (0.93	   to	  0.83	   in	   SKM-­‐49)	  and	  a	  more	   significant	   increase	   in	   the	   maximum	   activation	   of	   the	   reporter	   (39%	   to	  21%	   in	   SKM-­‐49)	   (Table	   1),	   we	   can	   conclude	   that	   the	   trans	   version	   of	   this	  compound	  is	  the	  more	  active	  one.	  	   In	  general,	  the	  analysis	  of	  all	  the	  structure/function	  data	  seems	  to	  point	  to	  the	   fact	   that	   F1	   is	   already	   best	   of	   its	   class,	   or	   that	   at	   least	   it	   cannot	   be	  significantly	   improved.	   In	   pharmacology,	   Tis	   are	   expected	   to	   be	   at	   least	   a	   few	  logs	   over	   what	   is	   observed	   with	   SKM-­‐4/F1	   and	   its	   analogues	   (where	   Ti	   ≈	   1).	  Nevertheless,	   since	   F1	   was	   already	   shown	   to	   be	   effective	   in	   the	   treatment	   of	  conformational	   disease	   models	   (96),	   its	   dose	   dependent	   parameters	   are	   not	  necessarily	  the	  best	  in	  this	  HeLa-­‐luc	  reporter	  system.	  However,	  due	  to	  its	  ease	  of	  use	  and	  its	  amenability	  for	  HTP,	  this	  system	  remains	  a	  very	  useful	  and	  powerful	  tool	  for	  the	  study	  of	  small	  molecule	  activators	  of	  the	  HSR.	  However,	  this	  system	  should	   always	   be	   used	   as	   a	   starting	   point	   to	   be	   followed	   by	   more	   thorough	  investigation	  in	  other	  systems.	  	  
2.3.	  Endogenous	  effects	  on	  stress	  pathways	  
2.3.1.	  Activation	  of	  the	  endogenous	  HSR	  by	  SKM-­4/F1	  analogues	  	   To	   follow	   up	   on	   potential	   interesting	  modifications	   of	   the	   F1	   structure,	  and	   to	   validate	   our	   HSR	   HeLa-­‐luc	   results	   at	   the	   level	   of	   endogenous	   gene	  expression,	   we	   selected	   a	   group	   of	   6	   analogues	   that	   are	   representative	   of	   the	  different	   dose-­‐dependent	   parameter	   variations	   we	   observed,	   as	   well	   as	   the	  different	   substructures	   that	  were	  modified	   (Table	  2).	  The	  small	  molecules	   that	  we	  chose	  to	  perform	  more	  detailed	  studies	  on	  were:	  SKM-­‐2	  as	  an	  example	  of	  a	  molecule	   that	   slightly	   increases	   EC50	   (9.53)	   and	   LD50	   (7.87)	   but	   does	   not	  significantly	   affect	   the	   Ti;	   SKM-­‐14	   as	   the	   representative	   of	   compounds	   where	  these	  same	  changes	  are	  more	  accentuated	  (EC50	  of	  16.22	  and	  LD50	  of	  14.96)	  and	  also	  accompanied	  by	  a	  slight	  Ti	  improvement	  (0.92	  to	  0.77	  in	  SKM-­‐4);	  SKM-­‐17	  as	  a	  compound	  with	  a	  change	   in	   the	  allylidene	   linker	  that	  still	   remains	   functional,	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albeit	  with	  reduced	  activity	  (38%	  in	   the	  HeLa	  reporter);	  SKM-­‐22	  as	  a	  chemical	  that	  maintains	  toxicity	  but	  with	  an	  increased	  EC50,	  thus	  resulting	  in	  a	  worsened	  Ti,	   (only	  0.38);	   SKM-­‐23U,	   as	  one	  of	   the	   few	  compounds	   that	   actually	   improved	  the	  EC50	  of	  F1	  from	  7.19	  to	  4.53	  and	  maintained	  Ti,	  but	  not	  without	  a	  decrease	  in	  maximal	  reporter	  activation	  (reduced	  by	  34%);	  and	  SKM-­‐27,	  as	  a	  small	  molecule	  that	  maintains	  Ti	   and	   is	   even	  able	   to	   activate	   the	   reporter	  13%	  more	   than	   the	  initial	  reference	  compound	  (even	  though	  it	  has	  a	  slightly	  worsened	  EC50	  of	  9.36).	  
	  	   	  These	   6	   analogues,	   together	   with	   SKM-­‐4/F1,	   were	   tested	   for	   a	   more	  comprehensive	   study	   of	   HSR	   activation	   in	   three	   different	   murine	   cell	   types,	  chosen	   to	   reflect	  different	   tissues	  with	  distinct	   intracellular	   environments	  and,	  potentially,	   different	   proteostasis	   network	   compositions.	   The	   cell	   types	  
!"#$ %&'()&('$ *+,-.$,/0$1-+2 3456 7856 9-/:7856;3456< =/*">/?)@A"&+2/:0$B/&+/CD<
%E*FG/:CFD< HH IJDK 5J5I 6JII D66J66
!"#$% &'()*+,-./01 2345 6376 8375 25392
!"#$:9 &'()*+,-./01 :;3%% :932; 832% 76347
!"#$:6 &<<=</>?0? 963;7 :8329 83%5 563;2
!"#$%% @*'A/BC'*B? :534: 4382 8357 ::5379
!"#$%5D @*'A/BC'*B? 9345 5355 8369 ;53;:
!"#$%6 @*'A/BC'*B? 235; 63%4 8366 ::%3;;
Table	  2.	  Structure	  and	  dose	  response	  parameters	  of	  HeLa-­luc	  reporter	  activation	  for	  F1	  and	  the	  6	  
analogues	   chosen	   for	   further	   study.	   Shown	   are	   the	   structure,	   modified	   region,	   the	   half	   maximal	  effective	  concentration	  (EC50)	  and	  the	  median	  lethal	  dose	  (LD50)	  for	  each	  compound,	  which	  allowed	  us	  to	  determine	  their	  therapeutic	  index	  (Ti	  =	  LD50/EC50).	  We	  also	  calculated	  the	  maximum	  reporter	  activation	  of	  each	  compound,	  compared	  to	  SKM-­‐4/F1	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investigated	  were	  Neuro2a	  (neuroblastoma	  cells),	  C2C12	  (myoblasts),	  and	  MEF	  (mouse	  embryonic	  fibroblasts).	  
	  
















































































































































































































































































































































































































































































































	   Given	   that	   our	  HeLa	   reporter	   system	  measures	   activity	   from	   the	  Hsp70	  promoter,	   we	   started	   by	   investigating	   the	   effects	   of	   our	   analogues	   on	   Hsp70	  mRNA	  levels	  in	  the	  three	  cell	  types	  (Figure	  3).	  Our	  results	  show	  that	  SKM-­‐4/F1	  up-­‐regulates	  Hsp70	   in	  all	  analyzed	  cell	   types,	   in	  a	  dose	  dependent	  manner.	  We	  also	   observed	   that	   5μM	   is	   sufficient	   to	   increase	   mRNA	   levels	   by	   10-­‐fold	   in	  fibroblasts	   (Figure	   3A)	   and	   6-­‐fold	   in	   muscle	   cells	   (Figure	   3C),	   but	   not	   in	   the	  seemingly	  more	  resistant	  neuronal	  cells	  (Figure	  3B),	  that	  only	  respond	  to	  higher	  concentration	   of	   SKM-­‐4/F1	   (20μM,	   up-­‐regulating	   Hsp70	   by	   3-­‐fold).	   The	  analogues,	   SKM-­‐17,	   SKM-­‐23U	   and	   SKM-­‐27	   were	   the	   most	   potent	   inducers	   of	  Hsp70	  mRNA	   across	   the	   3	   cell	   types.	   SKM-­‐23U	   and	   SKM-­‐27	   showed	   levels	   of	  Hsp70	  mRNA	  expression	  that	  were	  similar	  to	  F1	  in	  fibroblasts,	  neuroblasts	  and	  myoblasts.	  Surprisingly,	   induction	  of	  Hsp70	  mRNA	  following	  SKM-­‐17	  treatment	  was	  higher	  in	  MEFs	  (over	  200-­‐fold	  at	  20μM,	  Figure	  3A)	  and,	  to	  a	  lower	  extent,	  in	  C2C12	   cells	   (30-­‐fold,	   Figure	   3C)	   than	   when	   treated	   with	   SKM-­‐4/F1.	   This	  compound	  performed	  poorly	  in	  the	  HeLa-­‐luc	  reporter	  system,	  showing	  only	  38%	  of	   reporter	   activation	   when	   compared	   to	   F1	   and	   activation	   at	   25μM	   or	   more	  (Table	   2	   and	   Appendix	   1).	   There	   are	   two	   plausible	   explanations	   for	   this	  occurrence.	  On	   one	  hand,	  maybe	   the	  different	   cell	   systems	   (HeLa-­‐luc	   cells	   and	  the	  murine	  cell	  types)	  have	  cellular	  environments	  that	  are	  too	  distinct	  and	  react	  to	   SKM-­‐17	   very	   differently;	   on	   the	   other	   hand,	   the	   reporter	   system	   that	  measures	  production	  of	   luciferase	  protein	  might	  not	  be	   completely	  accurate	   in	  predicting	  the	  level	  of	  endogenous	  mRNA	  expression	  caused	  by	  a	  compound	  due	  to,	   for	   example,	   positional	   effects	   of	   the	   transgene.	   Alternatively,	   since	   the	  reporter	   measures	   protein	   levels	   and	   the	   qRT-­‐PCR	   measures	   mRNA	   levels,	   it	  might	  be	  that	  SKM-­‐17	  interferes	  with	  translation.	  In	  this	  way,	  it	  would	  only	  up-­‐regulate	  Hsp70	  at	  the	  mRNA	  level,	  but	  this	  change	  would	  not	  be	  translated	  into	  the	  protein	   levels.	  SKM-­‐2,	  SKM-­‐14	  and	  SKM-­‐22	  activated	  Hsp70	  at	   lower	   levels	  than	  their	  analogue	  counterparts.	  SKM-­‐14	  had	  a	  similar	  pattern	  of	  activation	  to	  SKM-­‐4/F1,	  but	  always	  with	  a	  slightly	  weaker	  activation	  of	  Hsp70	  (Figure	  3).	  Both	  SKM2	   and	   SKM22	   exhibited,	   cell	   type-­‐dependent	   effects:	   for	   example	   SKM-­‐2	  behaved	  similarly	  to	  SKM-­‐4/F1	  in	  MEFs	  and	  muscle	  cells,	  inducing	  Hsp70	  by	  30-­‐fold	   (Figure	   3A)	   and	   13-­‐fold	   (Figure	   3C)	   respectively.	   However,	   in	   neurons,	  where	  SKM-­‐4/F1	  up-­‐regulated	  Hsp70	  by	  more	  than	  3-­‐fold,	  SKM-­‐2	  only	  increased	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Hsp70	  mRNA	  by	  1.7-­‐fold	  (Figure	  3B).	  This	  was	  equally	   true	   for	  SKM-­‐22,	  which	  only	  weekly	  activated	  Hsp70	  at	  the	  highest	  concentrations	  in	  fibroblasts	  (9-­‐fold,	  Figure	   3A)	   and	   muscle	   (less	   than	   3-­‐fold,	   Figure	   3C)	   and	   was	   ineffective	   in	  neurons	  (Figure	  3B).	  This	  opens	  up	  the	  exciting	  possibility	  that	  the	  F1	  family	  of	  barbiturate	   chemicals	   could	   be	   structurally	   manipulated	   to	   obtain	   small	  molecules	  that	  act	  specifically	  in	  some	  cell	  types,	  which	  would	  help	  understand	  the	   differences	   in	   the	   composition	   of	   the	   proteostasis	   network	   in	   different	  tissues.	  In	  order	  to	  show	  that	  SKM-­‐4/F1	  and	  its	  analogues	  are	  activating	  the	  HSR	  in	  general,	  and	  not	  only	  inducing	  Hsp70	  expression,	  we	  looked	  at	  an	  additional	  HSR	   gene,	   the	   Dnaj/Hsp40	   co-­‐chaperone	   of	   Hsp70.	   Both	   SKM-­‐4/F1	   and	   its	  analogues	   up-­‐regulated	   Hsp40	   in	   all	   3	   cell	   types	   (Figure	   4)	   in	   a	   manner	   that	  correlates	  with	  induction	  of	  Hsp70.	  Interestingly,	  SKM-­‐17	  also	  strongly	  induced	  Hsp40	  mRNA	   in	  MEFs	   (26-­‐fold	   at	  20μM,	  Figure	  4A).	   In	   comparison,	   SKM-­‐4/F1	  induced	  Hsp40	   expression	   by	   approximately	   8-­‐fold	   at	   the	   same	   concentration.	  While	   SKM-­‐17	   and	   SKM-­‐4/F1	   had	   similar	   levels	   of	   Hsp40	   up-­‐regulation	   in	  neuronal	   cells	   (2-­‐fold,	   Figure	   4B),	   SKM-­‐4/F1	   was	   found	   to	   be	   the	   strongest	  activator	  of	  this	  gene	  in	  the	  C2C12	  muscle	  cells	  (11-­‐fold	  against	  8-­‐fold	  from	  SKM-­‐17,	  Figure	  4C).	  SKM-­‐23U	  and	  SKM-­‐27	  again	  showed	  a	  similar	  or	  slightly	  higher	  activation	  of	  Hsp40	  than	  SKM-­‐4/F1	  (as	  was	  observed	  for	  Hsp70)	  while	  SKM-­‐14	  was	  slightly	   less	  effective	  at	  up-­‐regulating	  Hsp40	  mRNA.	  Finally,	  SKM-­‐22	   failed	  to	  produce	  significant	  up-­‐regulation	  of	  Hsp40,	  only	  leading	  to	  a	  3-­‐fold	  increase	  in	  mRNA	   levels	   in	   MEFs	   (Figure	   4A)	   (with	   the	   other	   compounds	   reaching	  activations	  of	   6-­‐	   to	  26-­‐fold)	  but	   failing	   to	  properly	   induce	  Hsp40	   in	   any	  of	   the	  other	  cell	  types,	  while	  SKM-­‐2	  induced	  Hsp40	  mRNA	  by	  10-­‐fold	  in	  MEFs	  but	  had	  little	   effect	   in	   Neuro2A	   or	   C2C12	   cells	   (Figure	   4A,	   4B	   and	   4C,	   respectively),	  thereby	   demonstrating	   a	   similar	   pattern	   of	   expression	   as	   was	   observed	   with	  Hsp70.	  In	  summary,	  up-­‐regulation	  of	  Hsp70	  and	  Hsp40	  mRNA	  by	  the	  SKM-­‐4/F1	  analogues	  showed	  that	  these	  small	  molecules	  result	  in	  an	  endogenous	  activation	  of	  the	  HSR	  across	  different	  cell	  types,	  albeit	  at	  different	  levels	  of	  activation.	  While	  some	   (SKM-­‐17,	   SKM-­‐27,	   SKM-­‐23U)	   show	   higher	   levels	   of	   HSR	   activation	   than	  
	  60	  
SKM-­‐4/F1,	   others	   (SKM-­‐2,	   SKM-­‐14,	   SKM22)	   are	   less	   potent	   in	   activating	   this	  stress	  response.	  	  
	  
Figure	  4.	  Hsp40	   induction	   	  by	  SKM-­4/F1	  and	   its	  analogues	   in	  3	  different	   cell	   types:	  MEF	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2.3.2.	   Activation	   of	   other	   stress	   pathways	   by	   the	   barbiturate	   small	  
molecules	  	   It	   was	   previously	   shown	   that	   F1	   also	   activates	   other	   stress	   pathways,	  specifically	   the	   ER	   unfolded	   protein	   response	   (UPR)	   and	   the	   oxidative	   stress	  pathways	   (96).	   We	   wanted	   to	   check	   for	   activation	   of	   these	   pathways	   in	   the	  different	  cell	  types	  using	  SKM-­‐4/F1	  and	  the	  selected	  analogues.	  We	  also	  decided	  to	  extend	   these	  analyses	   to	   the	  mitochondrial	  UPR,	   as	   the	  effects	  of	  F1	  on	   this	  pathway	  had	  not	  previously	  been	  described	  in	  detail.	  We	   first	   looked	   at	   activation	   of	   the	   ER	   UPR,	   by	   checking	   if	   the	   ER	  homologue	   of	   Hsp70	   (Grp78/	   BiP)	   was	   up-­‐regulated	   by	   treatment	   with	   the	  known	  ER	  UPR	   activator	   tunicamycin,	   as	   a	   control	   and	   in	   parallel	  with	   or	   our	  small	  molecules.	  We	  found	  that	  tunicamycin	  up-­‐regulated	  BiP	  mRNA	  by	  5-­‐fold	  in	  MEFs	  (Figure	  5A)	  and	  C2C12	  cells	  (Figure	  5C)	  but	  did	  not	  have	  any	  effect	  on	  BiP	  mRNA	  in	  Neuro2a	  cells	  (Figure	  5B).	  Interestingly,	  we	  did	  not	  observe	  induction	  of	  BiP	  after	  treatment	  with	  SKM-­‐4/F1	  (black	  bars)	  in	  any	  of	  the	  three	  cell	  types	  (Figure	   5).	   However,	   treatment	   with	   SKM-­‐17	   and	   SKM-­‐27	   caused	   a	   modest	  upregulation	  of	  BiP	  mRNA	  (≈2-­‐fold)	  in	  fibroblasts	  (Figure	  5A),	  an	  effect	  that	  was	  also	  observed	  in	  muscle	  cells	  after	  treatment	  with	  SKM-­‐2	  and	  SKM-­‐27	  (1.5-­‐fold)	  (Figure	  5C).	  Given	  these	  results,	  it	  is	  possible	  that	  to	  achieve	  clearer	  induction	  of	  BiP	  we	  would	  need	  to	  incubate	  the	  cells	  with	  the	  compounds	  for	  longer	  than	  the	  4h	  we	  used	  or	  collect	  RNA	  at	  later	  time	  points	  after	  treatment.	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Figure	   5.	   Up-­regulation	   of	   BiP	   by	   SKM-­4/F1	   and	   its	   analogues	   in	   MEF	   fibroblasts	   (A),	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Figure	  6.	  CHOP	  induction	  by	  SKM-­4/F1	  and	  its	  analogues	  in	  MEF	  fibroblasts	  (A),	  Neuron2A	  

















































































































































































































































































































































































































































































































balanced	   activation	   of	   CHOP	   can	   be	   beneficial	   (138),	   as	   is	   the	   case	   for	   the	  moderate	   activation	   of	   most	   cell	   stress	   responses.	   Treatment	   with	   SKM-­‐4/F1	  resulted	  in	  up-­‐regulation	  of	  CHOP	  mRNA	  in	  fibroblasts	  and	  in	  muscle	  cells	  by	  4-­‐fold	   and	  2.5-­‐fold	   respectively	   (Figure	  6A	   and	  6C).	  However,	   these	   effects	  were	  not	  observed	  in	  the	  neurons	  (Figure	  6B).	  SKM-­‐2,	  SKM-­‐17,	  SKM-­‐23U	  and	  SKM-­‐27	  noticeably	   up-­‐regulated	   CHOP	  mRNA	   in	   the	  MEFs,	   with	   levels	   of	   5	   to	   8.5-­‐fold	  activation	   (obtained	  with	   SKM-­‐27,	   Figure	  6A),	  while	   only	   SKM-­‐17	   and	   SKM-­‐27	  (both	  4-­‐fold)	  had	  the	  same	  effect	  in	  C2C12	  muscle	  cells	  (Figure	  6C).	  Intriguingly,	  only	   treatment	   with	   SKM-­‐17	   or	   SKM-­‐22	   (which	   had	   been	   showing	   the	   lowest	  levels	   of	   activation	   for	   all	   other	   genes	   and	   cells)	   resulted	   in	   up-­‐regulation	   of	  CHOP	   mRNA	   (≈2-­‐fold)	   in	   neuronal	   cells	   (Figure	   6B).	   It	   is	   of	   note	   that	   for	   all	  compounds	  and	  cell	  types	  this	  gene	  was	  not	  strongly	  up-­‐regulated	  (never	  more	  than	  10-­‐fold),	  at	   least	  when	  compared	  with	  the	  UPR-­‐inducing	  tunicamycin	  (40-­‐	  and	   45-­‐fold	   in	   MEFs	   and	   C2C12s,	   Figures	   6A	   and	   6C	   respectively),	   which	   is	  encouraging	  given	  its	  cell	  death-­‐related	  properties.	  Given	   these	   observations	   it	   is	   possible	   that	   the	   SKM-­‐4/F1	   analogues	  induce	  CHOP	  at	  levels	  that	  would	  still	  keep	  the	  cells	  in	  a	  healthy	  state.	  	   In	   order	   to	  monitor	   activation	   of	   the	  mitochondrial	   UPR,	   we	  measured	  mRNA	   levels	   of	   the	   canonical	   mitochondrial	   chaperone	   Hsp60.	   	   Our	   findings	  show	   that	   SKM-­‐4/F1	   (black	   bars)	   treatment	   does	   not	   significantly	   induce	   this	  gene	   in	  any	  of	   the	   cell	   types	   tested	   (Figure	  7),	  with	   the	  exception	  of	   a	  1.5-­‐fold	  induction	  in	  C2C12	  myoblast	  cells	  at	  10μM	  (Figure	  7C).	  The	  same	  vestigial	  level	  of	  Hsp60	  up-­‐regulation	  in	  muscle	  cells	  was	  also	  observed	  using	  SKM-­‐2	  at	  5μM,	  or	  SKM-­‐17	   and	   SKM-­‐27	   at	   20μM	   (Figure	   7C).	   No	   induction	   of	   Hsp60	  mRNA	  was	  observed	   in	   the	  Neuro2A	   cells	   (Figure	  7B),	  with	   any	   of	   the	   tested	   compounds.	  Hsp60	   up-­‐regulation	   was	   most	   pronounced	   in	   MEFs	   after	   SKM-­‐17	   treatment	  (more	   than	  4-­‐fold	  at	  20μM)	  or	  with	  SKM-­‐2	  and	  SKM-­‐27	  (≈2-­‐fold	   in	  both	  cases,	  Figure	  7A).	  	   We	   also	   looked	   for	   induction	   of	   the	   mitochondrial	   Hsp70	   homologue	  (HspA9).	   Levels	   of	   mtHSP70	   mRNA	   did	   not	   vary	   in	   neuronal	   (Figure	   8B)	   or	  muscle	   cells	   (Figure	   8C)	   after	   treatment	   with	   any	   of	   the	   small	   molecules.	   In	  contrast,	   MEFs	   demonstrated	   a	   2-­‐fold	   induction	   of	   mtHSP70,	   after	   treatment	  with	  SKM-­‐17	  but	  no	  other	  molecules	  (Figure	  8A).	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Figure	  7.	   Induction	  of	   the	  canonical	  mitochondrial	  UPR	  gene	  Hsp60	  by	  SKM-­4/F1	  and	  its	  













































































































































































































































































































































































































































































































Figure	  8.	   Induction	  of	  mitoHsp70	  by	  SKM-­4/F1	  and	   its	  analogues	   in	  MEF	   fibroblasts	   (A),	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SKM-­‐17	   and,	   to	   a	   lesser	   extent	   SKM-­‐2	   and	   SKM-­‐27,	   can	  modestly	   activate	   this	  stress	  pathway.	  	  
	  
Figure	   9.	   Up-­regulation	   of	   HO1	   by	   SKM-­4/F1	   and	   its	   analogues	   in	   MEF	   fibroblasts	   (A),	  











































































































































































































































































































































































































































































































	   Finally,	   we	   decided	   to	   assess	   whether	   our	   analogues	   had	   differential	  effects	   on	   the	   oxidative	   stress	   response.	   To	   achieve	   this,	   we	  measured	  mRNA	  levels	   of	   the	   ROS-­‐inducible	   genes,	   heme	   oxygenase	   1	   (HO1),	   and	  GCLM,	  which	  encodes	  the	  regulatory	  subunit	  of	  the	  glutamate-­‐cysteine	  ligase.	  As	  was	  observed	  for	  Hsp70,	  SKM-­‐17	  treatment	  strongly	  induced	  HO1	  expression.	  20μM	  of	  SKM-­‐17	  up-­‐regulated	  HO1	  by	   63-­‐fold	   compared	   to	   treatment	  with	  DMSO	   in	   fibroblasts	  (Figure	  9A)	  and,	   in	  comparison,	   the	  maximal	   induction	  of	  HO1	  after	  SKM-­‐4/F1	  treatment	  was	  14-­‐fold	   in	   the	   same	  cells.	   Interestingly,	   SKM-­‐4/F1	  was	   the	   least	  potent	  inducer	  of	  H01	  in	  MEFs.	  All	  other	  analogues	  tested	  increased	  HO1	  mRNA	  levels	  by	  approximately	  50%	  more	  than	  SKM-­‐4/F1	  (between	  20-­‐fold	  for	  SKM-­‐2	  and	  24-­‐fold	  for	  SKM-­‐14,	  SKM-­‐23U	  and	  SKM-­‐27,	  Figure9A).	  In	  Neuro2A	  neuronal	  cells,	  the	  same	  pattern	  of	  expression	  was	  observed,	  with	  2.5-­‐fold	  of	  HO1	  mRNA	  upregulation	   by	   SKM-­‐4/F1,	   6-­‐fold	   for	   SKM-­‐17	   and	   the	   remaining	   analogues	  showing	   intermediate	  activation	  between	  3-­‐	  and	  4-­‐fold	   (Figure	  9B).	  For	  C2C12	  myoblasts,	   again	   SKM-­‐17	   had	   a	   stronger	   activation	   than	   the	   other	   compounds	  tested,	   with	   a	   47-­‐fold	   up-­‐regulation	   observed	   (Figure	   9C).	   Nevertheless,	   in	  C2C12	  cells,	  F1	  was	  as	  effective	  as	  SKM-­‐14,	  SKM-­‐22,	  SKM-­‐23U	  and	  SKM-­‐27,	  all	  of	  which	   upregulated	  HO1	   between	   17-­‐	   and	   20-­‐fold,	  with	   only	   SKM-­‐2	   showing	   a	  more	  modest	  activation	  (12-­‐fold,	  Figure	  9C).	  	  	   GCLM	   was	   not	   up-­‐regulated	   in	   Neuro2A	   neuronal	   cells	   by	   any	   of	   the	  barbiturate-­‐like	  small	  molecules	  (Figure	  10B).	  In	  the	  fibroblast	  cells,	  as	  had	  been	  observed	  for	  HO1,	  the	  lowest	  activation	  of	  this	  gene	  was	  achieved	  by	  SKM-­‐4/F1	  (close	   to	   2-­‐fold),	   and	   all	   the	   analogues	   showed	   a	   comparable	   up-­‐regulation	   of	  between	  3-­‐	  and	  5-­‐fold	  (Figure	  10A).	  Lastly,	  all	  compounds	  (including	  SKM-­‐4/F1)	  showed	   a	   similar	   activation	   of	   GCLM	   in	   the	   C2C12	  muscle	   cells,	   of	   between	  2-­‐	  and	  3-­‐fold	  (Figure	  10C).	  	   In	   short,	   all	   of	   the	   barbiturate-­‐like	   small	   molecules	   tested	   activated	   at	  least	  one	  gene	  involved	  in	  the	  oxidative	  stress	  response	  in	  the	  three	  assayed	  cell	  types.	  The	  6	  analogues	  of	  SKM-­‐4/F1	  seemed	  to	  be	  higher	  activators	  of	  oxidative	  stress	  than	  their	  counterpart	  SKM-­‐4/F1,	  and	  this	  effect	  was	  more	  obvious	  with	  SKM-­‐17.	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Figure	  10.	  Induction	  of	  GCLM	  in	  MEF	  fibroblasts	  (A),	  Neuron2A	  neuroblasts	  (B)	  and	  C2C12	  
myoblasts	   (C)	  by	  SKM-­4/F1	  and	   its	  analogues.	  mRNA	   levels	  of	  GCLM	  up-­‐regulation	  after	  4h	  incubation	  with	  the	  barbiturate	  small	  molecules.	  Of	  the	  7	  compounds	  analyzed,	  SKM-­‐4	  (F1,	  black	  bars)	   induces	   GCLM	   at	   the	   lowest	   levels.	   In	   MEFs	   (A),	   F1	   up-­‐regulated	   GCLM	   2-­‐fold	   and	   the	  analogues	  between	  3-­‐	  and	  5-­‐fold.	  No	  compounds	  were	  able	  to	  induce	  this	  gene	  in	  Neuro2A	  cells	  













































































































































































































































































































































































































































































































various	  cell	  lines	  tested	  (for	  example	  SKM-­‐17),	  others	  showed	  the	  ability	  to	  up-­‐regulate	  stress	  responsive	  genes	  in	  some	  cell	  types	  but	  not	  others.	  For	  example,	  SKM-­‐2	   activated	  Hsp70	   in	  MEFs	   and	   C2C12	   cells	   but	   not	  Neuro2As	   (Figure	   3)	  and	   also	   up-­‐regulated	   CHOP,	   but	   exclusively	   in	  MEFs	   (Figure	   6A).	   Compounds	  with	   these	   characteristics	   might	   be	   important	   tools	   to	   understand	   the	  configuration	  of	  cell-­‐specific	  proteostasis	  network	  constituents	  or	  maybe	  for	  the	  treatment	  of	  tissue	  specific	  diseases.	  A	   global	   analysis	   of	   stress	   responses	   using	   the	   six	   SKM-­‐4/F1	   analogues	  prompted	  us	  to	  choose	  SKM-­‐17	  and	  SKM-­‐27	  for	  additional	   testing	   in	  models	  of	  protein	   misfolding.	   We	   chose	   SKM-­‐17	   for	   its	   high	   levels	   of	   activation	   of	   HSR	  (Figures	  3	  and	  4)	  and	  oxidative	  stress	  (Figures	  9	  and	  10),	  while	  also	  showing	  up-­‐regulation	  of	  the	  UPR	  by	  BiP	  (even	  at	  low	  levels,	  Figure	  5)	  and	  CHOP	  (Figure	  6).	  It	   is	  also	   the	  only	  compound	  that	  consistently	  activated	   the	  mitochondrial	  UPR	  (Figures	   7A,	   7C	   and	   8A),	   thus	   constituting	   an	   important	   compound	   to	   study	  whether	   the	   activation	  of	   all	   these	   stress	  pathways	   correlates	  with	   a	   rescue	  of	  conformational	  disease	  models.	  SKM-­‐27	  was	  selected	  for	  constantly	  being	  one	  of	  the	  strongest	  inducers	  of	  the	  different	  stress	  genes	  studied,	  like	  Hsp70	  (Figure	  3)	  and	  Hsp40	  (Figure	  4),	  but	  mainly	  in	  the	  UPR	  (Figures	  5A,	  5C	  and	  6)	  where	  many	  of	  the	  other	  analogues	  caused	  no	  or	  weak	  activation.	  	  
2.4.	  Effect	  of	  SKM-­4/F1	  analogues	  in	  the	  Q35	  C.	  elegans	  model	  
2.4.1.	  Aggregation	  and	  toxicity	  effect	  in	  Q35-­YFP	  C.	  elegans	  	   To	   complement	   our	   cell	   culture	   studies,	   we	   investigated	   the	   effect	   of	  structural	   changes	  on	   the	  ability	  of	  SKM-­‐4F1	   to	   restore	  protein	  homeostasis	   in	  models	  of	  protein	  misfolding.	  As	  explained	  above,	  we	  selected	  SKM-­‐17	  and	  SKM-­‐27	   for	   these	   experiments.	   Caenorhabditis	   elegans	   nematodes	   expressing	   a	  polyglutamine	  stretch	  that	  contains	  35	  CAG	  repeats	  in	  fusion	  with	  YFP	  in	  muscle	  cells	  (Q35::YFP)	  (112)	  were	  treated	  with	  SKM-­‐4/F1,	  SKM17	  or	  SKM27	  for	  4	  days	  of	  life	  (starting	  at	  the	  second	  larval	  stage	  of	  life	  until	  worms	  are	  day-­‐3	  adults).	  By	  the	   third	   day	   of	   adulthood,	   Q35::YFP	   worms	   show	   a	   considerable	   number	   of	  fluorescent	   aggregated	   foci	   in	   the	   body	   wall	   muscle	   cells	   and	   measurable	  movement	  defects	  in	  comparison	  to	  wild-­‐type	  (WT)	  worms	  (Figures	  11A	  and	  C,	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“DMSO”	   images).	   The	   three	   barbiturate	   compounds	   had	   similar	   effects	   in	  rescuing	  polyglutamine	  toxicity	  by	  improving	  motility,	   from	  around	  70%	  of	  the	  wild-­‐type	   body	   lengths	   per	   second	   (BLPS)	   to	   85-­‐90%	   relative	   motility	  (Figure11A).	   However,	   when	   scoring	   for	   the	   reduction	   of	   fluorescent	   foci,	   we	  noticed	  that	  SKM-­‐17	  was	  as	  effective	  as	  SKM-­‐4/F1,	  reducing	  aggregates	  by	  25%	  in	   the	   body	   wall	   muscle	   cells	   of	   Q35	   worms,	   while	   SKM-­‐27	   showed	   only	   an	  intermediate	  rescue,	  of	  13%	  (Figure11B).	  	  
	  
	  







































































































total	   n	   of	   40	   or	   more	   individual	   worms	   scored.	   Error	   bars	   are	   S.E.M.	   *	   indicates	   statistically	  significant	  differences	  with	  p	  <	  0.05	  (Student	   t-­‐test).	   **	   indicates	  p	  <	  0.01	  and	  ***	  refers	   to	  p	  <	  0.001.	  (C)	  Representative	  pictures	  of	  small	  molecule-­‐treated	  Q35	  worms,	  at	  day	  3	  of	  adulthood.	  Pictures	  were	   taken	  with	  YFP	   fluorescence	  and	  with	  bright	   field,	  with	   the	   same	   light	   exposure	  and	  magnification.	  	  	   We	   took	   microscopy	   images	   of	   the	   treated	   nematodes	   to	   support	   our	  findings	   (Figure11C).	  These	   confirmed	   that	  17-­‐AAG,	   the	  positive	   control,	   is	   the	  compound	  with	   a	   stronger	   effect	   in	   reducing	   aggregation	   in	   Q35,	   followed	   by	  both	  SKM-­‐4/F1	  and	  SKM-­‐17.	  In	  comparison,	  SKM-­‐27	  had	  a	  more	  modest	  effect.	  These	   experiments	   confirmed	   the	   efficacy	   of	   SKM-­‐4/F1	   analogues	   in	   reducing	  aggregation	  and	  toxicity	  in	  a	  whole-­‐organism	  model	  of	  protein	  misfolding.	  SKM-­‐17	  was	  as	  efficient	  in	  ameliorating	  the	  Q35	  phenotypes	  as	  SKM-­‐4/F1,	  while	  SKM-­‐27	  was	  as	  effective	  in	  improving	  toxicity-­‐related	  motility	  (Figure	  11A),	  but	  not	  in	  reducing	  aggregation	  (Figures	  11B	  and	  C).	  
2.4.2.	   Activation	   of	   stress	   pathways	   by	   the	   SKM-­4/F1	   analogues	   in	   Q35	  
worms	  	   To	  follow	  up	  our	  phenotypic	  data	  in	  Q35	  animals,	  we	  extracted	  RNA	  from	  worms	   treated	   with	   SKM-­‐4/F1	   or	   its	   analogues,	   and	   looked	   for	   activation	   of	  different	   stress	   response	   pathways.	   In	   comparison	   to	   our	   cell	   culture	  experiments,	   treatment	   with	   our	   small	   molecules	   only	   had	   modest	   effects	   on	  stress	  gene	  induction	  (Figure12A).	  This	  could	  be	  due	  to	  the	  fact	  that	  we	  assessed	  gene	  expression	  at	  the	  end	  of	  treatment	  when	  worms	  were	  at	  day	  3	  of	  adulthood,	  an	   age	   that	   has	   been	   shown	   to	   correlate	  with	   reduced	   potency	   of	   stress	   gene	  induction	   (87)	   in	   C.	   elegans.	   Alternatively,	   this	   may	   also	   be	   due	   to	   a	   reduced	  exposure	   of	   cells	   to	   the	   compounds	   as	   a	   result	   of	   reduced	   penetration	   of	   the	  worm	   cuticle.	   Taking	   samples	   of	   treated	   animals	   at	   an	   earlier	   time	   point	   (for	  example,	  day	  1	  adults)	  could	  have	  created	  a	  better	  dynamic	  range	   for	  checking	  alterations	   of	   these	   responses,	   but	   we	   did	   not	   perform	   that	   experiment.	  Nevertheless,	  our	  results	  show	  that	  when	  compared	  to	  SKM-­‐4/F1,	  SKM-­‐17	  and	  SKM-­‐27	   do	   not	   significantly	   change	   activation	   of	   the	   HSR	   of	   the	   day	   3	   Q35	  animals	   (1.6-­‐fold	   for	   F1,	   1.25-­‐fold	   for	   SKM-­‐17	   and	   SKM-­‐27)	   (Figure	   12A,	  C12C8.1),	  and	  actually	  have	  a	  lower	  activation	  of	  the	  UPR	  (2-­‐fold	  for	  SKM-­‐4/F1,	  not	  activated	  for	  the	  analogues)	  (Figure	  12A,	  hsp-­4).	  This	  is	  different	  than	  what	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we	  observed	  in	  the	  different	  tissue	  culture	  cell	  types	  (even	  when	  comparing	  with	  C2C12	   cells,	   that	   are	   equally	  muscle	   cells),	   but	   these	  might	   just	  mean	   that	   the	  compounds	   are	   acting	   on	   the	   different	   proteostasis	   networks	   of	   the	   different	  organisms.	   Interestingly,	   we	  were	   able	   to	   reproduce	   the	   higher	  mitochondrial	  stress	  activation	  of	  these	  two	  analogues	  as	  we	  found	  that	  they	  up-­‐regulate	  hsp-­6	  expression	  to	  almost	  2-­‐fold,	  while	  SKM-­‐4/F1	  only	  up-­‐regulates	  this	  gene	  to	  1.3-­‐fold	   (Figure	   12A,	   hsp-­6).	   Even	   so,	   SKM-­‐27	   proved	   to	   be	   the	   least-­‐effective	  compound	   in	   terms	   of	   ameliorating	   aggregation	   in	   Q35	   worms	   (Figure	   12B),	  which	  seems	  to	  indicate	  that	  activation	  of	  the	  mitochondrial	  UPR	  is	  not	  needed	  for	   this	   rescue	   to	   occur.	   Finally,	   we	  were	   not	   able	   to	   see	   up-­‐regulation	   of	   the	  oxidative	  stress	  genes	  analyzed	  (except	  for	  a	  modest	  up-­‐regulation	  of	  1.4-­‐fold	  of	  
sod-­3	   by	   SKM-­‐27)	   (Figure	   12A,	   sod-­1	   and	   sod-­3).	   We	   know	   that	   all	   the	  barbiturate-­‐like	   small	   molecules	   that	   we	   tested	   activated	   this	   response	   in	  different	  tissue	  culture	  cell	  types,	  so	  maybe	  this	  was	  not	  the	  best	  method	  and/or	  time	  point	  to	  look	  into	  this	  stress	  response	  in	  the	  Q35	  worms.	  	   To	   ensure	   that	   reduced	   aggregation	   from	   treatment	   with	   our	   small	  molecules	   is	   not	   simply	   due	   to	   reduced	   expression	   of	   the	   Q35	   transgene,	   we	  determined	  the	  mRNA	  levels	  of	  YFP	  that	  resulted	  from	  treatment	  with	  the	  three	  small	  molecules	  and	  saw	  that	  they	  were	  mostly	  unchanged	  (Figure12B).	  In	  fact,	  YFP	  mRNA	  was	  even	  slightly	  up-­‐regulated	  (1.5-­‐fold);	  however,	  we	  do	  not	  think	  that	  this	  up-­‐regulation	  would	  be	  enough	  to	  change	  any	  of	  the	  results,	  and	  if	  so,	  it	  should	   be	   doing	   so	   in	   the	   opposite	   direction,	   i.e.,	   causing	   more	   toxicity	   by	  increasing	  the	  amount	  of	  aggregation-­‐prone	  protein.	  Nevertheless,	  we	  also	  saw	  that	  the	  YFP	  levels	  were	  the	  same	  between	  the	  three	  compounds,	  which	  proves	  that	  the	  differences	  in	  effect	  observed	  are	  not	  related	  to	  YFP	  variations.	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Figure	  12.	   	   Stress	   responsive	  genes	  activation	   in	  worms	  by	  SKM-­4/F1	  and	   its	  analogues,	  
SKM-­17	  and	  SKM-­27.	  (A)	  mRNA	  levels	  measured	  by	  qRT-­‐PCR	  with	  40	  day	  3	  adult	  Q35,	  with	  the	  indicated	   treatment.	   Control	   were	   DMSO-­‐treated	   nematodes,	   represented	   by	   the	   dotted	   line.	  C12C8.1	  is	  one	  of	  the	  worm	  Hsp70s	  and	  was	  chosen	  as	  a	  representative	  of	  HSR	  activation;	  hsp-­4,	  one	  of	  the	  2	  worm	  BiPs,	  represents	  UPR	  induction;	  hsp-­6	  is	  of	  the	  Hsp70	  family	  and	  is	  involved	  in	  the	  mitochondrial	   UPR;	   sod-­1	   and	   sod-­3	   are	   related	   to	   activation	   of	   oxidative	   stress	   response.	  Experiment	  was	  done	  with	  at	  least	  3	  biological	  replicates.	  Error	  bars	  =	  S.E.M.	  (B)	  mRNA	  levels	  of	  YFP	  with	  the	  different	  treatments,	  relative	  to	  DMSO-­‐treated	  worms.	  n=3;	  error	  bars	  =	  S.E.M.	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Figure	  13.	  SKM-­4/F1	  rescues	  a	  neuronal	  phenotype	  of	  locomotion	  deficiency	  in	  C.	  elegans	  




























































































relevant	   for	   neurodegenerative	   diseases.	  We	   followed	   up	   on	   these	   findings	   by	  testing	  F1	  in	  neuronal	  mammalian	  models.	  	  
2.6.	   Protective	   effect	   of	   F1	   in	   rat	   brain	   slices	   and	   neuronal	   co-­culture	  
models	  expressing	  Htt-­N90Q73	  	   Since	  SKM-­‐4/F1	  showed	  prowess	  in	  neuronal	  models	  of	  both	  mammalian	  cells	  (96)	  and	  C.	  elegans	  (this	  thesis),	  we	  wanted	  to	  follow	  up	  on	  this	  finding	  by	  testing	  this	  small	  molecule	  in	  brain	  slice	  and	  neuronal	  co-­‐culture	  models.	  These	  commonly	  act	  as	  a	  bridge	  between	  the	  more	  classical	  tissue	  culture	  and	  mouse	  models,	   for	   studying	   new	   compounds.	   We	   used	   tissue	   transfected	   with	   Htt-­‐N90Q73,	   which	   contains	   the	   first	   90	   amino	   acid	   residues	   of	   full-­‐length	  Huntingtin	  in	  fusion	  with	  a	  polyglutamine	  stretch	  with	  73	  CAG	  repeats,	  as	  a	  way	  to	   challenge	   the	   cells.	  We	   then	  assessed	   the	   ability	  of	   F1	   to	   suppress	  neuronal	  toxicity	   in	   this	   system.	   These	   experiments	   were	   performed	   by	   Dr.	   Barbara	  Calamini	   and	   Denise	   Dunn	   in	   the	   Lo	   laboratory	   at	   Duke	   University,	   and	  commercial	  F1	  was	  used	  for	  the	  assays.	  
	  	   	  	   Our	  brain	  slice	  experiments	  (Figure	  14)	  revealed	  that	  samples	  transfected	  with	   the	  Htt-­‐N90Q73	  construct,	   together	  with	  YFP,	   caused	  significant	  neuronal	  death,	   with	   only	   57%	   of	   healthy	   cortical	   neurons	   remaining	   compared	   to	  transfection	   of	   the	   brain	   slices	   with	   YFP	   alone.	   The	   positive	   control	   used	   (a	  combination	   of	   compounds	   KW6002	   +	   SP600125,	   used	   for	   HTS	   of	   new	  compounds	   in	   the	  Lo	   lab)	  rescued	  this	  phenotype	   to	  92.5%	  of	  healthy	  neurons	  scored	   and,	   extraordinarily,	   F1	   at	   1μM	   rescued	   the	   number	   of	   healthy	   cortical	  
Figure	   14.	   F1	   has	   a	   neuroprotective	   effect	  
in	   rat	   brain	   slices.	   Rat	   brain	   slices	   were	  prepared	  from	  pup	  brains	  and	  plated	  in	  culture	  media	   Slices	   were	   transfected	   with	   YFP	   only	  (black	   bar)	   or	   YFP	   +	   Htt-­‐N90Q73	   and	  incubated	  at	  32°C	  for	  4	  days	  with	  compounds.	  DMSO	   (white)	   was	   the	   negative	   control	   and	  KW6002	   +	   SP600125,	   a	  mix	   of	   2	   compounds,	  was	   the	   positive	   control	   (light	   grey).	   F1	   was	  tested	  at	  different	  concentrations.	  The	  relative	  number	   of	   healthy	   neurons	   was	   counted	   on	  day	   4.	   n	   =	   12.	   Error	   bars	   are	   S.E.M.	   ***	  represents	   statistical	   significant	   differences	  with	  p	  <	  0.001.	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neurons	   to	   100%,	   exactly	   as	   YFP	   alone	   (in	   the	   absence	   of	   Htt-­‐N90Q73),	  demonstrating	  a	  clear	  neuroprotective	  effect.	   	  	   This	   effect	  was	   further	   confirmed	  by	   performing	   a	   co-­‐culture	   of	   striatal	  and	  cortical	  neurons	  prepared	  from	  embryonic	  rat	  brains.	  Cells	  were	  transfected	  separately	   with	   the	   Htt-­‐N90Q73	   and	   then	   plated	   together	   as	   co-­‐cultures.	  Expression	  of	  the	  Huntingtin	  construct	  was	  induced	  and	  cells	  treated	  with	  F1	  or	  the	   neurotrophin	   BDNF	   as	   a	   positive	   control	   of	   neuron	   protection.	   Results	  showed	   that	   co-­‐cultures	   where	   Htt-­‐N90Q73	   expression	   was	   not	   induced	   had	  100%	   more	   healthy	   cortical	   neurons	   (Figure15	   A)	   and	   60%	   more	   striatal	  neurons	  (Figure	  15B)	  then	  when	  expressing	  the	  aggregation-­‐prone	  protein.	  The	  BDNF	  neurotrophin,	  used	  as	  a	  positive	  control	  for	  neuroprotection,	  increased	  the	  number	  of	  healthy	  neurons	  in	  the	  cortex	  by	  150%	  and	  in	  the	  striatum	  by	  80%,	  in	  co-­‐cultures	   expressing	   Htt-­‐N90Q73.	   F1	   also	   had	   the	   ability	   of	   significantly	  improving	  the	  number	  of	  healthy	  neurons	  in	  these	  co-­‐cultures.	  This	  was	  visible	  both	   in	   the	   cortex,	  where	   the	  number	  of	  healthy	  neurons	   increased	  by	  26%	  at	  0.3μM	   and	   by	   31%	   at	   0.8μM	   (Figure	   15A)	   and,	   even	   more	   evidently,	   in	   the	  striatum,	   where	   the	   rescue	   increased	   by	   53%	   and	   58%	   at	   0.3	   and	   0.8μM,	  respectively,	   being	   these	   levels	   comparable	   to	   those	   in	   unchallenged	   neurons	  expressing	   YFP-­‐alone	   (Figure	   15B).	   We	   also	   collected	   images	   of	   the	   neuronal	  populations,	  which	  show	  that	  more	  cortical	  and	  striatal	  neurons	  can	  be	  observed	  after	   treatment	  with	   F1,	   when	   the	   cells	   are	   challenged	  with	   the	   expression	   of	  HttN90-­‐Q73	  (Figure	  15C).	  	   These	   are	   exciting	   results	   that	   also	   show	   a	   wide	   concentration	   range	  between	   where	   the	   beneficial	   effects	   of	   the	   F1	   small	   molecule	   are	   observed	  (starting	   at	   0.3μM)	   and	   where	   the	   toxicity	   of	   the	   compound	   is	   already	  detrimental	  to	  the	  overall	  phenotype	  (22μM).	  The	  therapeutic	  index	  (Ti)	  (137)	  in	  this	   situation,	   more	   pharmacologically	   relevant	   than	   the	   previously	   shown	  models,	  is	  also	  much	  improved	  (≈	  100).	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Figure	  15.	  F1	  rescues	  proteotoxicity	  of	  Htt-­N90Q73	   in	  co-­cultures	  of	  cortical	  and	  striatal	  
neurons.	   Primary	   striatal	   and	   cortical	   neuronal	   cultures	   were	   prepared	   from	   embryonic	   rat	  brains	  and	  transfected	  separately	  with	  either	  Htt-­‐N90Q73	  +	  YFP	  for	  the	  cortical	  neurons,	  or	  Htt-­‐N90Q73	   +	   mCherry	   for	   the	   striatal	   neurons.	   Neurons	   were	   combined	   together	   and	   plated.	  “Induced”	   refers	   to	   activation	   of	   Htt-­‐N90Q73	   expression	   by	   endoxifene.	   Compounds	   were	  incubated	  with	  the	  co-­‐cultures	  for	  1	  week.	  Negative	  control	  was	  1.2%	  DMSO.	  Positive	  control	  was	  30ng/mol	   BDNF.	   F1	   was	   tested	   at	   different	   concentrations	   and	   showed	   a	   protective	   effect,	  increasing	  the	  number	  of	  healthy	  cortical	  (A)	  and	  striatal	  (B)	  neurons.	  (C)	  Cells	  were	  fixed	  and	  images	  were	   captured	  using	   a	  Cellomics	  Arrayscan	  VTI	   (Thermo	  Fisher	   Scientific).	  The	   images	  were	   analyzed	   using	   the	   Cellomics	   Target	   Activation	   algorithm,	   optimized	   to	   identify	   specific	  neuronal	  cells	  bodies	  and	  to	  quantify	  the	  results	  shown	  in	  (A)	  and	  (B).	  n=6.	  Error	  bars	  are	  S.E.M.	  *	  indicates	  statistically	  significant	  differences	  with	  p	  <	  0.05	  (Student	  t-­‐test).	  **	  indicates	  p	  <	  0.01	  and	  ***	  refers	  to	  p	  <	  0.001.	  	  
2.7.	  Insights	  into	  the	  molecular	  mechanism	  of	  action	  of	  the	  barbiturate-­like	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pathways	  might	  be	  necessary	  for	  the	  compound	  to	  be	  acting	  on	  the	  improvement	  of	  proteostasis.	  The	  nematode	  C.	  elegans	   is	  a	  useful	  tool	  for	  performing	  reverse	  genetics,	  given	  its	  amenability	  to	  RNAi	  techniques.	  We	  used	  the	  Q35	  aggregation	  phenotype	   (which	   above	   showed	   more	   robustness	   than	   the	   motility	  assessments)	  to	   look	  for	  the	  requirement	  of	  representative	  stress	  transcription	  factors	   (TFs)	   for	   the	   activity	   of	   SKM-­‐4/F1.	   We	   performed	   our	   liquid	   culture	  assay,	  used	  earlier	   in	  this	  chapter	  for	  determining	  the	  activity	  of	  the	  SKM-­‐4/F1	  analogues,	  to	  see	  with	  which	  knockdowns	  of	  stress	  TFs	  the	  SKM-­‐4/F1	  compound	  is	  still	  functional.	  For	  this,	  we	  grew	  animals	  in	  different	  cultures	  of	  RNAi	  bacteria	  (instead	   of	   the	   standard	   OP50	   bacteria)	   and	   performed	   the	   assay	   in	   the	   same	  way.	  We	  chose	  to	  look	  at	  hsf-­1	  (as	  the	  master	  regulator	  of	  the	  HSR),	  atf-­6	  (stress	  TF	   for	   the	  ER	  UPR),	  atfs-­1	   (regulator	  of	   the	  mitochondrial	  UPR)	  and	   skn-­1	   and	  
daf-­16	  (involved	  in	  the	  oxidative	  stress	  pathways).	  We	   started	   by	   looking	   at	   the	   efficiency	   of	   the	   knockdown	   (KD)	   of	   the	  different	   mRNAs,	   in	   the	   day	   3	   adult	   Q35	   worms.	   For	   hsf-­1,	   atfs-­1	   and	   daf-­16,	  there	  was	  a	  decrease	  of	  at	  least	  50%	  of	  the	  mRNA	  levels,	  more	  precisely	  of	  52%	  for	   hsf-­1,	   65%	   for	   atfs-­1	   and	   54%	   for	   daf-­16	   (Figure16A).	   atf-­6	   had	   a	   more	  modest	  KD,	  but	  we	  were	  still	  able	  to	  reduce	  its	  level	  by	  29%.	  As	  for	  skn-­1,	  even	  though	  we	  know	  this	  RNAi	  construct	   is	  efficient	   in	   lowering	  skn-­1	  mRNA	  levels	  when	  worms	  are	  grown	  in	  normal	  NGM	  plates,	  the	  liquid	  culture	  assay	  combined	  with	   the	   RNAi	   construct	   effect	   induced	   skn-­1	   by	   around	   3-­‐fold.	  We	   speculated	  that	   this	   might	   be	   a	   result	   of	   the	   DMSO	   percentage	   in	   the	   growth	   media	   and	  repeated	   the	  assay	  with	   the	   lowest	  DMSO	  amount	   that	  would	  allow	  having	   the	  small	  molecules	  dissolved.	   Even	   at	   0.5%	  DMSO,	   skn-­1	  was	   still	   up-­‐regulated	   at	  similar	   levels	   (Figure	  16A).	  Since	   this	  experiment	  would	  not	  be	  possible	   in	   the	  absence	  of	  DMSO,	  we	  decided	  to	  proceed	  with	  only	  daf-­16	  as	  a	  representative	  TF	  for	  the	  antioxidant	  stress	  pathways.	  	   Next,	   we	   wanted	   to	   confirm	   if,	   by	   growing	   the	   Q35	   worms	   in	   the	   four	  representative	   stress	   TFs	   RNAis,	   the	   aggregation	   phenotype	   of	   day	   3	   adults	  would	  be	   changed.	   Figure16B	   shows	   that	  none	  of	   the	  RNAis	   caused	   significant	  differences	  in	  the	  number	  of	   fluorescent	  foci	  at	  that	  stage	  of	  adulthood.	  Finally,	  we	  looked	  at	  the	  rescue	  of	  aggregation	  by	  SKM-­‐4/F1	  in	  the	  presence	  of	  hsf-­1,	  atf-­
6,	  atfs-­1	  and	  daf-­16	  RNAi	  (Figure16C).	  The	  number	  of	  relative	  foci	  in	  day-­‐3	  adult	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Q35s	   showed	   a	   rescue	   of	   30%	   when	   SKM-­‐4/F1	   was	   present	   in	   control	   RNAi	  bacteria	  (L4440).	  It	  had	  been	  showed	  before	  that	  hsf-­1	  is	  required	  for	  the	  activity	  of	  F1	  (96).	  We	  confirmed	  that,	  as	  expected	  when	  hsf-­1	  was	  knocked	  down,	  only	  a	  rescue	  of	  6%	  of	  fluorescent	  foci	  could	  be	  observed.	  In	  addition,	  we	  now	  verified	  that	   KD	   of	   other	   stress	   pathways	   (ER	   UPR,	   mitochondrial	   UPR	   and	   oxidative	  stress)	  does	  not	  impair	  the	  beneficial	  effect	  of	  SKM-­‐4/F1	  in	  the	  day	  3	  adult	  Q35	  
C.	   elegans.	   In	  atf-­6	  RNAi,	   SKM-­‐4/F1	   still	   reduced	  aggregation	  by	  21%;	   in	  atfs-­1	  knockdown	  it	  improved	  the	  phenotype	  by	  25%;	  and,	  lastly,	  with	  daf-­16	  reduced	  aggregation	  levels	  by	  20%.	  


























































































































Figure	   16.	   Stress	   transcription	   factors	   (TFs)	  
requirement	  for	  activity	  of	  SKM-­4/F1.	  (A)	  Efficiency	  of	   RNAi	   K.D.	   for	   the	   different	   TFs,	   relative	   to	   mRNA	  expression	   of	   each	   gene	   in	   vehicle	   L4440	   control	  bacteria.	  Grey	  bars	  represent	  RNAis	   that	  showed	  good	  levels	  of	  K.D.:	  except	  for	  atf-­6,	  all	  other	  RNAis	  produced	  at	  least	  a	  50%	  decrease	  in	  mRNA	  levels.	  The	  black	  bars	  show	  attempts	  to	  K.D.	  skn-­1	  with	  the	  normal	  amount	  of	  DMSO	   in	   the	   media	   (1.67%)	   or	   with	   reduced	   DMSO	  levels	   (0.5%).	   n	   ≥	   3.	   (B)	   None	   of	   the	   RNAi	   bacteria	  caused	   noteworthy	   changes	   in	   the	   aggregation	  phenotype	  of	  day	  3	  adult	  Q35	  worms,	  compared	  to	  the	  negative	   control	   L4440.	   n	   ≥	   2	   (C)	   Effect	   of	   F1	   on	   the	  Q35	   aggregation	   phenotype,	   with	   the	   different	   RNAi	  bacteria.	   Results	   are	   relative	   to	   the	   vehicle	   negative	  control,	   1.67%	  DMSO.	  Positive	   control	   for	   aggregation	  suppression	   was	   50μM	   17-­‐AAG.	   n	   ≥	   2.	   Error	   bars	   =	  S.E.M.	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3.	   Discussion:	   SKM-­4/F1	   and	   its	   class	   have	   the	   potential	   for	  
more	  advanced	  studies	  	   In	   this	   chapter,	   we	   showed	   that	   the	   small	   molecule	   SKM-­‐4/F1	   is	   a	  compound	   with	   activity	   in	   various	   cellular	   stress	   responses	   that	   seems	   to	   be	  already	   “best-­‐of-­‐its-­‐class”.	   In	   fact,	   even	   though	   we	   analyzed	   over	   60	   chemical	  modifications	  in	  the	  barbiturate-­‐like	  structure	  of	  SKM-­‐4/F1,	  we	  were	  not	  able	  to	  clearly	   improve	   its	   performance	   in	   activating	   the	   HSR	   (as	   measured	   by	   a	  reporter	  assay).	  Nevertheless,	  our	  SAR	  studies	  gave	   important	  clues	  as	  to	  what	  chemical	   moieties	   are	   necessary	   for	   SKM-­‐4/F1	   to	   function,	   most	   notably	   the	  carbon-­‐carbon	  double	  bonds	  that	  exist	  in	  its	  allylidene	  linker.	  We	  also	  saw	  that	  SKM-­‐4/F1	  works	   better	   in	   the	   activation	   of	   the	  HSR	   as	   a	   planar,	   2D	  molecule.	  Finally,	  we	  found	  locations	  in	  the	  molecule	  where	  it	  is	  possible	  to	  add	  side	  chains	  without	  completely	  losing	  HSR	  activation.	  This	  will	  be	  important	  to	  allow	  tagging	  SKM-­‐4/F1	  in	  a	  way	  that	  will	  allow	  performing	  pull	  downs	  of	  proteins,	  to	  uncover	  direct	  binding	  partners.	  	   Some	  interesting	  analogues	  of	  SKM-­‐4/F1	  showed	  different	  capabilities	  in	  up-­‐regulating	  stress	  responses,	  namely	  the	  HSR,	  the	  ER	  UPR,	  the	  mitochondrial	  UPR	  and	  the	  antioxidant	  stress	  response.	  In	  particular,	  SKM-­‐17	  and	  SKM-­‐27	  are	  SKM-­‐4/F1	  analogues	  that	  showed	  improvements,	  when	  compared	  to	  SKM-­‐4/F1,	  in	   activating	   the	   mitochondrial	   and	   ER	   UPRs,	   respectively.	   We	   tested	   these	  compounds	   in	   parallel	   with	   SKM-­‐4/F1	   and	   observed	   that,	   even	   though	   they	  could	   still	   reproduce	   the	   effects	   of	   SKM-­‐4/F1	   in	   C.	   elegans	   models	   of	   protein	  misfolding,	   they	   did	   not	   act	   to	   a	   further	   extent	   than	   the	   original	   SKM-­‐4/F1	  molecule.	  These	  results	  were	  consistent	  with	  our	  findings	  using	  RNAi	  techniques	  in	   C.	   elegans,	   showing	   that	   only	   HSF-­‐1	   knockdown	   significantly	   altered	   the	  rescue	  of	   the	  aggregation	  phenotype,	   in	  Q35	  worms.	  Transcription	   factors	   that	  regulate	   UPR	   in	   the	   ER	   and	   mitochondria,	   or	   oxidative	   stress	   response,	   were	  down-­‐regulated	  without	  affecting	  SKM-­‐4/F1	  activity.	  	   Finally,	  the	  efficacy	  of	  SKM-­‐4/F1	  in	  improving	  proteotoxicity	  phenotypes	  in	   neuronal	  models	   of	   C.	   elegans	   led	   us	   to	   test	   this	   small	  molecule	   in	   primary	  neuronal	  cell	  models,	  with	  relevance	  for	  the	  study	  of	  Huntington’s	  disease.	  These	  models	   also	   help	   bridge	   the	   gap	   between	   simpler	   whole	   organism	   animal	  models,	   like	   C.	   elegans,	   the	   fruitfly	  Drosophila	   or	   yeast,	   and	   the	  mouse	  models,	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which	  are	  the	  reference	  model	  for	  more	  advanced	  studies	  with	  new	  compounds	  of	  pharmacological	  interest.	  F1	  showed	  an	  extraordinary	  ability	  to	  protect	  these	  neuronal	   cells	   against	   toxicity	   induced	   by	   expression	   of	   an	   aggregation-­‐prone	  fragment	  of	  Huntingtin	  (Htt).	  	   These	  results	  pointed	  to	  the	  potential	  of	  SKM-­‐4/F1	  for	  follow-­‐up	  studies	  in	   higher	   organisms,	   or	   at	   least	   as	   a	   powerful	   tool	   to	   better	   unravel	   the	  mechanisms	   of	   proteostasis,	   and	   how	   they	   can	   be	   helpful	   for	   getting	   closer	   to	  developing	  treatments	  for	  protein	  conformational	  diseases.	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IV – A High Throughput Screen for new 
Chemical Regulators of the Heat Shock 
Response 	  	  
	  1.	  Background	  Genetic	   or	   pharmacological	   enhancement	   of	   chaperone	   levels	   has	   been	  shown	  to	  ameliorate	  disease	  progression	  in	  cell,	  worm,	  fly,	  and	  mouse	  models	  of	  protein	   conformational	   disease.	   	   As	   a	   consequence,	   it	   has	   been	   proposed	   that	  proteostasis	  regulators	  can	  provide	  a	  powerful	  new	  therapeutic	  approach	  for	  the	  treatment	   of	   protein	   conformation	   disorders	   such	   as	   cystic	   fibrosis	   (CF),	  Huntington’s	  disease	   (HD),	  Alzheimer’s	  disease	   (AD),	  Parkinson’s	  disease	   (PD),	  Machado-­‐Joseph	  disease	  (MJD),	  and	  others	  (96).	  	  However,	   to	   translate	   these	   findings	   to	   the	   clinic	   and	   obtain	   maximal	  efficiency,	  it	  is	  essential	  that	  we	  identify	  well-­‐tolerated	  small	  molecules	  that	  act	  at	   discrete	   targets.	   To	   this	   end,	   the	   mechanism	   of	   action	   (MoA)	   of	   small	  molecules	  should	  be	  investigated.	  Activation	  of	   the	  HSR	   is	   an	  effective	  way	   to	  enhance	   the	  protein	   folding	  environment	   of	   the	   cell.	   Therefore,	   we	   adapted	   a	   High	   Throughput	   screening	  (HTS)	  protocol	   that	  measures	  the	  activation	  of	   the	  HSR	  using	  a	  HeLa	   luciferase	  reporter	  system.	  Luciferase	   is	  expressed	   in	   these	  cells	  under	   the	  control	  of	   the	  proximal	  promoter	  sequence	  of	  human	  Hsp70.1	  and	  increased	  luciferase	  activity	  can	  be	  detected	  after	  exposure	  to	  stress	  stimuli	  (126)	  (139).	  We	  used	  this	  system	  to	  search	  for	  novel	  regulators	  of	  the	  HSR.	  In	  addition	  to	  activators,	  we	  employed	  a	  strategy	  that	  allowed	  us	  to	  also	  detect	  inhibitors	  and	  co-­‐activators	  of	  the	  HSR,	  in	  a	  library	  of	  new	  compounds.	  These	  last	  two	  last	  classes	  of	  HSR	  regulators	  have	  been	  proposed	  as	  potential	  therapies	  for	  diseases	  such	  as	  cancer	  (HSR	  inhibitors,	  reviewed	  in	  (107))	  and	  amyotrophic	  lateral	  sclerosis	  (ALS)	  (the	  HSR	  co-­‐inducer	  arimoclomol,	  which	  only	  acts	  on	  previously	  stressed	  cells	  (140)).	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2.	  Results	  
2.1.	  Optimization	  of	  an	  HTP	  screen	  for	  activators	  of	  the	  HSR	  In	   order	   to	   establish	   our	   screening	   conditions,	   we	   performed	   a	   set	   of	  initial	   optimization	   steps	   based	   on	   previous	   protocols,	   to	   demonstrate	   the	  suitability	  of	  this	  method	  in	  our	  hands.	  We	  began	  by	  establishing	  the	  optimal	  cell	  density	   for	   the	  HeLa::Luc	  cells.	  Between	  4,500	  and	  7,500	  cells	  were	  plated	   in	  a	  25μl	  volume	  of	  media	  culture	  onto	  384-­‐well	  assay	  plates.	  These	  densities	  were	  chosen	  based	  on	  previous	  protocols	  and	  the	  differences	  in	  size	  of	  the	  multi-­‐well	  plates	  used	  (96).	  We	  used	  two	  molecules	  that	  were	  previously	  shown	  to	  strongly	  activate	   the	   reporter	   system	   as	   positive	   controls:	   the	   proteasome	   inhibitor	  MG132	  (30μM)	  and	  the	  toxic	  heavy	  metal	  CdCl2	  (50μM).	  In	  addition,	  based	  on	  a	  previously	   described	   protocol,	   we	   defined	   the	   temporal	   parameters	   of	   our	  screen	  as	  a	  4h	  incubation	  of	  cells	  after	  plating,	  followed	  by	  16-­‐18h	  of	  treatment	  with	   compounds.	   Maximizing	   the	   reporter	   signal	   was	   important	   to	   create	   a	  dynamic	   range	   that	   could	   provide	   more	   reliable	   hits	   from	   the	   screening.	   We	  found	  that	  7,500	  cells	  were	  the	  optimal	  seeding	  number	  for	  our	  assay	  conditions	  as	  signal	   intensity	  was	  maximal,	  while	  cell	  density	  still	   remained	  sub-­‐confluent	  throughout	   the	   duration	   of	   the	   experiment	   (Figure	   1).	   Luciferase	   activity	   was	  increased	   by	   2,200	   to	   3,350	   relative	   light	   units	   (RLU)	   with	   MG132	   and	   from	  22,000	   to	   33,000	   with	   CdCl2.	   	   Importantly,	   signal	   was	   increased	   by	  approximately	   50%	  when	   using	   an	   initial	   density	   of	   7,500	   cells,	   compared	   to	  4,500	  cells	  with	  both	  HSR	  activators	  (Figure	  1).	  	  Next,	  we	   determined	   the	   response	   of	   the	   reporter	   system	   to	   increasing	  concentrations	  of	  DMSO.	  Given	  that	  DMSO	  is	  the	  solvent	  for	  the	  molecules	  in	  our	  library,	  this	  is	  essential	  to	  define	  the	  maximum	  levels	  of	  the	  vehicle	  that	  can	  be	  used	  without	  confounding	  effects	  on	  our	  screening	  system.	  We	  tested	  DMSO	  at	  concentrations	   of	   0.05	   to	   2%	   of	   the	   final	   volume	   and	   found	   that	   luciferase	  activity	   is	   gradually	   increased	   at	   concentrations	   up	   to	   1%	   (v/v)	   DMSO.	  Furthermore,	   luciferase	   signal	   is	   increased	   after	   treatment	   with	   MG132	   up	   to	  2.3-­‐fold	  and	  with	  CdCl2	  up	  to	  1.5-­‐fold,	  in	  the	  presence	  of	  these	  elevated	  levels	  of	  DMSO	  (Figure	  2).	  In	  addition,	  we	  were	  able	  to	  observe	  that	  2%	  DMSO	  is	  already	  detrimental	   to	   the	   cells	   in	   the	   assay,	   as	   there	   was	   a	   decrease	   of	   the	   signal.	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Overall,	  we	  established	  that	  DMSO	  concentration	  should	  not	  exceed	  0.2	  –	  0.3%	  to	  minimize	  confounding	  effects	  in	  our	  screen.	  	  
	  
Figure	  1.	  Determination	  of	  the	  optimal	  cell	  density	  for	  performing	  a	  HeLa-­luc	  HTP	  assay	  in	  
384-­well	  plates.	   Increasing	  densities	  of	   cells	  were	  plated	   in	   triplicate	   and	  HSR	  activation	  was	  induced	   by	   the	   indicated	   condition.	   7500	   cells/well	  maximized	   the	   signal	   obtained	   in	   relative	  light	   units	   (RLU)	   for	   both	   CdCl2	   and	  MG132.	   All	   cell	   densities	   tested	   still	  maintained	   the	   cells	  under	  100%	  confluency	  throughout	  the	  duration	  of	  the	  experiment.	  Error	  bars	  are	  S.D.	  	  
Figure	  2.	  Effect	  of	  DMSO	  in	  the	  activation	  of	  the	  HeLa-­luc	  reporter.	  Concentrations	  between	  0.05%	  and	  2%	  (v/v)	  were	  tested	  in	  triplicate	  and	  we	  determined	  that	  a	  limit	  of	  0.2-­‐0.3%	  DMSO	  should	  be	  used	  to	  avoid	  an	  undesired	  effect	  of	  the	  vehicle	  on	  activation	  of	  the	  HSR.	  Also,	  we	  were	  able	   to	   observe	   that	   at	   2%,	   DMSO	   already	   causes	   a	   toxic	   effect,	   evident	   from	   the	   decrease	   in	  reporter	  activation.	  Error	  bars	  =	  S.D.	  	  To	   determine	   the	   ideal	   concentrations	   for	   our	   positive	   controls,	   we	  examined	   the	  effects	  of	  a	  series	  of	  concentrations	  of	  both	  MG132	  and	  CdCl2	  on	  the	   reporter	   cells.	   We	   observed	   that	   30μM	   and	   50μM	   were	   the	   optimal	  concentrations	  to	  be	  used	  for	  MG132	  and	  CdCl2,	  respectively,	  as	  positive	  controls	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in	   our	   assay	   (Figure	   3).	   Moreover,	   our	   data	   reproduced	   the	   dose-­‐dependent	  activation	   pattern	   previously	   described	   for	   these	   compounds	   in	   the	   same	  reporter	   system	   (96).	   Cadmium	   activates	   the	   reporter	   to	   very	   high	   levels	   of	  relative	   light	   units	   (RLU)	   (in	   the	   range	   of	   105)	   and	   allows	   for	   a	  wide	   dynamic	  range.	   Reporter	   activity	   after	   CdCl2	   treatment	   reaches	   the	   plateau	   at	   50μM	  before	  decreasing	  at	  concentrations	  of	  100μM	  and	  higher,	  most	  likely	  due	  to	  the	  toxic	   effects	   of	   CdCl2.	   MG132	   displayed	   a	   more	   sigmoidal	   profile	   in	   reporter	  activation,	  with	   30μM	   concentration	   showing	   little	   increase	   in	   signal	   from	   the	  lower	   concentrations	   of	   15	   and	   20μM	   (as	   in	   a	   sigmoidal	   profile).	   While	   we	  observed	   an	   increase	   in	   signal	   after	   treatment	  with	   40	   and	   60μM	  MG132,	   this	  also	   correlated	   with	   significantly	   higher	   cell	   death	   (as	   observed	   by	   light	  microscopy)	  and	  higher	  variability	  in	  results.	  Based	  on	  this	  data	  we	  used	  MG132	  and	   CdCl2	   at	   final	   concentrations	   of	   30	   and	   50μM	   as	   positive	   controls	   in	   our	  screen.	  We	  also	  used	  these	  experiments	  to	  optimize	  the	  time	  of	  incubation	  of	  the	  cells	  with	  the	  Steadylite	  luciferin	  reagent.	  We	  observed	  that	  different	  incubation	  times	   (from	   5	   to	   15min)	   did	   not	   result	   in	   significant	   alterations	   of	   the	   output	  signal	  (Figure	  3).	  Therefore,	  in	  accordance	  with	  these	  results,	  we	  decided	  to	  use	  a	   reagent	   incubation	   time	   of	   5min	   so	   that	   the	   assay	   could	   be	   performed	   at	   a	  higher	  throughput	  (see	  Material	  and	  Methods	  section	  for	  more	  screen	  details).	  
Figure	  3.	  Dose-­dependent	   induction	  of	   the	  Hsp70-­luc	   reporter	  by	  50μM	  CdCl2	  and	  30μM	  
MG132,	  with	  incubation	  of	  the	  Steadylite	  HTS	  reagent	  for	  5	  (white),	  10	  (grey)	  or	  15	  (black)	  
minutes.	  Cadmium	  shows	  a	  bell-­‐shaped	  curve	  of	  activation,	  while	  MG132	  has	  a	  progressive	  and	  slightly	  sigmoidal	  profile.	  Negative	  control	  was	  0.2%	  DMSO.	  Error	  bars	  represent	  S.D.	  	  Having	   defined	   the	   adequate	   parameters	   of	   cell	   density,	   DMSO	  percentage,	   positive	   control	   concentration	   and	   time	   of	   reagent	   incubation,	   we	  went	  on	  to	  calculate	  the	  Z’-­‐value	  (136)	  for	  the	  HTS	  of	  new	  activators	  of	  the	  HSR.	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This	   parameter	   is	   the	   standard	   measurement	   for	   reliability	   of	   a	   HTS	   and	   to	  decide	  whether	   the	   full-­‐scale	   screen	   should	  be	  performed.	   It	   can	  be	   calculated	  with	  the	  means	  and	  standard	  deviations	  of	  a	  negative	  and	  a	  positive	  control	  and,	  in	  general,	  a	  Z’	  of	  >	  0.5	  is	  consistent	  with	  an	  excellent	  setting	  for	  a	  screen,	  as	   it	  means	   that	   the	   2	   means	   are	   separated	   by	   at	   least	   12	   standard	   deviations	   (a	  perfect	   score	   would	   be	   Z’	   =	   1)	   (136).	   We	   calculated	   a	   Z’-­‐value	   for	   a	   HTS	  performed	  with	   7,500	   cells/25μl	   volume	   in	   a	   384-­‐well	   plate,	   with	   0.1%	   (v/v)	  DMSO	  as	  a	  negative	  control	  and	  either	  30μM	  MG132	  or	  50μM	  CdCl2	  as	  positive	  controls,	  incubating	  the	  Steadylite	  HTS	  (Perkin	  Elmer)	  reagent	  for	  5min	  (Figure	  4).	   We	   used	   a	   minimum	   of	   at	   least	   65	   individual	   samples	   per	   condition	   and	  striped	   them	  across	   the	  384-­‐well	   plate	   to	   account	   for	   edge	   or	   other	   positional	  effects.	   The	   calculated	   Z’	   for	   MG132	   was	   0.59	   and	   the	   Z’	   for	   CdCl2	   was	   0.62.	  Having	  established	  that	  both	  compounds	  would	  allow	  for	  an	  excellent	  screen,	  we	  finally	   decided	   to	   select	  MG132	   as	   the	   positive	   control,	   primarily	   because	   this	  activator	  is	  dissolved	  in	  DMSO,	  as	  is	  the	  small	  molecule	  library	  that	  was	  going	  to	  be	  screened,	  while	  CdCl2,	  is	  dissolved	  in	  water.	  
	  
Figure	   4.	   Our	   experimental	   settings	   were	   able	   to	   produce	   a	   high	   Z’-­value	   that	   enabled	  
pursuing	   a	   HTS	   for	   activators	   of	   the	   HSR.	   	   Z’	   is	   calculated	   as	   a	   function	   of	   the	   standard	  deviation	  (δ)	  and	  the	  mean	  (μ)	   for	  the	  positive	  and	  negative	  controls	  of	  a	  screen.	  n	  >	  65.	  Error	  bars	  =	  S.D.	  	  
2.2.	  Optimization	  of	  an	  HTP	  for	  inhibitors	  of	  the	  HSR	  	   For	  our	  new	  HTS,	  we	  screened	   the	  Kozmin	   library	  of	  6,769	  compounds,	  which	   is	   composed	   of	   common	   small	   molecule	   backbones	   where	   a	   variety	   of	  diverse	  polycyclic	  scaffolds	  were	  introduced	  (125).	  This	  library	  originated	  from	  the	   Chicago	   Tri-­‐Institutional	   Center	   for	   Chemical	   Methods	   and	   Library	  Development,	   a	   collaboration	   between	   University	   of	   Chicago,	   Northwestern	  
Z'-Value determination for CdCl2 













Z'-Value determination for MG132














University	   and	   the	  University	  of	   Illinois	   at	  Chicago.	  The	  goal	   for	   screening	   this	  library	  was	  to	  generate	  not	  only	  hits	  for	  activation	  of	  the	  HSR	  but	  also	  inhibitors	  of	   the	   same	   stress	   pathway.	   Inhibition	   of	   the	  HSR	   is	   of	   special	   interest	   for	   the	  treatment	   of	   cancer	   as	   typically	   tumor	   cells	   exhibit	   high	   levels	   of	   HSPs	   when	  compared	  to	  normal	  cells.	  Even	  though	  some	  HSR	  inhibitors	  have	  been	  described	  (141),	   HTP	   screens	   for	   this	   class	   of	   modulators	   have	   not	   been	   previously	  published.	  	   We	  used	  the	  conditions	  optimized	  for	  the	  HSR	  activator	  screen	  and	  added	  2	  extra	  steps:	  we	  incubated	  the	  library	  of	  compounds	  for	  1h	  at	  37°C,	  5%	  CO2	  and	  then	  added	  a	  known	  activator	  of	   the	  HSR	  as	  an	  agonist,	   in	  order	   to	  reveal	  how	  efficient	  a	  new	  small	  molecule	  inhibitor	  would	  be.	  Typically	  for	  inhibitor	  screens,	  the	  agonist	   is	  added	  at	   the	  concentration	  that	  yields	  80%	  of	  maximum	  activity.	  Therefore,	   in	   accordance	   with	   our	   own	   results	   (Figure	   3),	   we	   decided	   to	   use	  20μM	   MG132	   and	   37.5μM	   CdCl2	   as	   the	   HSR	   inhibition	   agonists.	   The	   positive	  control	  for	  inhibition	  of	  the	  HSR	  was	  triptolide,	  a	  diterpene	  triepoxide	  originated	  from	  the	  plant	  Triptergium	  wilfordii	   (124).	  We	  tested	  increasing	  concentrations	  of	   triptolide	   in	   the	   nanomolar	   range	   and	   determined	   50nM	   to	   be	   the	   optimal	  positive	  control	  for	  the	  screen	  (Figure	  5),	  with	  either	  of	  the	  agonists.	  Using	  this	  concentration	   of	   triptolide,	   only	   ≈6%	   of	   CdCl2	   activity	   remained,	   and	   ≈3%	   for	  MG132.	  
	  
Figure	  5.	  Dose-­dependent	  inhibition	  of	  the	  HSR	  by	  increasing	  concentrations	  of	  triptolide,	  with	  either	  37.5μM	  CdCl2	  or	  20μM	  MG132	  used	  as	  agonists	  of	  the	  inhibitor.	  In	  both	  cases,	  50nM	  triptolide	  showed	  >	  94%	  inhibition	  of	  the	  initial	  signal	  (obtained	  with	  the	  agonists	  alone).	  n	  =	  3.	  Error	  bars	  =	  S.D.	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   An	   experimental	   set	   up	   of	   7,500	   cells/25μl	   volume	   in	   a	   384-­‐well	   plate,	  with	  0.1%	  (v/v)	  DMSO	  plus	  each	  of	  the	  agonists	  as	  negative	  controls	  and	  50nM	  triptolide	   as	   the	   positive	   control	   yielded	   Z’	   values	   of	   0.62	   and	   0.79	   for	   the	  agonists	   CdCl2	   and	   MG132	   respectively,	   allowing	   both	   to	   be	   categorized	   as	  excellent	   assays	   (Figure	   6).	   Out	   of	   consistency	   with	   the	   activator	   screen,	   and	  because	  MG132	  is	  dissolved	  in	  DMSO	  (as	  explained	  in	  the	  previous	  section),	  we	  chose	  MG132	  as	  the	  agonist	  for	  the	  full	  HTP	  screen.	  	  	  
	  
Figure	  6.	  Z’-­values	  were	  also	  calculated	  for	  the	  HTS	  of	  inhibitors	  of	  the	  HSR.	  The	  means	  for	  negative	  and	  positive	  controls	  showed	  a	  high	  dynamic	  range	  and	  a	  reduced	  error.	  Therefore,	  like	  for	   the	   activators,	   the	   Z’-­‐values	   were	   consistent	   with	   an	   excellent	   assay	   and	   motivated	  performing	  the	  full-­‐scale	  screen.	  	  
2.3.	  Identification	  of	  new	  regulators	  of	  the	  HSR	  –	  activators,	  inhibitors	  and	  
a	  new	  class,	  co-­activators	  	   A	  double	  screen	  for	  activators	  and	  inhibitors	  of	  the	  HSR	  was	  performed	  in	  parallel,	   using	   the	   Kozmin	   library	   of	   6,769	   compounds	   (125).	   Tables	   1	   and	   2	  show	  the	  final	  protocols	  that	  were	  optimized	  for	  each	  screen.	  The	   screens	  were	  performed	   in	  5	  batches	  of	   384-­‐well	   plates	  during	   the	  course	   of	   3	  weeks	   and	   16	   samples	   of	   the	   negative	   and	   positive	   controls	  were	  always	  included	  in	  each	  plate,	  as	  a	  way	  to	  constantly	  verify	  the	  consistency	  and	  reproducibility	   of	   the	   assay.	   Interestingly,	   during	   the	   course	   of	   the	   HTP	  screening,	  it	  became	  clear	  that	  our	  experimental	  setup	  enabled	  the	  identification	  of	  a	  third	  class	  of	  HSR	  regulators:	  some	  of	  the	  new	  small	  molecules	  not	  only	  did	  not	   reduce	   the	   activation	  of	   the	  HSR	  by	  MG132	   in	   the	   inhibitor	   screen	   setting,	  but	  also	  further	  enhanced	  the	  signal	  that	  was	  obtained	  with	  the	  same	  control.	  We	  categorized	  this	  new	  class	  of	  HSR	  regulators	  as	  co-­‐activators	  of	  MG132-­‐mediated	  
Z'-Value determination with 37.5µM CdCl2 












Z'-Value determination with 20µM MG132













HSR,	   as	   they	   could	  not	   activate	   the	  HSR	  by	   themselves	   in	   the	   activator	   screen,	  but	  further	  improved	  the	  HSR	  that	  resulted	  from	  MG132	  action	  in	  the	  inhibitor	  screen,	   performed	   in	   parallel.	   Even	   though	   co-­‐inducers	   of	   the	   HSR	   have	   been	  previously	   identified	   (140),	   this	   is	   the	   first	   time,	   to	   our	   best	   knowledge,	   that	  small	  molecules	  with	  these	  characteristics	  were	  identified	  by	  a	  HTS.	  	  
Table	  1.	  Assay	  protocol	  for	  the	  activator	  HTP	  screen	  	   Step	   Condition	   Comments	  1	   Cell	  dispensing	   25μl/well	   7,500	  cells/well	  2	   1st	  incubation	  time	   4h	   37°C,	  5%	  CO2	  3	   Library	  addition	   50nl/well	  	   0.2%	  (v/v)	  DMSO	  final	  4	   2nd	  incubation	  time	   16-­‐18h	  	   37°C,	  5%	  CO2	  5	   Addition	  of	  Steadylite	  HTS	  reagent	   25μl/well	   	  6	   3rd	  incubation	  time	   5min	   Room	  temperature	  	  
Table	  2.	  Assay	  protocol	  for	  the	  inhibitor	  HTP	  screen	  	   Step	   Condition	   Comments	  1	   Cell	  dispensing	   25μl/well	   7,500	  cells/well	  2	   1st	  incubation	  time	   4h	   37°C,	  5%	  CO2	  3	   Library	  addition	   50nl/well	  	   To	  0.2%	  (v/v)	  DMSO	  4	   2nd	  incubation	  time	   1h	   37°C,	  5%	  CO2	  5	   Agonist	  addition	   25nl/well	   0.3%	  (v/v)	  DMSO	  final	  6	   3rd	  incubation	  time	   16-­‐18h	  	   37°C,	  5%	  CO2	  7	   Addition	  of	  Steadylite	  HTS	  reagent	   25μl/well	   	  8	   4th	  incubation	  time	   5min	   Room	  temperature	  	   The	  final	  results	  were	  normalized	  to	  the	  negative	  controls	  and	  expressed	  as	  fold	  increase	  of	  the	  DMSO	  background	  signal	  for	  the	  activators,	  percentage	  of	  inhibition	  of	  MG132	  luciferase	  activity	  for	  the	  inhibitors	  and	  fold	  increase	  of	  the	  same	   control	   for	   the	   co-­‐activators.	   At	   the	   end	   of	   the	   screens,	  we	  had	  3	   sets	   of	  primary	   hits:	   2	   activators,	   43	   inhibitors	   and	   27	   co-­‐activators	   (Table	   3).	   We	  considered	   an	   activator	   as	   a	   positive	   hit	   when	   activity	   of	   the	   reporter	   was	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increased	  by	  ≥	  2-­‐fold	  of	  the	  signal	  from	  DMSO	  treated	  samples.	  We	  classified	  HRS	  inhibitors	   as	   compounds	   that	   reduced	   the	  HSR	   activation	   obtained	  with	   20μM	  MG132	  by	   at	   least	  50%.	  Finally,	   co-­‐activators	  were	  defined	  as	   small	  molecules	  that	  further	  enhanced	  MG132-­‐mediated	  activation	  of	  the	  reporter	  by	  at	   least	  2-­‐fold.	  In	  order	  to	  exclude	  false	  positives,	  we	  performed	  a	  secondary	  screen	  for	  the	  hits	  with	   a	   7-­‐point	   dose-­‐dependent	   curve	   of	   concentrations	   ranging	   from	   1	   to	  20μM	  for	  each	  primary	  hit.	  Maintaining	   the	  same	  criteria	  of	  selection,	   this	  step	  allowed	  us	  to	  reduce	  the	  number	  of	  validated	  hits	  to	  2	  activators,	  26	  inhibitors	  and	  17	  enhancers.	  Table	  3	  lists	  the	  experimental	  setting	  and	  results	  of	  our	  three-­‐pronged	  high	  throughput	  screens	  for	  new	  chemical	  classes	  of	  HSR	  regulators.	  	  
Table	  3.	  Summary	  of	  High	  Throughput	  Screen	  parameters	  and	  results	  Class	  of	  HSR	  Regulator	   Activator	   Inhibitor	   Co-­‐activator	  Identified	  in	   Activator	  screen	   Inhibitor/Co-­‐activator	  screen	  Compounds	  tested	   6769	  Compound	  concentration	   10μM	  Positive	  Control	   30μM	  MG132	   50nM	  Triptolide	  Negative	  Control	   0.2%	  (v/v)	  DMSO	   20μM	  MG132	  Z’-­‐value	   0.59	   0.79	  Primary	  hit	  rate	  (%)	   0.03	   0.64	   0.40	  Secondary	  hit	  rate	  (%)	   0.03	   0.38	   0.25	  Number	  of	  validated	  hits	   2	   26	   17	  	  
2.4.	  Activity	  and	  toxicity	  profiles	  of	  validated	  screen	  hits	  	   To	  better	   characterize	   our	  new	   small	  molecule	  hits,	   it	  was	  necessary	   to	  assess	   their	   activity	   in	   parallel	   with	   their	   toxicity.	   We	   repeated	   the	   luciferase	  assay	   with	   the	   7-­‐point	   dose-­‐dependent	   curve	   of	   concentrations,	   while	   also	  determining	  cytotoxicity	  of	  the	  new	  compounds	  using	  the	  calcein	  AM	  assay	  (see	  Materials	   and	   Methods),	   to	   address	   cell	   viability	   in	   the	   HeLa	   cells.	   Since	   this	  experiment	  was	   still	   performed	  with	   the	   original	   library	   for	   HTP	   screening,	   it	  was	  only	  performed	  once,	  to	  preserve	  compounds	  for	  further	  study.	  
	  94	  
2.4.1.	  Activators	  We	   identified	   2	   small	  molecules	   that	   showed	   low	   levels	   of	   activation	   of	  the	   Hsp70.1	   promoter	   (Figure	   7,	   grey	   bars).	   Activator	   A731	   (A731)	   activated	  luciferase	  expression	  by	  5-­‐fold	  at	  10μM,	  while	  A735	  activated	  reporter	  activity	  by	   2-­‐fold	   at	   7.5μM.	   Both	   compounds	   exhibited	   high	   toxicity	   in	   the	   HeLa	   cells,	  with	   cell	   viability	   reduced	  by	  75%	  at	  7.5μM	  A731	  and	  5μM	  A735,	   respectively	  (Figure	  7,	  black	  bars).	  These	  compounds	  are	  of	  the	  same	  chemical	  class	  and	  have	  similar	   profiles	   of	   both	   activation	   and	   toxicity.	   A731	   is	   the	   compound	   with	  higher	   reporter	   activation	  and	  also	   showed	   the	   lower	   toxicity.	  Being	   that	   their	  chemical	   similarity	  makes	   it	   likely	   that	   both	   small	  molecules	  would	   act	   on	   the	  same	  genetic	  pathway,	  we	  chose	  to	  perform	  the	  follow	  up	  experiments	  only	  on	  A731,	  while	  A735	  was	  discarded.	  	  
	  
Figure	  7.	  Dose-­dependent	   curves	   for	   toxicity	   (black	  bars)	  and	  activity	   (grey	  bars)	  of	   the	  
two	  validated	  secondary	  hits	  for	  activation	  of	  the	  HSR,	  resulting	  from	  a	  HTS	  of	  6,769	  new	  
small	   molecules.	   A731	   and	   A735	   are	   similar	   in	   chemical	   structure	   and	   also	   presented	  comparable	  profiles.	  Of	  the	  two,	  A731	  displayed	  a	  higher	  activation	  of	  the	  HeLa-­‐luc	  reporter	  (5-­‐fold),	  while	  maintaining	  a	  higher	  percentage	  of	  living	  cells.	  We	  therefore	  elected	  A731	  as	  the	  HTP	  hit	  to	  be	  followed	  up	  on.	  	  
2.4.2.	  Inhibitors	  
	   In	  the	  inhibitor	  class,	  there	  was	  an	  even	  higher	  requirement	  for	  assessing	  toxicity	   of	   the	   HTP	   screen	   hits,	   given	   that	   their	   selection	   was	   based	   on	   a	  reduction	   of	   reporter	   signal.	   In	   theory,	   a	   decrease	   in	   luminescence	   could	   be	  simply	  due	  to	  a	  lower	  number	  of	  healthy	  cells.	  This	  would	  be	  a	  result	  of	  toxicity	  of	  the	  small	  molecules,	  and	  not	  an	  active	  process	  of	  HSR	  inhibition,	  thus	  creating	  misleading	  results.	  By	  simultaneously	  looking	  at	  the	  toxicity	  and	  activity	  profiles	  of	  our	  secondary	  hits	  (Figure	  8),	  we	  observed	  that	  many	  of	  the	  chemicals	  were	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false	   positives	   that	   changed	   the	   reporter	   signal	   based	   mostly	   on	   their	   high	  toxicity	   levels.	   This	   was	   particularly	   evident	   in	   cases	   where	   the	   activity	   and	  toxicity	  dose-­‐dependent	  profiles	   showed	   the	   same	   trend,	   for	  example	   for	   I367,	  I399,	  and	  I423	  (I	  =	  inhibitor),	  where	  a	  decrease	  in	  luciferase	  activity	  was	  exactly	  paralleled	  by	  a	  decrease	  in	  survival	  (Figure	  8).	  	   In	  other	  cases,	  we	  detected	  a	  slight	  reporter	  activation	  (between	  1.3	  and	  just	   below	   2-­‐fold)	   in	   the	   lower	   concentration	   range	   of	   the	   small	  molecules,	   in	  contrast	  to	  the	  higher	  concentration	  range,	  which	  revealed	  the	  inhibitory	  effect	  –	  I451,	   I735	   and	   I734	   (Figure	   8).	   This	   was	   mostly	   noticeable	   for	   I735,	   which	  curiously	   was	   also	   a	   hit	   in	   the	   activator	   screen	   (A735	   activated	   the	   HeLa-­‐luc	  reporter	  in	  the	  absence	  of	  MG132	  as	  well),	  providing	  a	  likely	  explanation	  for	  our	  observations:	  these	  compounds	  must	  be	  activating	  HSR	  as	  a	  “cellular	  emergency”	  mechanism	   solely	   by	   their	   toxicity.	   The	   toxicity	   was	   first	   reflected	   as	   HSR	  activation	   while	   some	   of	   the	   cells	   still	   survived,	   but	   was	   consistent	   with	   HSR	  inhibition	  when	  most	  of	  the	  cells	  are	  destroyed	  due	  to	  added	  toxicity	  of	  MG132.	  Therefore,	   these	   compounds	  were	   also	   discarded.	   Additionally,	   I630	   and	   I418	  did	  not	  reproduce	  their	  inhibition	  of	  at	  least	  50%	  of	  the	  MG132	  activation,	  even	  up	  to	  20μM.	  This	  shows	  the	  need	  for	  a	  systematic	  filtering	  of	  false	  positives	  when	  performing	  HTP	   screens,	   and	   how	   this	   technology	   is	   of	   indubitable	   value	   as	   a	  starting	  point	  when	  searching	   for	  new	  compounds	  of	  pharmacological	   interest,	  but	  should	  always	  be	   followed	  by	  more	  stringent	  and	  endogenous	  experiments	  in	  other	  systems.	  	   Finally,	   from	   the	   remaining	   small	   molecules,	   we	   looked	   for	   those	   that	  showed	   a	   higher	   dissociation	   of	   toxicity	   and	   activity.	   Compound	   I632	   showed	  60%	   inhibition	   of	   the	   luciferase	   reporter	   activity	  while	   only	   causing	   less	   than	  30%	   of	   cell	   death	   while	   compound	   I696	   (Figure	   8,	   marked	   with	   a	   *)	   showed	  higher	  potency,	  inhibiting	  the	  HSR	  signal	  by	  72%,	  with	  a	  similar	  toxicity	  as	  I632.	  In	  summary,	  from	  the	  26	  inhibitors	  of	  the	  HSR	  that	  had	  been	  validated	  in	  the	  HTS,	  we	  chose	  to	  follow	  up	  on	  the	  two	  that	  showed	  the	  best	  activity/toxicity	  relationships.	  The	  remaining	  22	  compounds	  demonstrated	  pronounced	  toxicity	  before	   inhibition	   of	   the	   luciferase	   signal	   and	   were	   therefore	   unlikely	   to	   be	  
bonafide	  inhibitors	  of	  the	  HSR.	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Figure	   8.	   Dose-­dependent	   curves	   for	   toxicity	   (black	   bars)	   and	   activity	   (grey	   bars)	   of	   26	  
secondary	   hits	   for	   inhibition	   of	   the	   HSR,	   resulting	   from	   a	   HTS	   of	   6,769	   new	   small	  
molecules.	  Compounds	   showed	   different	   kinds	   of	   profiles	   of	   toxicity/activity	   and	  we	   selected	  I632	  and	  I696	  (marked	  with	  a	  *)	  for	  testing	  endogenous	  expression	  of	  HSR	  genes,	  as	  they	  were	  the	  compounds	  where	  activity	  seemed	  more	  uncoupled	  from	  toxicity.	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Figure	   9.	   Dose-­dependent	   curves	   for	   toxicity	   (black	   bars)	   and	   activity	   (grey	   bars)	   of	   17	  
secondary	  hits	  for	  co-­activators	  of	  MG132-­induced	  HSR,	  resulting	  from	  a	  HTS	  of	  6,769	  new	  
small	  molecules.	  The	  primary	  target	  of	  this	  screen	  were	  inhibitors	  of	  HSR,	  but	  while	  the	  screen	  occurred	   it	   became	   clear	   that	   some	   compounds	   not	   only	   did	   not	   inhibit	   HSR,	   but	   also	   were	  further	   activating	   the	   response	   caused	  by	   the	   agonist	   (MG132),	   but	  did	  not	  have	   the	   ability	   to	  activate	  HSR	  by	  themselves	  (or	  they	  would	  have	  been	  hits	  in	  the	  activator	  screen	  ran	  in	  parallel).	  Of	  the	  15	  small	  molecules	  that	  had	  confirmed	  function	  after	  this	  assay,	  we	  selected	  C571,	  C694	  and	  C732	  (marked	  with	  a	  *)	  for	  additional	  testing.	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2.5.	  Induction	  of	  endogenous	  Hsps	  by	  the	  HSR	  regulators	  	   To	  determine	  whether	  our	  hits	  were	   an	   artifact	   of	   our	   reporter	   system,	  we	  tested	  the	  6	  small	  molecules	  selected	   in	  the	  previous	  sections	   in	  a	  different	  cell	   line,	   mouse	   embryonic	   fibroblast	   (MEF),	   for	   induction	   of	   endogenous	  expression	   of	   Hsp70	   mRNA.	   The	   chemical	   structures	   of	   these	   compounds	   are	  shown	  in	  Figure	  10.	  
	  
Figure	   10.	   Chemical	   structures	   of	   the	   HTP	   hits	   in	   3	   classes	   of	   HSR	   regulation:	   activator	  (A731),	   inhibitors	   (I632	   and	   I696)	   and	   co-­‐activators	   of	  MG132-­‐induced	  HSR	   (C571,	   C694	   and	  C732).	   It	   is	  noteworthy	  that	  our	  hits	  group	  into	  2	  structural	   families:	  A731	  and	  C732	  share	  the	  same	  chemical	  backbone,	  with	  different	  side	  groups	  and	  the	  other	  3	  compounds,	  both	  inhibitors	  and	  co-­‐activators,	  are	  also	  from	  a	  same	  family.	  It	  is	  an	  important	  validation	  of	  our	  screen	  that	  the	  hits	  cluster	  into	  chemical	  classes.	  However,	  it	  is	  still	  unclear	  how	  similar	  compounds	  are	  showing	  different	  effects	  in	  the	  HSR.	  	   	  	   Levels	   of	   Hsp70	   mRNA	   were	   measured	   in	   MEF	   cells	   by	   qRT-­‐PCR	   after	  treatment	  for	  4h	  with	  each	  of	  the	  different	  compounds	  and,	  where	  appropriate,	  the	   agonist	   MG132.	   We	   observed	   that	   treatment	   with	   activator	   A731	   alone	  induced	  endogenous	  expression	  of	  Hsp70	  at	  the	  mRNA	  level,	  by	  4.5-­‐fold	  at	  10μM	  and	  33.5-­‐fold	  at	  20μM	  (Figure	  11A).	  This	  activation	  was	  at	  much	  milder	   levels	  than	   the	  positive	   control	  MG132	   (110-­‐fold).	  However,	   this	  might	   be	  beneficial,	  since	   it	   is	   commonly	   accepted	   that	   a	   moderate	   activation	   of	   stress	   responses	  might	   be	   enough	   to	   adapt	   proteostasis,	   without	   overwhelming	   the	   cellular	  
A731 I632 I696 
C694 C571 
C732 
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environment	   with	   a	   more	   abrupt	   change.	   Furthermore,	   no	   obvious	   cell	   death	  was	  observed	  after	  this	  treatment	  period	  (assessed	  by	  light	  microscopy).	  
	  	  	  	   We	  also	  assessed	  the	  ability	  of	  the	  expected	  inhibitors,	  I632	  and	  I696,	  to	  lower	  levels	  of	  Hsp70	  mRNA	  after	  activation	  of	  the	  HSR	  with	  20μM	  MG132	  (as	  an	  agonist)	   in	   MEFs.	   We	   observed	   that	   I632	   reduced	   the	   level	   of	   expression	   of	  Hsp70	  by	  30%	  at	  both	  10	  and	  20μM	  (Figure	  11B).	  Even	  though	  this	  is	  less	  than	  the	  50%	  expected	  inhibition,	  it	  is	  still	  an	  encouraging	  result,	  given	  that	  this	  small	  molecule	  did	  not	  show	  significant	  toxicity	  at	  the	  same	  concentrations	  in	  the	  HeLa	  cells	  (Figure	  8).	  I696,	  however,	  did	  not	  reproduce	  the	  results	  obtained	  with	  the	  Hela	  luciferase	  reporter.	  In	  fact,	  this	  compound	  did	  not	  show	  any	  level	  of	  Hsp70	  inhibition,	  showing	  that	  it	  was	  a	  false	  positive	  hit.	  This	  result	  might	  be	  due	  to	  the	  intrinsic	   differences	   of	   measuring	   the	   protein	   levels	   of	   luciferase	   in	   a	   given	  reporter	   system,	  versus	  measuring	  endogenous	  mRNA	   levels.	  Another	  possible	  













































































































































Figure	   11.	   Alterations	   in	   endogenous	   Hsp70	  
mRNA	  expression	  by	  the	  HTP	  hits	  in	  MEFs.	  (A)	  Activator	  A731	  up-­‐regulates	  Hsp70	   at	  moderate	  levels.	  Negative	  control	  were	  1%	  DMSO	  and	  also	  untreated	   cells.	   Positive	   control	   was	   30μM	  MG132.	   (B)	   Only	   inhibitor	   I632	   down-­‐regulates	  activation	  of	  endogenous	  Hsp70	  mRNA	  by	  20μM	  MG132,	   whereas	   I696	   was	   a	   false	   positive.	  Negative	  control	  was	  DMSO	  +	  20μM	  MG132	  and	  positive	   control	   for	   inhibition	   was	   50nM	  triptolide	   +	   20μM	   MG132.	   (C)	   Hsp70	   mRNA	  endogenous	  levels	  by	  co-­‐activators	  from	  the	  HTS	  showed	   that	   only	   C732	   can	   further	   increase	   the	  levels	   of	   expression	   registered	   with	   20μM	  MG132	  alone	   (negative	  control).	  C571	  and	  C694	  were	  false	  positives.	  n	  =	  2,	  error	  bars	  =	  S.E.M.	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explanation	  is	  that	  compound	  I696	  inhibits	  the	  activity	  of	  luciferase	  itself,	  which	  would	  result	  in	  the	  decrease	  of	  luminescence	  signal	  observed.	  	   Finally,	   we	   also	   assessed	   whether	   the	   co-­‐activators	   resulting	   from	   the	  HTS	  were	  able	  to	  further	  enhance	  Hsp70	  mRNA	  up-­‐regulation	  by	  20μM	  MG132.	  The	  qRT-­‐PCR	  results	  showed	  that	  C571	  and	  C694	  were	  false	  positives	  and	  were	  unable	  to	  further	  activate	  endogenous	  Hsp70	  mRNA	  expression.	  As	  for	  the	  false	  positive	  inhibitors,	  the	  results	  previously	  obtained	  (Figure	  9)	  were	  probably	  an	  artifact	  of	  the	  luciferase	  reporter	  system.	  C732,	  however,	  had	  a	  significant	  effect	  on	  endogenous	  Hsp70	  activation,	  which	  was	  of	  37%	  at	  10μM	  and	  70%	  at	  20μM	  (Figure	   11C).	   This	   is	   an	   exciting	   result,	   because	   C732	   is	   chemically	   similar	   to	  activator	   A731	   (Figure	   10).	   We	   speculate	   that	   even	   though	   both	   compounds	  might	  be	  acting	  on	  the	  same	  chemical	   target,	   the	  differences	   in	  C732	  and	  A731	  structures	  cause	  the	  former	  to	  require	  a	  previous	  change	  in	  proteostasis,	  caused	  in	   this	   case	   by	   MG132,	   so	   that	   it	   can	   be	   functional.	   Compounds	   with	   these	  characteristics	   could	   be	   used	   synergistically	   with	   other	   small	   molecules	   that	  show	  a	  sub-­‐optimal	  toxicity,	  but	  that	  could	  be	  used	  at	  lower	  concentration	  in	  the	  presence	  of	  a	  co-­‐activator	  like	  C732.	  	   Testing	   the	   regulation	   of	   endogenous	   Hsp70	   mRNA	   levels	   by	   the	   HSR	  regulator	  candidates	  was	  an	  important	  step	  in	  defining	  which	  small	  molecules	  in	  the	  screened	  library	  do	  in	  fact	  have	  an	  effect	  on	  the	  HSR.	  This	  final	  refinement	  of	  our	  results	   resulted	   in	   three	  new	  confirmed	  regulators	  of	   the	  HSR,	  one	   in	  each	  class:	  A731	  is	  an	  activator	  of	  the	  HSR,	  with	  potency	  in	  the	  μM	  range.	  C732	  is	  a	  co-­‐activator	   of	  MG132-­‐mediated	  HSR	   and	  might	   act	   by	   a	   similar	  mechanism	   than	  A731,	  given	  their	  structural	  similarity;	  I632	  is	  a	  weak	  inhibitor	  of	  HSR	  (activated	  by	   MG132)	   that	   can	   potentially	   show	   higher	   efficiency	   when	   used	   at	   higher	  concentrations.	  Of	  the	  3	  new	  regulators,	  we	  decided	  to	  do	  a	  more	  detailed	  study	  of	  the	  activator,	  A731.	  	  
2.6.	  A731,	  a	  new	  activator	  of	  the	  HSR	  
2.6.1.	  Activation	  of	  general	  HSR	  by	  A731	  	   A731	   was	   shown	   in	   the	   previous	   section	   to	   up-­‐regulate	   expression	   of	  Hsp70	   at	   the	  mRNA	   level.	  We	  wanted	   to	   test	   if	   this	   compound	  was	   a	   specific	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inducer	  of	  Hsp70	  or	  if	  it	  caused	  a	  more	  general	  HSR.	  We	  tested	  up-­‐regulation	  of	  three	   other	   heat	   shock	   genes	   and	   observed	   that	   A731	   also	   induces	   the	  expression	   of	   Hsp40	   (Figure12A),	   Hsp25	   (Figure	   12B)	   and	   Hsp110	   mRNA	  (Figure	   12C),	   in	   a	   dose-­‐responsive	   manner	   from	   10	   to	   50	   μM.	   10μM	   A731	  induces	  the	  expression	  of	  Hsp40	  by	  3-­‐fold,	  Hsp25	  and	  Hsp110	  by	  ≈2-­‐fold,	  but	  at	  50μM	  it	  reaches	  inductions	  of	  36-­‐,	  5-­‐	  and	  11-­‐fold,	  respectively.	  This	  shows	  a	  link	  to	  a	  more	  general	  activation	  of	  the	  HSR	  and	  not	  an	  Hsp70-­‐specific	  effect.	  
	  





























































































































protein	  level	  (Figure	  12D),	  thereby	  confirming	  the	  function	  of	  A731	  as	  a	  general	  activator	  of	  the	  HSR.	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regulation	   of	   Hsp70	   with	   50μM	   A731	   in	   the	   wild-­‐type	   MEFs	   was	   completely	  abolished	  when	  HSF1	   is	   disrupted	   (Figure	  13A).	   Similar	   results	  were	   obtained	  for	  Hsp40	  (Figure	  13B),	  Hsp25	  (Figure	  13C)	  and	  Hsp110	  (figure	  13D).	  	   In	   conclusion,	   we	   find	   that	   treatment	   with	   A731	   results	   in	   the	   up-­‐regulation	  of	  multiple	  heat	  shock	  genes	  and	  this	  occurs	   in	  an	  HSF-­‐1	  dependent	  manner.	  
2.6.2.	   Effect	   of	   A731	   on	   proteotoxicity	   in	   C.	   elegans	   models	   of	   protein	  
misfolding	  	   Since	   A731	   significantly	   activates	   the	   HSR,	  we	   reasoned	   that	   treatment	  with	   A731	   might	   rescue	   proteotoxic	   effects	   in	   models	   of	   misfolding.	   We	   first	  wanted	  to	  determine	  whether	  A731	  could	  activate	  the	  HSR	  in	  a	  C.	  elegans	  model	  of	  protein	  misfolding.	  We	  performed	  our	   liquid	  media	  assay	  (see	  Materials	  and	  Methods)	  and	  treated	  L2	  Q35	  animals	  for	  4	  days	  (until	  they	  were	  day-­‐3	  adults)	  with	   A731	   and	   SKM-­‐4/F1	   (see	   Chapter	   III)	   as	   a	   positive	   control.	   Our	   results	  showed	  that	  10	  or	  20μM	  A731	  up-­‐regulated	  C12C8.1,	  one	  of	   the	  Hsp70s	  of	   the	  worm,	  by	  the	  same	  level	  as	  SKM-­‐4/F1	  (1.6-­‐fold,	  Figure	  14A).	  Since	  we	  measured	  these	  up-­‐regulation	   in	  day-­‐3	  adults,	  where	  activation	  of	   the	   stress	  pathways	   is	  already	   known	   to	   be	   less	   intense	   (87),	  we	  might	   had	  observed	   an	   even-­‐higher	  up-­‐regulation	  whether	  we	   had	   assessed	   the	   Hsp70	   up-­‐regulation	   at	   an	   earlier	  timepoint.	  However,	  we	  saw	  that	  C12C8.1	  was	  induced	  at	  the	  same	  level	  of	  SKM-­‐4/F1,	  a	  compound	  with	  a	  known	  effect	  in	  ameliorating	  proteostasis	  (96).	  	   	  










































































A B Figure	  14.	  A731	  induces	  expression	  
of	  C12C8.1	   in	  Q35	  C.	   elegans,	   but	   it	  
does	  not	  alter	   the	  YFP	   levels	   in	   the	  
same	   worms.	   (A)	   mRNA	   levels	  measured	   by	   qRT-­‐PCR	  with	   40	   day-­‐3	  adult	   Q35,	   with	   the	   indicated	  treatment.	   Control	  was	   DMSO-­‐treated	  nematodes,	  represented	  by	  the	  dotted	  line.	   C12C8.1	   is	   one	   of	   the	   worm	  Hsp70s	   and	   was	   chosen	   as	   a	  representative	   of	   HSR	   activation.	   (B)	  mRNA	  levels	  of	  YFP	  with	  the	  different	  treatments,	   relative	   to	   DMSO-­‐treated	  worms.	  n	  ≥	  3;	  error	  bars	  =	  S.E.M.	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   We	  completed	  this	  observation	  by	  showing	  that	  A731	  does	  not	   interfere	  with	   the	   levels	   of	   YFP	   expression	   in	   the	   Q35	   C.	   elegans,	   when	   compared	   to	  DMSO-­‐only	   treated	   worms	   (Figure	   14B).	   Therefore,	   any	   effect	   that	   we	   could	  observe	   with	   A731	   in	   ameliorating	   proteotoxicity	   in	   Q35s	   would	   not	   be	   an	  artifact	  of	  altered	  YFP	  levels.	  	   We	  then	  incubated	  A731	  with	  wild	  type	  (N2)	  C.	  elegans	  for	  4	  days	  (since	  the	   L2	   larval	   stage	   until	   the	   third	   day	   of	   adulthood)	   in	   liquid	   media	   (see	  Materials	  and	  Methods)	  and	  assayed	  the	  effect	  of	  A731	  on	  motility	  of	  these	  wild-­‐type	   worms,	   in	   order	   to	   ascertain	   whether	   A731	   treatment	   had	   pronounced	  toxicity	  in	  worms.	  We	  found	  that	  this	  was	  not	  the	  case,	  suggesting	  that	  treatment	  of	  worms	  with	  20	  μM	  A731	  is	  well	  tolerated	  by	  nematodes	  (Figure	  15A).	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in	  triplicate	  and	  n	  is	  the	  number	  of	  worm	  track	  as	  measured	  by	  wrMTrck	  plugin	  in	  the	  motility	  experiments,	   or	   the	   total	   number	   of	   worms	   scored	   for	   aggregation.	   Error	   bars	   are	   S.E.M.	   *	  indicates	  statistically	  significant	  differences	  with	  p	  <	  0.05	  (Student	  t-­‐test).	  **	   indicates	  p	  <	  0.01	  and	  ***	  refers	  to	  p	  <	  0.001.	  (D)	  Representative	  figures	  of	  Q35	  worms	  treated	  with	  only	  the	  DMSO	  vehicle,	  50μM	  17-­‐AAG	  or	  10μM	  activator	  A731.	  Pictures	  were	  taken	  with	  YFP	  fluorescence	  and	  with	  bright	  field,	  with	  the	  same	  light	  exposure	  and	  magnification.	  
	   	  
	   Next,	  we	   repeated	   this	   experiment	  with	  Q35	  worms,	   a	  model	   for	   PolyQ	  disorders	  (112),	  since	  we	  had	  determined	  that	  A731	  was	  inducing	  Hsp70	  mRNA	  expression	   in	   these	   worms	   (Figure	   14A).	   We	   tested	   A731	   for	   reduction	   of	  aggregates	  and	  also	  for	  rescue	  of	  the	  motility	  defect	  of	  these	  worms,	  which	  is	  a	  readout	   of	   toxicity	   caused	   by	   the	   polyQ	   in	   their	   body	   wall	   muscle	   cells.	   Our	  observations	  showed	  that	  A731	  at	  10μM	  improved	  the	  motility	  defect	  from	  70%	  of	   the	  body	   lengths	  per	   second	   (BLPS)	  of	  N2	  wild-­‐type	  worms	   to	  91%	   (Figure	  15B).	   An	   increase	   in	   the	   A731	   concentration	   (to	   20μM)	   did	   not	   show	   an	  improvement	   in	   the	   rescue	   of	   this	   phenotype,	   slightly	   lowering	   the	   rescue	   to	  84%.	  Furthermore,	  treatment	  with	  A731	  reduced	  the	  number	  of	  fluorescent	  foci	  in	  day-­‐3	  adult	  Q35	  C.	  elegans	  by	  15%,	  less	  efficient	  than	  the	  positive	  control	  17-­‐AAG	  (42%)	  but	  still	  resulting	  in	  a	  statistically	  significant	  difference	  (Figure	  15C).	  We	  also	  took	  fluorescence	  images	  of	  representative	  worms	  of	  each	  condition,	  to	  further	   support	   our	   findings	   (Figure	   15D).	  With	   these	   set	   of	   experiments,	   we	  were	   able	   to	   show	   that	   A731	   produces	   some	   mild	   rescue	   of	   the	   proteotoxic	  effects	  observed	  at	  day-­‐3	  of	  adulthood	  in	  Q35	  worms.	  	   Given	  the	  mild	  but	  encouraging	  effects	  of	  A731	  treatment	  on	  Q35	  toxicity,	  we	  decided	  to	  test	  whether	  A731	  treatment	  could	  influence	  disease	  progression	  in	   other	  worm	  models	   of	   protein	  misfolding.	  We	   tested	  A731	   in	   two	   neuronal	  models	  of	  C.	  elegans:	  the	  Q67	  neuronal	  PolyQ	  model	  (113)	  and	  the	  ataxin-­‐3	  Q114	  model	   (nAT3q130)	   for	   Machado-­‐Joseph	   disease	   (117)	   and	   assayed	   them	   for	  locomotion	  deficiency.	  	   Our	   results	   with	   both	   models	   were	   encouraging	   because	   they	   showed	  that	   in	   the	   Q67	   C.	   elegans	   A731	   treatment	   rescued	   the	   number	   of	   locomotion	  defective	  worms	   from	   47%	   (treated	  with	   DMSO)	   to	   22%	  when	   using	   A731	   at	  25μM	   (Figure	  16A).	  This	   is	   very	   close	   to	   the	  10%	  of	  wild-­‐type	  N2	  worms	   (the	  positive	  control)	  that	  show	  the	  same	  defect.	  As	  for	  the	  AT3q130	  worms,	  47%	  of	  the	  animals	  grown	  in	  DMSO	  only	  ex
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only	   10%	   of	   N2s	   and	   21%	   of	   the	   non-­‐aggregation-­‐prone	   AT3q14.	   For	   the	  nematodes	   treated	   with	   A731,	   only	   18%	   were	   locomotion	   defective	   (Figure	  16B).	  The	  combination	  of	  these	  two	  experiments	  showed	  a	  promising	  ability	  to	  rescue	   neuronal	   models	   of	   gain-­‐of-­‐toxic-­‐function	   conformational	   disorders,	  making	   A731	   an	   interesting	   new	   activator	   of	   the	   HSR	   that	   encourages	   more	  advanced	  studies.	  
	  
Figure	  16.	  A731	  rescues	  neuronal	  phenotypes	  in	  C.	  elegans	  models	  of	  protein	  misfolding.	  
(A)	   Q67	   worms	   treated	   with	   25μM	   A731	   show	   a	   rescue	   of	   a	   severe	   locomotion	   defective	  phenotype.	   Negative	   control	   was	   Q67	   animals	   treated	   with	   the	   DMSO-­‐vehicle	   alone.	   Positive	  control	  was	  wild-­‐type	  N2	  C.	   elegans	  with	  DMSO.	   (B)	  A731	   improves	   the	   locomotion	  deficiency	  phenotype	   of	   AT3q130	   animals	   and	   reverts	   it	   to	   the	   level	   of	   the	   positive	   control,	   animals	  expressing	  a	  non-­‐aggregation-­‐prone	  polyQ	  length	  (AT3q14)	  treated	  with	  only	  DMSO.	  Additional	  positive	  control	  were	  N2	  worms	  and	  negative	  control	  were	  AT3q130	  C.	  elegans	  with	  DMSO.	  n	  >	  3.	  Error	   bars	   =	   S.E.M.	   ***	   indicates	   statistically	   significant	   differences	  with	   p	   <	   0.001	   (Student	   t-­‐test).	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chemistry	   and	   new	   mechanisms	   of	   action	   (MoA)	   of	   small	   molecules.	   Many	  already-­‐described	  compounds	  do	  not	  have	  a	  known	  MoA,	  and	  that	  would	  be	  the	  next	   step	   in	   further	   understanding	   how	   A731	  works	   in	   the	   cell.	   However,	   we	  have	   shown	   here	   that	   A731	   is	   a	   previously	   unidentified	   compound	   with	   the	  ability	   to	  activate	  a	  general	  HSR,	  and	  ameliorate	   toxicity	   in	  neuronal	  models	  of	  protein	  conformational	  disease.	  	   The	   other	   hits	   that	   resulted	   from	   the	   screen	   could	   also	   provide	   new	  insights	  into	  HSR	  regulation	  and	  its	  relationship	  with	  the	  protective	  mechanisms	  of	   proteostasis.	   Our	   best	   inhibitor,	   I632,	   did	   not	   show	   a	   high	   efficiency	   in	  reducing	   endogenous	   Hsp70	  mRNA	   expression.	   Nevertheless,	   it	   remains	   to	   be	  seen	  how	  this	  compound	  would	  act	  on	  other	  cell	  types.	  Given	  that	  it	  is	  a	  known	  fact	   that	  many	   tumor	   types	   have	   elevated	   levels	   of	   different	  Hsps,	   it	  would	   be	  interesting	  to	  determine	  whether	  I632	  has	  a	  better	  efficacy	  in	  cell	  types	  relevant	  for	   cancer	   studies	   and	   whether	   prolonged	   treatment	   has	   greater	   effects	   on	  impairment	  of	   the	  HSR.	  Alternatively,	   I632	  might	  represent	  a	  chemical	  scaffold	  with	  a	  higher	  potential	  for	  Hsp70	  inhibition,	  which	  could	  be	  altered	  in	  structure-­‐activity	  relationship	  (SAR)	  studies,	  to	  originate	  analogues	  with	  better	  inhibition	  rates.	  	   The	   co-­‐activator	   C732	   represents	   an	   interesting	   new	   class	   of	   HSR	  regulators.	   As	   of	   now,	   we	   have	   only	   shown	   that	   this	   small	   molecule	   is	   a	   co-­‐activator	  of	  MG132-­‐induced	  HSR,	  but	  it	  would	  be	  interesting	  to	  ascertain	  if	  this	  effect	  is	  specific	  of	  this	  agonist,	  or	  if	  it	  would	  also	  work	  cooperatively	  with	  HSR	  activators	   with	   a	   different	   pathway,	   like	   the	   heavy	   metal	   response	   activator	  CdCl2	  or	  heat	   shock	   itself.	  These	   results	  would	  provide	  an	   idea	  of	  how	  C732	   is	  acting,	  mechanistically.	  	   Nevertheless,	   our	   screening	   efforts	   provided	   interesting	   hits	   in	   all	   the	  classes	   that	  we	   proposed	   to	   describe,	   warranting	   small	  molecules	   that	   can	   be	  developed	  and	  studied	  to	  a	  higher	  detail.	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V – General Discussion and Conclusions 	  	  	  
1.	  HRS	  regulation	  to	  ameliorate	  proteostasis	  	   The	  proteostasis	  network	   (PN)	   is	   one	  of	   the	  major	  defenses	   against	   the	  many	   challenges	   facing	   an	   aging	   organism.	   The	   deleterious	   effects	   of	   errors	   in	  translation,	   expression	   of	  mutant	   proteins,	   and	  protein	  misfolding	   are	   negated	  by	   the	   PN,	   thereby	   suppressing	   age-­‐related	   accumulations	   in	   protein	   damage	  and	  aggregation.	  	  The	  presence	  of	  aggregation	  prone	  proteins	  disrupts	  the	  global	  balance	   of	   proteostasis	   and	   leads	   to	   aggregation	   and	   mislocalization	   of	  metastable	  proteins	   jn	  C.	  elegans	   (79).	  A	  similar	  observation	  was	  made	  in	  HeLa	  cells,	   by	   using	   luciferase	   mutants	   as	   folding	   sensors	   that	   misfolded	   upon	   a	  decrease	   in	   proteostasis	   capacity,	   in	   response	   to	   the	   expression	   of	  neurodegenerative	  disease-­‐related	  proteins	   (142).	   Furthermore,	   reduced	   levels	  of	  molecular	   chaperones	   such	   as	   Hsp70	   and	  Hps40	   (143)	   (144),	   alterations	   in	  protein	   degradation	   pathways	   (145)	   (36),	   and	   impairment	   of	   stress	   responses	  	  (146)	   (147)	   (148)	   (149)	   have	   been	   described	   in	   multiple	   models	   of	   protein	  conformational	  disease.	  This	  suggests	  that	  the	  chronic	  expression	  of	  aggregation	  prone	  proteins	  may	  disrupt	  the	  PN	  at	  many	  levels	  during	  disease	  progression.	  	   In	   support	   of	   this	   theory,	   over-­‐expression	   of	  molecular	   chaperones	   has	  been	  shown	  to	  ameliorate	  disease	  progression	  in	  yeast,	  mammalian	  cell	  culture,	  worm,	   fly,	   and	   mouse	   models	   of	   protein	   folding	   disorders	   (150)	   (151)	   (152)	  (153)	   (154).	  However,	   over-­‐expression	   of	   individual	   chaperones	   appears	   to	   be	  far	  less	  efficacious	  than	  up-­‐regulation	  of	  multiple	  chaperones,	  through	  activation	  of	  HSF1.	  	   One	   strategy	   for	   maintaining	   proteostasis	   and	   delaying	   disease	  progression	   is	   through	   the	   use	   of	   small	   molecule	   compounds,	   proteostasis	  regulators	  (PRs)	  that	  can	  enhance	  the	  protein	  folding	  environment	  of	  the	  cell	  or	  pharmacological	  chaperones	  (PCs)	  that	  bind	  and	  stabilize	  specific	  proteins	  (1).	  In	  this	   dissertation,	   we	   described	   new	   mechanistic	   insights	   into	   the	   mode	   of	  function	   of	   a	   previously	   described	   PR,	   named	   F1,	   through	   an	   exhaustive	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structure/activity	   relationship	   (SAR)	   study.	   We	   have	   also	   described	   the	  discovery	  and	  characterization	  of	  a	  new	  small	  molecule	  activator	  of	  the	  HSR,	  one	  of	   the	  major	  cytoprotective	  pathways	  of	  cellular	  response	   to	  stress,	  which	  may	  have	   therapeutic	   application	   in	   protein	   folding	   disorders.	   Some	   previously	  described	  HSR	  activators	  operate	  through	  Hsp90	  inhibition.	  Some	  examples	  are	  Geldanamycin,	  an	  antibiotic	  of	  the	  benzoquinone	  ansamycin	  class,	  and	  radicicol,	  an	  antibiotic	  of	  the	  macrolide	  class,	  that	  inhibit	  the	  chaperone	  activity	  of	  Hsp90	  (155)	   (156).	   However,	   even	   though	   these	   compounds	   show	   great	   efficacy,	  inhibition	  of	  Hsp90	  (one	  of	  the	  most	  abundant	  proteins	  in	  the	  cell)	  would	  not	  be	  compatible	  with	  a	  long-­‐term	  treatment,	  given	  the	  importance	  of	  this	  chaperone	  for	  cell	  function.	  Also,	  small	  molecules	  with	  a	  capacity	  to	  activate	  multiple	  stress	  pathways,	   such	   as	   F1,	   might	   have	   a	   wider	   range	   of	   applications	   in	   treating	  diseases	  that	  affect	  different	  cell	  environments,	  and	  deserve	  further	  attention.	  	  
2.	   Structure,	   activity	   and	  MoA	   of	   barbiturate-­like	   activators	   of	  
the	  HSR	  
2.1.	  Manipulating	   the	   chemistry	   of	   barbiturate-­like	   small	  molecules	   for	   a	  
better	  understanding	  of	  proteostasis	  disorders	  	   We	  had	  aimed	  at	  determining	  the	  chemical	  aspects	  in	  the	  structure	  of	  F1	  (96)	   that	  are	   required	   for	   its	  proper	   function.	  By	  undergoing	  an	  extensive	  SAR	  study	  with	  chemical	  analogues	  of	  SKM-­‐4/F1,	  we	  showed	  that	  this	  activator	  of	  the	  HSR	   seems	   to	   be	   at	   a	   structural	   balance.	   In	   fact,	   all	  modifications	   in	   the	   three	  different	   substructures	   of	   F1	   (allylidene	   linker,	   aromatic	   ring	   region	   and	  barbiturate-­‐like	   region)	   failed	   to	   clearly	   improve	   the	   activity	   of	   F1	   and,	   when	  they	  did,	  the	  improved	  activity	  came	  at	  the	  cost	  of	  increased	  toxicity.	  It	  became	  apparent	   that	   for	   this	   class	   of	   HSR	   activators,	   activity	   and	   toxicity	   seem	   to	   go	  hand	   in	   hand.	  Whenever	   the	  EC50	   of	   a	   compound	  was	   improved,	   the	   LD50	   also	  became	   lower	   and	   Ti	   could	   not	   be	   significantly	   altered	   by	   a	   fold	   change.	  Nevertheless,	   the	   F1	   compound	   had	   already	   shown	   great	   characteristics	   in	  rescuing	   models	   of	   protein	   misfolding	   and	   is	   a	   valid	   lead	   for	   more	   advanced	  studies.	  
	   117	  
	   Classically,	   barbiturates	   were	   described	   as	   an	   anticonvulsant	   and	  anaesthetic	  agent	  (reviewed	  in	  (157))	  and	  also	  for	  the	  treatment	  of	  intracranial	  hypertension	  after	   traumatic	  brain	   injury	  (158).	  To	  our	  best	  knowledge,	  only	  a	  few	   recent	   papers	   have	   previously	   associated	   barbiturate-­‐like	   compounds	   and	  HSR	   activation	   (111)	   (109)	   (110)	   (96).	   Our	   results,	   showing	   that	   analogue	  compounds	  of	   SKM-­‐4/F1	   activate	  multiple	   stress	  pathways	   and	   rescue	  protein	  misfolding	  models,	  provide	  a	  deeper	  understanding	  of	  this	  chemical	  class	  and	  its	  relationship	  with	  the	  HSR.	  	   Another	   important	   aspect	   of	   the	   comparison	   of	   SKM-­‐4/F1	   analogues	   in	  activation	  of	  multiple	  stress	  pathways	  was	  the	  observation	  that	  chemicals	  from	  similar	  chemical	  classes	  can	  modulate	  different	  stress	  pathways.	  As	  an	  example,	  SKM-­‐27	  activated	  the	  ER	  UPR	  more	  noticeably	  than	  SKM-­‐4/F1,	  and	  SKM-­‐17	  was	  the	   only	   compound	   able	   to	   clearly	   activate	   the	   mitochondrial	   UPR.	   These	  observations	  demonstrate	  that	  relatively	  discrete	  modifications	  of	  a	  scaffold	  can	  have	  pronounced	  effects	  on	  the	  PN.	  This	  suggests	  the	  possibility	  that	  compounds	  with	  a	  recognized	  value	  in	  improving	  proteostasis	  could	  be	  adapted	  to	  disorders	  affecting	  different	  cell	  compartments	  by	  targeting	  their	  action	  to	  a	  specific	  stress	  response.	  F1	  has	  been	  shown	  to	  ameliorate	  the	  F508del-­‐CFTR	  mutant,	  which	  is	  normally	   retained	   at	   the	   ER	   and	   targeted	   for	   premature	   degradation	   (96).	  Therefore,	  it	  would	  be	  interesting	  to	  see	  if,	  for	  example,	  SKM-­‐27	  is	  more	  efficient	  in	   the	   same	   system,	   since	   it	   induces	   the	   ER	   UPR	   more	   actively.	   Likewise,	  barbiturate-­‐like	   molecules	   such	   as	   SKM-­‐2	   showed	   a	   tissue-­‐specificity	   in	  activating	   the	  HSR	   (only	   in	   fibroblasts	   and	  myoblasts,	   but	   not	   in	   neuroblasts).	  Cell	  specific	  proteomes	  and	  different	  cell	  environments	  have	  already	  been	  shown	  to	   have	   different	   proteostasis	   requirements	   (159)	   (Czyz,	   Guisbert	   et	   al.,	  manuscript	   in	   review).	  Also,	   it	   is	   believed	   that	   different	  neuron	  populations	   in	  the	   mammalian	   brain	   have	   variations	   in	   chaperone	   gene	   expression,	   which	  points	  at	  their	  differential	  vulnerability	  to	  misfolding	  proteins	  that	  cause	  disease	  (160).	   Therefore,	   compounds	   with	   characteristics	   like	   SKM-­‐2	   could	   help	   to	  design	   approaches	   to	   reveal	   tissue-­‐specific	   components	   of	   the	   proteostasis	  network	   (PN).	   They	   might	   also	   provide	   a	   starting	   point	   to	   develop	   small	  molecules	  with	  a	  higher	  specificity	  of	  targets.	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2.2.	  F1	  has	  potential	  applications	  in	  neuronal	  models	  of	  protein	  misfolding	  	   F1	   was	   previously	   described	   as	   a	   compound	   that	   not	   only	   improved	  toxicity	   phenotypes	   in	   both	   mammalian	   and	   C.	   elegans	   models	   for	  conformational	   disorders,	   but	   also	   as	   the	   first	   small	  molecule	   that	   showed	   an	  efficacy	  in	  models	  related	  to	  different	  cell	  compartments,	  namely	  the	  cytosol	  and	  the	  ER	  (96).	  We	  now	  demonstrate	  that	  together	  with	  these	  important	  capabilites,	  SKM-­‐4/F1	   can	   also	   rescue	   neuronal	   models	   of	   polyglutamine	   and	   ataxin-­‐3	   in	  worms,	  and	  is	  neuroprotective	  for	  rat	  brain	  slices	  and	  co-­‐cultures	  of	  cortical	  and	  striatal	   neurons,	   challenged	   by	   an	   aggregation-­‐prone	   fragment	   of	   mutant	  Huntingtin.	   Together,	   these	   observations	   point	   to	   the	   need	   of	   better	  understanding	   the	   F1	   mechanism	   of	   action	   (MoA)	   and	   its	   direct	   interaction	  partners	   in	   the	   cell.	   Revealing	   the	   identity	   of	   the	   molecular	   interactors	   of	   F1	  could	   then	   justify	   testing	   it	   in	  mouse	  models	   for	  neurodegenerative	  diseases,	  a	  necessary	   and	   desired	   stepping	   stone	   on	   the	  way	   to	   clinical	   trials.	   At	   the	   very	  least,	  finding	  the	  MoA	  of	  F1	  has	  the	  potential	  to	  reveal	  new	  genetic	  pathways	  for	  proteostasis	   regulators	   (PRs),	   which	   could	   in	   turn	   identify	   novel	   targets	   for	  therapeutic	  intervention	  in	  protein	  folding	  diseases.	  	  
2.3.	  The	  HSR	  is	  necessary	  for	  disease	  model	  amelioration	  in	  the	  Q35	  worms	  
by	  F1,	  but	  other	  stress	  pathways	  are	  not	  	   The	  activation	  of	  multiple	  stress	  response	  pathways	  has	  been	  shown	  to	  be	  integral	  to	  lifespan	  extension	  and	  suppression	  of	  protein	  folding	  disease,	  mostly	  by	  a	  tight	  control	  of	  the	   insulin/insulin-­‐like	  growth	  factor	  1	  pathway	  (IIL),	   that	  links	  neurodegeneration	  to	  the	  aging	  process	  (161)	  (162)	  (163).	  These	  pathways	  are	   under	   the	   control	   of	   the	   transcription	   factors	   HSF1,	   DAF-­‐16/FOXO3a,	  SKN1/NRF2,	  ATF6,	   and	  XBP1.	   (164)	   (112)	   (163)	   (165)	   (166).	  We	  observed	   the	  activation	  of	  multiple	  stress	  pathways	  by	  SKM-­‐4/F1	  and	  its	  analogues.	  However,	  RNAi	   studies	   in	   C.	   elegans	   revealed	   that	   from	   the	   stress	   pathways	  we	   studied	  (HSR,	  ER	  UPR,	  mtUPR	  and	  the	  oxidative	  stress	  response)	  only	  the	  HSR	  seems	  to	  be	  needed	  for	  the	  F1-­‐related	  rescue	  of	  protein	  aggregation	  in	  Q35	  worms.	  In	  fact,	  the	  knockdown	  of	  genes	  controlling	  the	  other	  stress	  pathways	  (atf-­6,	  atfs-­1	  and	  
daf-­16)	   did	   not	   significantly	   affect	   the	   phenotype	   rescue	   by	   SKM-­‐4/F1.	   These	  
	   119	  
data	  are	   intriguing	  since	  there	  have	  been	  reports	  that	  also	  daf-­16,	  and	  not	  only	  
hsf-­1,	   is	   required	   for	   protecting	   the	   cells	   from	   PolyQ-­‐	   and	   Aβ1-­‐42-­‐mediated	  proteotoxicity	   (112)	   (164)	   (115)	   (167)	   in	   C.	   elegans.	   However,	   it	   was	   also	  reported	  that	  the	  HSF1	  and	  DAF16	  transcription	  factors	  have	  opposing	  activities	  for	  the	  protection	  of	  proteotoxicity.	  While	  HSF1	  promoted	  disaggregation	  in	  the	  Aβ1-­‐42	   model,	   DAF16	   led	   to	   a	   protective	   active	   aggregation	   into	   less	   toxic	  oligomeric	   species.	   This	   seems	   to	   point	   to	   a	   fundamental	   difference	   between	  disease	  phenotypes	  and	  the	  role	  of	  HSF1	  and	  DAF16	  in	  protecting	  against	  them.	  While	  DAF16	   contributed	   to	   a	   rescue	   of	   toxicity	   in	  Q35	  C.	   elegans	   by	   reducing	  aggregation	  (164),	  it	  did	  so	  on	  Aβ1-­‐42	  by	  enhancing	  aggregation,	  but	  reducing	  its	  toxicity	   (167).	   This	   points	   to	   a	   requirement	   of	   DAF16	   in	   the	   suppression	   of	  protein	   folding	   disease	   only	   at	   severe	   aggregation	   load	   environments,	   such	   as	  the	   Aβ1-­‐42	   model	   in	   worms,	   when	   the	   normal	   disaggregation	   and	   degradation	  mechanisms	   are	   already	   overloaded	   (168),	   and	   it	   also	   provides	   a	   good	  explanation	  for	  our	  findings.	  	   Even	   though	   this	   experiment	   needs	   to	   be	   completed	   by	   testing	   other	  stress	  transcription	  factors	  (TFs)	  in	  the	  worm,	  like	  xbp-­1	  for	  the	  ER	  UPR	  or	  skn-­1	  for	  the	  oxidative	  stress	  response,	  it	  correlated	  nicely	  with	  our	  observations	  that	  SKM-­‐17	   and	   SKM-­‐27,	   analogues	   that	   up-­‐regulated	   the	   mtUPR	   and	   ER	   UPR,	  respectively,	   to	   a	   larger	   extent	   than	   SKM-­‐4/F1,	   did	   not	   further	   decrease	   the	  number	  of	  fluorescent	  foci	  in	  these	  worms.	  A	  more	  detailed	  continuation	  of	  this	  experiment	  will	  show	  if	  the	  HSR	  is	  not	  only	  necessary,	  but	  also	  sufficient,	  for	  F1	  activity.	  For	   this	  purpose,	  we	  can	   test	   the	  Q35	  rescue	  by	  F1	   in	   the	  presence	  of	  two	  or	  more	  RNAi	  clones	  and	  map	  out	  if	  any	  other	  pathway	  is	  still	  contributing	  to	  a	  decrease	  in	  aggregation.	  	  	   In	  conclusion,	  we	  were	  able	  to	  deepen	  the	  study	  of	  the	  small	  molecule	  F1,	  using	   chemical	   genetics	   approaches	   to	   better	   describe	   its	   chemical	   and	  mechanistical	   characteristics,	   as	   well	   as	   expand	   the	   type	   of	   conformational	  disease	  models	  in	  which	  its	  action	  is	  relevant.	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3.	  Concerted	  efforts	  for	  new	  HSR	  regulators	  of	  different	  classes	  
3.1.	  Refining	  a	  screen	  	   High	   throughput	   screening	   (HTS)	   has	   been	   an	   invaluable	   tool	   for	  deepening	  our	  knowledge	  of	  proteostasis.	  At	  the	  genetic	  level,	  many	  constituents	  of	  the	  PN	  were	  identified	  in	  HTSs,	  for	  example	  for	  inducers	  (122)	  or	  suppressors	  (123)	  of	  protein	  aggregation.	  In	  fact,	  these	  genetic	  and	  pharmacological	  findings	  can	   contribute	   to	   a	   concerted	   effort	   in	   proteostasis	   regulation.	   The	   genetic	  components	  revealed	  in	  those	  screens	  might	  be	  the	  molecular	  partners	  of	  small	  molecules	   found	   by	   screens	   like	   ours	   and	   the	   definition	   of	   a	   PN	   allows	   for	  candidate-­‐based	  approaches	   for	   the	   identification	  of	   the	  physical	   targets	  of	   the	  proteostasis	  regulators	  (PRs).	  	  	   The	   hit	   compounds	   identified	   in	   our	   HTS	   were	   the	   product	   of	   a	  refinement	   of	   the	   results	   from	   the	   initial	   screen.	   We	   were	   able	   to	   perform	  different	   rounds	   of	   selection	   that	   resulted	   in	   the	   most	   interesting	   activator	  (A731),	   inhibitor	   (I632)	   and	   co-­‐activator	   (C732)	   of	   the	   HSR	   in	   the	   library	   we	  screened.	  An	  ordered	  and	  rigorous	  refinement	  of	  the	  primary	  hits	  of	  a	  HTS	  is	  a	  necessary	   and	   desired	  method	   that	   allows	   focusing	   time	   and	   resources	   in	   the	  most	   promising	   small	   molecules.	   By	   separating	   the	   first	   small	   molecule	  candidates	  from	  the	  final	  validated	  hits,	  we	  can	  then	  expand	  our	  comprehension	  of	  a	  chemical	  that	  can	  potentially	  be	  developed	  into	  a	  therapeutic	  lead.	  	  
3.2.	  The	  newly	  identified	  regulators	  of	  the	  HSR	  	   The	   inhibitor	   I632	   did	   not	   show	   an	   elevated	   efficacy	   in	   decreasing	   the	  levels	  of	  Hsp70	  mRNA,	  in	  MEF	  cells.	  However,	  a	  compound	  with	  its	  low	  toxicity	  can	  be	  a	  starting	  point	  for	  developing	  HSR	  inhibitors	  by	  SAR	  studies.	  Maintaining	  the	  toxicity	  of	   I632	  and	  enhancing	   its	  activity	  would	  originate	  compounds	  with	  potential	  uses	  in	  situations	  where	  high	  levels	  of	  HSR	  are	  undesired.	  One	  notable	  example	  are	  cancer	  cells,	  where	  Hsps	   induction	   is	  at	  higher	   levels	   than	   in	  cells	  with	   a	   normal	   physiology	   (104)	   (99)	   (169)	   (170).	   Inhibitors	   of	   the	   HSR	   could	  then	   be	   valuable	   instruments	   as	   therapeutics	   for	   cancer.	   In	   fact,	   inhibiting	  certain	  Hsp70s	  as	  been	  shown	  to	  selectively	  cause	  the	  death	  of	  breast	  cancer	  cell	  lines,	  while	  this	  did	  not	  result	  in	  the	  death	  of	  breast	  epithelial	  cells	  that	  were	  not	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tumorigenic	  (171)	  (172).	  It	  has	  also	  been	  shown	  that	  the	  inhibition	  of	  Hsp90	  can	  be	  useful	  for	  cancer	  treatment,	  given	  that	  Hsp90	  shows	  a	  greater	  affinity	  for	  its	  inhibitors	   in	   cancer	   cells	   than	   in	  normal	   cells	   (173)	   (174).	   Even	   though	  Hsp90	  inhibition	  results	  in	  a	  general	  HSR,	  this	  is	  still	  a	  great	  example	  of	  how	  selectively	  inhibiting	   one	   heat	   shock	   protein	   might	   lead	   to	   cancer	   therapeutics.	   Also,	  because	  total	  Hsp90	  inhibition	  results	   in	   lethality	   in	  eukaryotes,	  modulating	   its	  function	   with	   small	   molecule	   compounds	   that	   alter	   its	   function	   but	   do	   not	  abolish	  it	  might	  be	  the	  best	  strategy	  in	  these	  cases	  (175)	  (176)	  (177).	  	   C732,	  our	  best	  co-­‐activator	  of	  MG132-­‐induced	  HSR,	   is	  an	   intriguing	  new	  small	   molecule.	   It	   shares	   remarkable	   chemical	   similarities	   with	   our	   activator,	  A731.	  However,	  it	  only	  had	  an	  effect	  on	  activation	  of	  the	  luciferase	  reporter	  used	  for	   the	   HTS	   in	   the	   presence	   of	   MG132,	   and	   not	   by	   itself,	   like	   A731.	   The	  differences	  in	  structure	  between	  the	  two	  compounds	  might	  be	  enough	  to	  explain	  these	   differences.	   The	   whole	   class	   of	   HSR	   co-­‐activator	   hits	   provides	   a	   few	  unanswered	   questions.	   It	   was	   noticeable	   in	   our	   results	   that	   none	   of	   the	   co-­‐activators	  enhanced	  the	  fold	  activation	  of	  MG132	  alone	  by	  more	  than	  4.2-­‐fold.	  It	  is	   possible	   that	   these	   new	   HSR	   regulators	   act	   upstream	   of	   MG132	   and	   just	  facilitate	  its	  action	  (for	  example,	  by	  improving	  the	  cellular	  uptake	  of	  MG132),	  as	  they	   are	   not	   able	   to	   activate	   the	   HSR	   by	   themselves.	   These	   questions	   can	   be	  answered	  by	  testing	  the	  co-­‐activator	  class	  with	  different	  triggers	  of	  the	  HSR,	  like	  the	  heavy	  metal	  response	  activator	  CdCl2	  or	  by	  a	  chemical	  independent	  approach	  such	   as	   heat	   shock.	   Only	   a	   few	   co-­‐activators	   of	   the	   HSR	   have	   been	   previously	  reported.	   The	   discovery	   that	   sodium	   salicylate	   activated	   the	   DNA-­‐binding	  activity	  of	  HSF1	  but	  did	  not	  induce	  the	  transcription	  of	  heat	  shock	  genes	  was	  the	  one	  of	  the	  first	  clues	  that	  the	  heat	  shock	  response	  is	  a	  multistep	  process	  and	  the	  first	   compound	   that	   could	   trigger	   the	   HSR	   but	   not	   activate	   it	   itself	   (178).	  Hydroxylamine	   derivatives	   are	  mall	  molecules	   that	   co-­‐induce	   up-­‐regulation	   of	  HSR	  proteins	  and	  have	  already	  shown	  efficacy	  in	  models	  for	  misfolding	  diseases,	  where	   its	   activity	   was	   sufficient	   to	   ameliorate	   proteotoxicity	   phenotypes	   and	  delay	   disease	   progression	   (140)	   (179).	   In	   models	   with	   these	   characteristics,	  where	   the	   folding	   environment	   and	   proteostasis	   are	   already	   altered,	   stress	   is	  therefore	   activated,	   which	   prompts	   the	   possibility	   that	   also	   C732	   could	   prove	  efficient	  in	  models	  for	  conformational	  diseases.	  Co-­‐activator	  small	  molecules	  are	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interesting	   compounds	   that	   point	   to	   mechanisms	   of	   HSR	   regulation	   where	  synergy	  between	  different	  small	  molecules	  could	  allow	  the	  use	  of	  both	  molecules	  at	  less	  toxic,	  concentrations.	  In	  some	  diseases,	  this	  might	  even	  be	  the	  best	  chance	  for	   therapeutics.	   In	  Cystic	  Fibrosis	  patients,	   it	  has	  been	  suggested	  that	   the	  best	  mode	  of	  treatment	  might	  be	  to	  use	  a	  “corrector”	  pharmacological	  chaperone	  (PC)	  to	   promote	   correct	   folding	   and	   export	   from	   the	   ER,	   combined	   with	   a	  “potentiator”,	  to	  enhance	  the	  activity	  of	  the	  mutated,	  partially	  functional	  channel,	  at	  the	  membrane	  (180).	  	  	   The	   activator	   of	   the	  HSR	  A731	   is	   a	   new	   regulator	   that	  we	  were	   able	   to	  study	  in	  more	  detail.	  From	  our	  experiments,	  we	  learned	  that	  A731	  activates	  an	  HSF1-­‐dependent	   general	  HSR	   (and	   is	   not	   a	   specific	  Hsp70	   inducer)	   and	   that	   it	  ameliorates	   proteotoxicity-­‐related	   phenotypes	   in	   C.	   elegans	   models	   of	   protein	  misfolding.	   Interestingly,	   A731	   showed	   all	   these	   characteristics	   even	   though	   it	  only	  activated	  the	  HeLa	  luciferase	  reporter	  by	  ≈5-­‐fold	  of	  the	  background	  levels.	  This	   might	   either	   mean	   that	   A731	   is	   a	   weak	   activator	   of	   the	   HSR	   at	   the	  concentrations	  tested,	  which	  we	  also	  observed	  for	  the	  mRNA	  induction	  of	  Hsp70,	  Hsp40,	  Hsp25	  and	  Hsp110	  with	  10μM	  A731.	   If	   this	   is	   the	   case,	   it	  points	   to	   the	  theory	   that	   a	   small	   increase	   in	   chaperone	   levels	   might	   be	   preferred	   for	   a	  balanced	   enhancement	   of	   proteostasis	   (1),	   as	   opposed	   to	   an	   abrupt	   up-­‐regulation	   that	   could	   overwhelm	   the	   cellular	   environment.	   Another	   point	   we	  have	   not	   yet	   tested	   is	  whether	   A731	   activates	   other	   cellular	   stress	   responses,	  and	   whether	   those	   correlate	   with	   its	   activity	   in	   improving	   proteostasis.	   Even	  though	  we	  still	  do	  not	  understand	  the	  MoA	  of	  A731,	  it	  is	  a	  promising	  new	  small	  molecule	   that	   we	   will	   look	   to	   further	   pursue.	   	   Finding	   its	   MoA	   would	   be	   an	  important	   contribution	   for	   identifying	   novel	   genetic	   targets	   for	   therapeutic	  intervention.	  	  
4.	  Conclusions	  and	  Future	  Directions	  	   For	   a	   small	  molecule	   hit	   to	   be	   a	   possible	   candidate	   for	   translating	   into	  therapeutic	  applications	  we	  have	  to	  chemically	  refine	  that	  molecule,	  understand	  the	  long	  term	  implications	  of	  a	  treatment	  and	  to	  fully	  understand	  its	  MoA.	  That	  requires	  the	  complete	  characterization	  of	  any	  compounds	  that	  result	  from	  HTSs.	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   With	  F1,	  we	  are	  closer	  to	  defining	  a	  mechanism.	  We	  now	  know	  that	  while	  F1	  activates	  multiple	  stress	  pathways,	  only	  the	  HSR	  (or	  at	  least	  HSF1)	  seems	  to	  be	   required	   for	   F1	   to	   ameliorate	   the	   Q35	   phenotype	   of	   protein	   misfolding.	  However,	  it	  is	  possible	  that	  this	  is	  a	  specific	  effect	  of	  the	  model	  we	  used.	  F1	  might	  rescue	  Q35	  only	  by	  promoting	  an	  activation	  of	  the	  HSR,	  but	  it	  might	  lead	  to	  the	  rescue	  of	  different	  disease	  phenotypes	  (like	  the	  CFTR	  channel	  gating,	  shown	  in	  (96))	   by	   the	   activation	   of	   other	   stresses,	   such	   as	   the	   ER	   UPR.	   It	   would	   be	  extremely	   interesting	   to	   perform	   a	   similar	   assay	   but	   with	   a	   different	  aggregation-­‐prone	  model	  and	  to	  compare	  both	  results.	  Nevertheless,	  one	  way	  to	  narrow	  down	   the	   targets	  of	   F1	   for	   the	   rescue	  of	  Q35	  aggregation	   is	   to	  use	   the	  same	  RNAi	  techniques	  described	  in	  this	  thesis	  (for	  checking	  the	  requirements	  of	  different	  TFs)	  and	  apply	  them	  to	  the	  HSR	  downstream	  targets	  of	  HSF1.	  With	  this	  approach,	   checking	   if	   a	   knocked	  down	  gene	   abolishes	   the	   rescue	  of	  Q35	  day-­‐3	  adult	   aggregation	   by	   F1,	   would	   point	   to	   a	   more	   specific	   pathway	   and	   target.	  Additionally,	  our	  chemical	  genetics	  approach	  led	  to	  the	  identification	  of	  locations	  in	  the	  F1	  structure	  where	  insertion	  of	  side	  chains	  is	  allowed	  without	  a	  significant	  loss	  of	  activity.	  This	  will	  allow	  us	  to	  tag	  F1	  and	  use	  it	  in	  a	  pull	  down	  experiment,	  followed	   by	   mass	   spectrometry	   identification	   of	   its	   binding	   partners,	   in	   an	  approach	  similar	  to	  that	  previously	  described	  for	  celastrol	  (108).	  	   Models	   of	   protein	   conformational	   disorders	   have	   provided	   essential	  contributions	   in	   improving	   our	   understanding	   of	   loss-­‐	   and	   gain-­‐of-­‐function	  diseases	   affecting	   human	   populations.	   The	   complementary	   use	   of	   different	  model	  organisms	  (mammalian,	  C.	  elegans,	   the	  fruitfly	  Drosophila	  or	  yeast)	  or	  of	  models	   that	   represent	   deficiencies	   in	   different	   cellular	   environments	   result	   in	  more	   sustained	   evidence	   of	   the	   significance	   of	   a	   new	   small	   molecule.	  Accordingly,	  we	  will	   test	  SKM-­‐17,	  SKM-­‐27	  and	  also	  A731	   in	  the	  rat	  brain	  slices	  and	   co-­‐culture	   models	   expressing	   Htt-­‐N90Q73,	   to	   assess	   their	   likelihood	   into	  further	  compound	  development.	  	   Many	   regulators	   of	   the	   HSR	   have	   been	   described	   that	   act	   through	  different	  MoAs	  (181)	   (182)	   (183)	   (184).	  Also,	   it	  was	  shown	  for	  F1	   that	   its	  MoA	  was	   not	   by	   Hsp90	   or	   proteasome	   inhibition,	   hinting	   that	   it	   has	   a	   novel	  mechanism	  different	  to	  the	  ones	  that	  had	  previously	  been	  reported	  (96).	  We	  will	  look	  into	  discovering	  the	  cellular	  MoA	  on	  our	  newly	  identified	  regulators	  of	  the	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HSR.	   Uncovering	   a	   new	   MoA	   could	   provide	   new	   tools	   for	   both	   a	   finer	  comprehension	  of	   the	  proteostasis	  mechanisms	  and	  network,	   as	  well	   as	   create	  new	  potential	  compounds	  to	  treate	  misfolding	  diseases,	  such	  as	  Alzheimer’s,	  ALS	  or	  Cystic	  Fibrosis.	  	  	   The	  work	  shown	   in	   this	   thesis	  has	   shown	  different	  aspects	  and	  steps	  of	  the	   development	   of	   small	   molecule	   compounds	   with	   potential	   applications	   in	  diseases	  affecting	  human	  populations.	  We	  expect	  that	  these	  compounds	  will	  one	  day	  be	  developed	   into	   therapeutics	  and	  help	   to	  overcome	   the	  many	  challenges	  affecting	   an	   aging	   world.	   If	   not,	   they	   will	   certainly	   contribute	   to	   our	  understanding	   of	   the	  many	   pathways	   and	   defense	  mechanisms	   trying	   to	   keep	  our	   organisms	   in	   a	   healthy,	   homeostatic	   state,	   through	   a	   longer	   and	   better	  maintenance	  of	  proteostasis.	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APPENDIX I – ACTIVITY AND 
TOXICITY PROFILES OF SKM-4/F1 
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Appendix I – Activity 
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Activity	  and	  toxicity	  profiles	  of	  SKM-­4/F1	  analogues.	  Cells	  were	   incubated	   for	  24h	  with	   the	  compounds,	   after	   which	   activity	   was	   determined	   by	   measuring	   luciferase	   activity	   with	   the	  Steadylite	   HTS	   reagent	   (Perkin	   Elmer).	   In	   parallel,	   toxicity	   was	   assessed	   using	   Calcein	   AM	  (Invitrogen).	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